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Abstract
Objectives
Long-term use of benzodiazepine medication results in dependence, tolerance, withdrawal
symptomatology, and reduced pharmacological efficacy. In addition, long-term use of
benzodiazepines can have adverse effects on cognitive, psychomotor and psychological
functioning. In response to these problems prescribing guidelines clearly discourage the
long-term use of benzodiazepines.
The aim of the study was to examine the long-term use of benzodiazepine medication in a
primary care population. The study included patients who were prescribed benzodiazepines
by their general practitioners for sleep problems. Detailed information was collected
regarding psychopathology, sleep difficulties and benzodiazepine dependence in this patient
group with the aim of establishing whether a common psychological profile prevailed
amongst those individuals who had been taking prescribed benzodiazepine medication for
longer than the recommended period of time.
This research study could therefore offer support to general practitioners by providing a
greater psychological understanding of this client group, and this knowledge could inform
alternative treatment options.
Design
The research design employed was a cross-sectional survey of an identified population using
standardised questionnaires. The design therefore utilised between subject measures to
examine the relationships between subjects on a number of variables.
Method
Eighty-four participants, recruited from two rural primary care practices, took part in the
study. Data were collected using a semi-structured interview and administration of four self-
report questionnaire measures (The Pittsburgh Sleep Quality Index; The Brief Symptom
Inventory; The Severity of Dependence Scale; The Psychological Mindedness Scale).
Results
Results found significant psychopathology (somatisation and phobic anxiety) in long-term
benzodiazepine users. Anxiety was found to significantly predict benzodiazepine
dependence and sleep difficulties. The use of long-term benzodiazepine medication did not
relieve sleep difficulties. Older benzodiazepine users and daily benzodiazepine users were
significantly less psychologically minded than younger users and non-daily users.
Conclusion
The study concluded that long-term benzodiazepine use is ineffective in treating sleep
difficulties and it would appear that anxiety is a significant feature in this cohort. Therefore,
the study proposes that to address the problem of long-term benzodiazepine use in the
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Chapter 1: The Benzodiazepines
What are benzodiazepines?
Benzodiazepine is the name given to a sub-group of drugs, that sit within the larger
classification of psychotropic drugs. Benzodiazepines are referred to as minor tranquillisers.
Whilst most people are unfamiliar with the word benzodiazepine, with the exception of illicit
drug users who refer to benzodizepines as "benzos", the general public are familiar with the
word "tranquilliser". Taken from the adjective "tranquil" which means "Serene, free from
agitation or disturbance" (Concise Oxford Dictionary), "a tranquilliser" is a sedative drug.
The pursuit and use of compounds to relieve anxiety stretches back thousands of years, for
example the discovery of alcohol some 8000 years ago is well documented, along with the
use of opium and other naturally occurring drugs across other cultures. However, it was not
until the nineteenth century, following the Industrial Revolution and the subsequent growth
of chemical knowledge and manufacturing, that the development of pharmaceutical remedies
gave rise to the production of synthetic compounds which could be used for sedation.
At the turn of the twentieth century the most widely used synthetic drugs for sedation were
the barbiturates. First developed in 1903, the popularity of barbiturates steadily rose until the
1950s when it levelled off. By the 1970s the abuse and dependence-inducing properties of
these compounds had been well publicised and prescribing doctors were strongly encouraged
to replace the barbiturates with benzodiazepines. In addition, the barbiturates were found to
have a lower degree of selectivity, increased CNS suppression, cause more drug interaction
and were found to be more lethal in overdose than benzodiazepines.
The development of the benzodiazepines began in Poland in the mid-1930's, but not until
1957 were the benzodiazepines clearly established as having hypnotic and sedative effects
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(Sternbach 1980). The first benzodiazepine to be introduced on to the market was
chlordiazepoxide (Librium) in 1960, closely followed by its more successful associate,
diazepam (Valium) in 1963.
What are benzodiazepines used for and how do thev work?
Following four decades of use, benzodiazepines remain one of the most widely prescribed
drugs. Their role has been expanded from their original use in the treatment of anxiety and
sleep disorders, for use with epilepsy, anaesthesia, some motor disorders and occasionally in
acute psychosis and mania. Nevertheless, despite these additional uses for benzodiazepines a
sizeable majority of patients still receive their prescription for sleep and anxiety problems.
Benzodiazepines used for their sleep-inducing properties are classed as hypnotics and those
used to reduce anxiety are classed as anxiolytics.
The main effect of benzodiazepines is that of increasing the activity of the neurotransmitter
GABA (gamma-aminobutyric acid). GABA exerts an inhibitory effect by reducing the
sensitivity of neurons with the result that it takes more to excite them. It is thought that a
deficiency of GABA may explain overarousal, a key feature of anxiety. Therefore, raising
GABA levels or enhancing its effect should reduce anxiety. At the cell membrane level,
benzodiazepines bind to a receptor site on a GABA receptor and enhance the effect of
GABA, with the result that the GABA chloride channel opens more often, releasing chloride
ions that hyperpolarize the cell, making it less likely to fire.
The range of indications and the relative effectiveness of benzodiazepines (certainly in the
short-term) have contributed to their popularity and wide-spread use. In general,
benzodiazepines are well tolerated and their main "apparent" side-effect is one of drowsiness
and sedation, this compares more favourably with many other regularly prescribed
medications in general medicine. However, after many years of usage, and a significant
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amount of published research, benzodiazepines are now known to cause a wide range of
adverse effects, particularly with long-term use. As evidence materialised supporting both
acute and chronic side-effects as well as toxicity, changes were made to the guidelines
regarding benzodiazepine prescribing.
There are approximately 50 benzodiazepine derivatives available for clinical use, although of
these only around a dozen are in regular use. Differences between different benzodiazepines
are relatively small but can be clinically significant. In clinical practice it is not uncommon
to encounter patients who report that the efficacy of a particular benzodiazepine is not
matched when they are transferred to a different one. However, it has been argued that this
specificity of action is likely to be psychologically based (Tyrer 1991). Research has shown
that when patients were changed to another benzodiazepine (equivalent doses) under double-
blind conditions there was no difference between the withdrawal symptoms of those patients
that had changed benzodiazepine and the group that had remained on the same one (Murphy
and Tyrer 1991). Nevertheless, this finding concerns withdrawal symptoms, not variations in
potency effects or onset of action.
Differences between benzodiazepines: Half-life, duration of action and potency
Benzodiazepines are usually classified according to their beta elimination half-life. Beta
half-life is defined as "the rate of decline due to drug elimination through metabolism to
inactive conjugated forms and excretion" (p.70 Nelson and Chouinard 1999).
Benzodiazepines that are more rapidly cleared from the body are labelled as having a "short
half-life" and those with a longer rate of elimination are referred to as having a "long half-
life". Elimination half-life varies considerably from 2 to 100 hours. Estimates for three
benzodiazepines are given below (Table 1). In addition, some benzodiazepines have
pharmacologically active metabolites that may produce cumulative effects (Aston 1994).
Cumulative effects are an important consideration when prescribing benzodiazepines
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particularly for older patients. Conversely, short-acting benzodiazepines with no metabolites
are more likely to give rise to withdrawal or rebound symptoms if doses are missed because
the drug leaves the body more rapidly.










(Source: p 27, Aston 1994)
Duration of action is another feature used to distinguish between different benzodiazepines.
Duration of action is not the same as elimination half-life; it is dependent on rate of
absorption, uptake in to the central nervous system and binding at the benzodiazepine GABA
receptor. Benzodiazepines will rapidly enter brain tissue once in the circulatory system,
therefore the onset of action is most closely related to absorption from the gastrointestinal
tract. Benzodiazepines that are absorbed more quickly include diazepam, which therefore has
a rapid onset of action and may sometimes produce more euphoria as a result.
Potency and half-life are not related. Potency refers to the receptor binding affinity of a
benzodiazepine, for example alprazolam (high potency) binds with greater affinity and is
therefore more potent than diazepam (medium potency); temazepam is an example of a
benzodiazepine that has a low potency.
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Physiological dependence: tolerance and withdrawal
Addiction is understood in terms of both psychological and physiological dependence.
Tolerance and withdrawal mediate physiological dependence. Different benzodiazepines
present with different risks of physiological dependence. This is because the risk is related to
factors such as long half-life, low clearance and cumulative drug load. Also, physiological
dependence implies a biological adaptation to the effects of the drug: this is referred to as
tolerance. Tolerance is explained in terms of the reduced efficacy of a drug with repeated
use, resulting in higher doses being required to achieve the same effect. Tolerance depends
on altered receptor function or a change in the numbers of receptors and is commonly
referred to as receptor adaptation. Tolerance can develop over several days or weeks and is
usually associated with hypnotics rather than anxiolytics.
Discontinuation of benzodiazepines can produce three types of symptoms: recurrence (a
return of the original symptoms), rebound (return of the original symptoms but more
intensely experienced than original baseline level) and withdrawal (new symptoms that were
not present in the original illness).
DIAGNOSTIC CRITERIA FOR 292.0 SEDATIVE,
HYPNOTIC, OR ANXIOLYTIC WITHDRAWAL
A. Cessation of (or reduction in) sedative,
hypnotic, or anxiolytic use that has been heavy
and prolonged.
B. Two (or more) of the following, developing
within several hours to a few days after criterion A:
(1) Autonomic hyperactivity (e.g. sweating or
pulse rate greater than 100)
(2) Increased hand tremor
(3) Insomnia
(4) Nausea or vomiting




(8) Grand mal seizures
C. The symptoms in criterion B cause clinically
significant distress or impairment in social,
occupational, or other important areas of
functioning.
D. The symptoms are not due to a general
medical condition and are not better accounted for
by another mental disorder.
Specify if: With Perceptual Disturbances.













"Nausea, loss of appetite
"Observable depression
"Depersonalization, derealization
"Increased sensory perception (smell, sight, taste,
touch)
"Abnormal perception or sensation of movement
"Symptoms more likely to represent true
withdrawal rather than an exacerbation or return of
original anxiety.
p. 138, Roy-Byrne and Nutt (1991)
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With abrupt discontinuation from benzodiazepine medication, symptoms can develop within
24 hours for the short and intermediate half-life drugs and within three to eight days with the
longer-acting drugs. Even following a gradual taper regime, large numbers of users
experience withdrawal symptoms. Schweizer et al (1990) found that more than 90% of long-
term users (over 8-12 months) experienced withdrawal symptoms regardless of whether they
withdrew slowly or rapidly. Noyes et al (1988) concluded from a review of studies that
almost half of those that had taken benzodiazepines for more than three years experienced a
withdrawal reaction when they stopped their medication. Nevertheless, the prevalence of
withdrawal symptomatology following discontinuation of benzodiazepines is difficult to
establish, as most studies have their own definition of what constitutes a withdrawal
symptom.
The likelihood of a withdrawal reaction is mediated by the following factors (Miller 1997):
Drug factors: Patient factors:
♦ Short half-life ♦ Traits of neuroticism
♦ High potency ♦Mild/moderate alcohol use
♦ Abrupt discontinuation ♦ Less well educated
♦ High dosage ♦More panic/anxiety/depression at baseline
♦Chronic use ♦ Prior history of alcohol/drug abuse
♦ Self report "addicted'V'hooked"
Withdrawal symptoms can be minimised by transferring the patient to a slowly eliminated




Historically, substance dependence has proved to be a difficult concept to define, and it has
undergone many revisions. In recent decades the introduction of the distinction between
physical and psychological dependence has caused both conceptual and operational
difficulties. Currently, substance dependence is defined in terms of both physiological
dependence and psychological dependence, neither being mutually exclusive. It would seem
likely that this terminology was developed from the earlier distinction made by the World
Health Organisation (1964) when the two terms "addiction" and "habituation" were used.
Much of the literature has focused on dependence as a physical response because it is easier
to establish than psychological dependence. It is argued that medical evidence in terms of
"withdrawal symptoms" and "tolerance" is widely understood and provides a perceptible
measure of physical dependence (Lader 1981).
However, focusing solely on physiological dependence does not satisfy those theorists that
support the concept of psychological dependence as a state arising from the process of
positive reinforcement, in contrast to negative reinforcement which underlies physiological
dependence (Ray and Kair 1987). Psychological dependence is characterised by the
reinforcing effects of a drug. The conceptualisation of drugs as reinforcers postulates that
drug-using and drug-seeking behaviours are examples of operant behaviour maintained by
their consequences. Reinforcing effects are found to correlate with drug self-ingestion
(Roache 1990). Benzodiazepines with increased speed of onset, short half-life, high
clearance and higher potency are said to have greater reinforcing effects and therefore have
an increased (psychological) addiction potential. The much-reported "addictive" properties
of the drug cocaine are explained in terms of psychological addiction because research has
failed to establish that physical dependence occurs with repeated use.
The Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV, American
Psychiatric Association 1994) describes substance dependence as follows:
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"The essential feature of Substance Dependence is a cluster of cognitive, behavioural, and
physiological symptoms indicating that the individual continues use of the substance despite
significant substance-related problems. There is a pattern of repeated self-administration that
usually results in tolerance, withdrawal and compulsive drug-taking behaviour."
The manual then proceeds to define tolerance, withdrawal and compulsion, but claims
because dependence can be present without tolerance or withdrawal (e.g. cannabis
dependence) a further specification is required:
"The specifiers: With Physiological Dependence and Without Physiological Dependence, are
provided to indicate the presence or absence of tolerance or withdrawal." (DSM-IV, 1994).
The dependence potential of benzodiazepine medication was not taken seriously during the
1960s and 1970s. Marks (1978) examined a significant amount of published research from
this period and concluded that the risk of dependence following benzodiazepine use was very
low, a conclusion that was out of step with guidelines published by the CRM (1980). This
document brought to attention to the potential to develop withdrawal symptoms even with
short-term usage, with the result that stricter prescribing guidelines were introduced. An
abundance of research followed during the 1980s, which demonstrated that not only was
dependency a possibility following high-dose usage of benzodiazepine medication, but that
therapeutic doses could also produce dependence. Withdrawal syndromes, regardless of
whether an individual was withdrawing from high-dose misuse or low-dose use, were found
to be the same (Hallstrom and Lader 1981).
Prevalence rates of benzodiazepine use
In the published literature there exists an abundance of reported prevalence rates for
benzodiazepine use, of which many vary considerably. The following four studies are cited
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because they were all concerned with prevalence rates in general practice populations and
are relatively up-to-date.
Zandstra et al (2002) assessed the effects of employing various definitions of benzodiazepine
use and various observation periods on the prevalence rate of benzodiazepine use, across 31
general practice populations in the Netherlands (N = 80,315). Prevalence rates varied
between 2.2 per cent and 17.6 per cent. Among long-term benzodiazepine users
approximately 80 per cent were older than 45 years.
Wilcock et al (1999) surveyed thirty-four Cornish general practices (N= 172,278) and found
that 2.62 per cent of the population were in receipt of a repeat prescription for a hypnotic,
with females more likely than males to be receiving hypnotic medication (3.45 per cent vs.
1.7 percent). This study revealed that hypnotic prevalence is clearly associated with older
age. Combining sex a repeat prescription rate of 4.61 per cent is reported in the 65 to 74-
year-old group, 9.14 per cent in those aged 75-84 years, and 16.42 per cent for those aged
over 85.
Escriva et al (2000) examined the prevalence of benzodiazepine use in a Spanish primary
care sample (N = 7356) and found a prevalence rate of 7.7 percent; 42 per cent of these
patients had been taking benzodiazepines for over 1 year.
A cross-sectional audit of general practice patients in Italy by Barburi et al (1998) assessed
long-term benzodiazepine use. The study involved twenty-six general practitioners who
provided details of all their patients that were taking benzodiazepines. The prevalence of
benzodiazepine use was 14.0 per cent, while the prevalence of daily use for 12 months or
more was 4.7 per cent.
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Prescribing guidelines for benzodiazepines
In 1980, an article was published in the British Medical Journal that was to be frequently
cited in future publications. The article was a report of a review carried out by the
Committee on the Review of Medicines (CRM) and was titled "Systematic review of the
benzodiazepines". The significance of this particular review was in the guidelines it
proposed for the data sheets on the most commonly used benzodiazepines. These new
guidelines were based on an examination of the efficacy and safety of benzodiazepine drugs
by the CRM. These guidelines drawn up over 20 years ago have remained virtually
unchanged to date.
Efficacy
The CRM reported that "all benzodiazepines were efficacious in the short-term treatment of
symptoms of anxiety and in insomnia" (p.910), although in terms of efficacy it stated that
there was no evidence to support the use of one benzodiazepine in preference to another in
the treatment of anxiety or insomnia. The committee also stated that benzodiazepines were
"unsuitable" for the treatment of conditions such as depression or tension headaches because
they had no antidepressant or analgesic properties.
The CRM stated that they were particularly concerned that there was a lack of evidence of
efficacy to support the long-term use of benzodiazepines in the treatment of anxiety and
insomnia. They cited evidence from a study carried out by the White House Office of Drug
Policy and National Institute on Drug Abuse (1979), which found that sleep laboratory
studies demonstrated that most hypnotics do not assist sleep following 3-14 days of
continuous use. In addition, the CRM said that there was a lack of evidence that




The CRM reported that they were concerned about the high numbers of repeat prescriptions
for benzodiazepines "in spite of the lack of satisfactory clinical studies establishing long-
term efficacy" (p.911). They highlighted the problem of withdrawal symptoms and advised
that benzodiazepine prescriptions be limited to short-term use, be withdrawn gradually and
only be used at doses within the therapeutic range (whenever possible). The committee also
drew attention to the problems of daytime sedation, the effect on reaction times and the
potentially dangerous interaction with alcohol.
Finally, the CRM highlighted the potential for more serious reactions in the elderly, in
particular, the slower elimination of benzodiazepines in elderly people, which has
implications for the use of the longer-acting drugs for insomnia. The data sheets recommend
that "half the normal adult dose may be sufficient for a therapeutic response in the elderly"
(p.912).
In 1988 the Committee on Safety of Medicines added a further recommendation that
benzodiazepines should not be used for more than 4 weeks, and then at only the lowest
possible dose to control symptoms. Subsequently, The Department of Health (1992) and
the British Medical Association (1993) have also discouraged the long-term use of
benzodiazepines.
Current prescribing guidelines for diazepam, nitrazepam and temazepam
DIAZEPAM
Dose: by mouth, anxiety, 2 mg 3 times daily increased if necessary to 15-30 mg daily in divided
doses; ELDERLY (or debilitated) half adult dose. Insomnia associated with anxiety, 5-15 mg at
bedtime.
NITRAZEPAM
Dose: 5-10 mg at bedtime; ELDERLY (or debilitated) 2.5-5 mg.
TEMAZEPAM
Dose: 10-20 mg at bedtime, exceptional circumstances 30-40 mg; ELDERLY (or debilitated) 10
mg at bedtime, exceptional circumstances 20 mg.
(Source: British National Formulary 2002)
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The adverse effects of benzodiazepines
Research has shown that benzodiazepine medication can have adverse effects on cognitive,
psychomotor and psychological functioning (Lader 1999).
Cognitive effects
Benzodiazepines can cause memory problems. A number of studies have shown that
following the administration of benzodiazepine medication the ability to learn new
information is impaired. It is said that benzodiazepines disrupt the process of taking
information from short-term stores into long-term memory storage (Curran 1991). Therefore,
an individual given a dose of a benzodiazepine will be able to remember immediate
information and information before the drug was taken, but they will have more difficulty
remembering information given to them whilst the benzodiazepine is active in their system
(anterograde memory). Dramatic effects are demonstrated when single doses are given to
individuals who do not normally use benzodiazepines. However, reduced effects are also
found in those individuals that receive repeated doses, suggesting that some tolerance to this
effect does develop but that it is incomplete and will vary according to the individual (Lader
1999).
Anterograde amnesia is increased with increased dose, faster absorption and higher potency
benzodiazepines. Older adults are most sensitive to memory effects by benzodiazepines, but
often their memory problems are blamed on ageing or may lead to a misdiagnosis of
dementia.
It is argued that the increased sensitivity of older adults to memory problems resulting from
benzodiazepine use is, in part, attributable to their lower baseline performance. In addition,
benzodiazepines have been shown to be the drugs most likely to exacerbate an underlying
dementia (Miller 1997). However, it is suspected that cognitive impairment in older adults
12
may develop insidiously and manifest as a complication following a long period of
benzodiazepine use, therefore; problems are not always linked to the drug.
Laboratory experiments have sought to establish which benzodiazepines have increased
amnesic effect and impact on reaction time. Table 2 gives a summary of a selection of the
published research in this area.
In addition, it is widely accepted that alcohol has powerful amnesic properties, in
combination with benzodiazepines, serious effects on memory and related cognitive function
have been observed (Subhan and Hindmarch 1983). Benzodiazepines are thought to
potentiate the action of sedative CNS depressants such as alcohol. This interaction is of
significance because the two drugs are often taken together.
Table 2: Summary of research evidence for memory impairment and decreased reaction time
resulting from benzodiazepine use
Hindmarch 1990 Diazepam 5 mg demonstrated a significant impairment (with respect to
control subjects) on recall tests and digit span memory tasks. Diazepam 10
mg significantly impaired a paired associate learning task. Diazepam 20 mg
produced a significant impairment on recognition tasks.
Gudgeon
and Hickey
1981 Diazepam 10-30 mg was found to significantly impair reaction time.
Gier et al 1981 Diazepam 5-20 mg per day significantly impaired overall driving





Diazepam 10 mg was found to significantly impair brake reaction time.
Betts and
Birtle
1982 Temazepam 20 mg was found to significantly impaired gap-judging ability.
Alford and
Hindmarch
1987 Nitrazepam 5 mg was found to significantly increase brake reaction time as
well as impair performance on other tests ofmotor car handling; the
morning after initial and repeated nocturnal doses
Murphy et al 1982 Nitrazepam 2.5 mg after four consecutive nights significantly impaired a
card sorting task in a group of elderly patients; by comparison, an equivalent
dose of triazolam had no effect.
Skegg et al 1979 A prospective study carried out in the UK estimated the risk of an accident
involving death or injury to be 4.9 times greater when prescribed
benzodiazepines are present.
Neutel 1995 Reported a "several-fold excess risk" for hospitalisation resulting from road






Elderly people taking benzodiazepines are significantly more likely to have
an injurious motor accident.
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Psychomotor effects
Psychomotor effects have been corroborated in laboratory experiments and in real-life
driving experiments. Ataxia, lack of coordination and vertigo have been demonstrated
(Miller 1997).
In their study examining benzodiazepine use among older adults in the community, Kirby et
al (1999) said, "Benzodiazepines with a long duration of action are particularly likely to
accumulate and therefore have a greater potential for sedative effects and psychomotor
impairment." (p.280). Accumulation is explained by reduced clearance in older adults, which
gives rise to higher plasma concentrations.
Of particular concern is the finding that older people have a significantly increased risk of
falling (Tinetti et al 1988) and of sustaining hip fractures (Ray et al 1989). The specific
problems of benzodiazepine use with older adults will be considered further in Chapter 4.
Psychological effects
Sedation is the desired effect of a benzodiazepine taken at night for sleep problems, but
when a benzodiazepine is taken during the day for generalised anxiety or panic disorder,
sedation is an unwanted side-effect. Sedation occurs in approximately one-third of patients
prescribed benzodiazepines for anxiety disorders (Salzman 1992). Also euphoria can be
experienced, especially with particular benzodiazepines such as diazepam. These effects are
observed particularly when the benzodiazepine is first commenced, but will be significantly
less noticeable after 1 or 2 weeks of daily use. Many patients report that the feeling of
sedation appears to "wear off', although often it is that they have stopped noticing the
sedation. Long-acting hypnotics, taken at night for sleep, are said to produce residual
sedative effects for a large proportion of the following day (Lader 1999).
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Many studies have linked suicidal thinking and suicide attempts to benzodiazepine use
(Zisook and DeVaul 1977; Miller and Gold 1991), adding weight to the proposal that
benzodiazepines can produce deterioration in mood. It has been postulated that because
many patients present with features of both depression and anxiety, a reduction in anxiety
following administration of benzodiazepines will result in the depressive features appearing
more apparent. It is also suggested that in some patients the euphoriant effects of
benzodiazepines can disguise depressive symptomatology (Lader 1999). However, there are
studies that argue that benzodiazepines do not induce or reduce depression.
Deterioration in affect and social behaviour in long-term benzodiazepine users has been
noted by observers but not by the individuals themselves (Griffiths et al 1983). This finding
suggests that effects of benzodiazepines may not always be reliably elicited by self-report.
Finally, the use of benzodiazepines to treat stress and bereavement reactions has been found
to result in the suppression of traumatic memories, for example physical and sexual abuse.
Such traumatic memories can be vividly evoked when the benzodiazepines are withdrawn,
often years later (Risse et al 1990). Similarly, benzodiazepines can delay the normal post¬
traumatic stress reaction (Bond 1990).
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Chapter 2: Insomnia and the use of benzodiazepines
Prevalence of insomnia
Insomnia usually means difficulty in falling asleep, disturbed sleep or the experience of
sleep, which leaves an individual feeling less than refreshed and feeling tired the next day.
The reported prevalence rates of insomnia vary across studies which predictably suffer from
discrepancies in the definition of insomnia. Crook et al (1987) reported that up to 40 per cent
of individuals over the age of 65 years complain of disturbed sleep. A Gallup Poll survey
(1991) carried out for the National Sleep Foundation reported that 36 per cent of the
American adult population said that they had problems with sleep. Twenty-seven per cent of
this group said that it was occasional and the other 9 per cent said that they had a chronic
sleep problem. More recently Smith et al (2002) reported that 10-15 percent of adults report
persistent sleep problems.
Many population-based surveys have reported that the prevalence of poor sleep increases
with age. However, an important consideration related to this finding is the extent to which
age-related declines in physical health contribute to the reported increase in sleep difficulties.
This would also include the contribution of various medications taken to control such
physical health problems. A study by Bliwise et al (1992) adjusted for such confounding
variables when reporting the prevalence of disturbed sleep in a population, ages 50-65 years.
This study found low prevalence of self-reported trouble falling asleep every night or almost
every night. Bliwise et al (1992) claimed their findings were lower than most previous
published studies and state "This implies that when overall physical health factors are taken
into account a decline in sleep quality is not necessarily an inevitable component of ageing
per se". (p.49).
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Longitudinal studies of insomnia have attempted to provide information about the stability of
insomnia over time. In one study Mendelson (1995) found that "most" patients with chronic
insomnia were found to be suffering from the same symptoms 64 months later. In another
study Ganguli et al (1996) found that two out of every three older patients that reported
insomnia at baseline, continued to report insomnia at 2-year follow-up.
Demographic features associated with insomnia
The following findings are commonly reported demographic features of insomnia:
• Insomnia complaints increase with age (Gallup Organisation 1991).
• Women report more insomnia than men (Mellinger et al 1985).
• Single individuals are more likely to report insomnia than individuals that are married
(Karacan and Williams 1983).
• Insomnia is reported more often in individuals of lower socioeconomic status than
individuals of higher socioeconomic status (Habte-Gabr et al 1991).
Causes and types of insomnia
The causes of insomnia are broadly categorised as physical, physiological, psychological,
psychiatric, and pharmacological (Beaumont 1990). Insomnia is usually classified as
transient (lasting a few days), short-term (lasting 1-3 weeks) and long-term (lasting more
than 3 weeks). The main differentiation lies between transient and/or short-term and long-
term insomnia. Usually, those individuals with transient insomnia are found to have a history
of normal sleep prior to a precipitant, the resolution of which results in the return of normal
sleep. A wide variety of situations and conditions may provoke transient/short term
insomnia.
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• Environment related include: unfamiliar sleep environments e.g, noise, temperature,
sleep surface, sleep position.
• Stress related: life events.
• Sleep schedule related: disruption of circadian rhythms (e.g. jet lag, shift work).
• Drug related: Drug discontinuation or drug initiation.
(Roehrs et al 1994).
Chronic long-term insomnia is more usually secondary to other conditions such as physical,
psychological or psychiatric conditions. In such cases careful consideration of differential
diagnosis is important. When insomnia is clearly the primary problem and not secondary to
another condition it is referred to as "Primary Insomnia" (DSM-IV 1994). This classification
does not mean that the individual is free from any other psychiatric or medical conditions,
but that these other conditions are not the cause of the insomnia. Primary insomnia includes
some of the less common sleep disorders which usually require more specialised treatment
from a sleep disorders clinic; examples of such types of sleep disorders would include, sleep
apnoea/hyponolea syndrome, narcolepsy, penodic limb movement syndrome.
The effect of age on sleep requirement
As mentioned above, as a group, it is older adults that present more frequently with
complaints of insomnia, with the result that medication is used most with this group (Clifit
1993). It is argued that older patients place an increase value in sleep because it reduces
loneliness and boredom and many older people do not appreciate that the number of hours of
sleep required by an individual reduce with age.
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Figure 1: Graph to show sleep requirements lessen with age (Clifit 1993)
The real difference in nocturnal sleep across age groups would appear to be as a result of
changes in patterns of sleep. In the older person daytime napping is most notable. When total
hours of sleep over 24 hours are calculated there is often very little difference between the
total hours of sleep of an older person and younger person.
However, sleep stage patterns do change with age. The percentage of rapid eye movement
(REM) sleep is inversely correlated with age (Benca et al 1992), but it is slow wave non
rapid eye movement (NREM) sleep that decreases most dramatically with age (Reynolds et
al 1991). NREM sleep comprises stages 1-4, with stage 4 being the "deepest" sleep. Stage 3
sleep and stage 4 sleep decrease with age until; for most older people, stage 4 sleep is absent.
Because older people experience very little of the "deeper" sleep stages, this is a likely
explanation for their more frequent nocturnal awakenings.
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The use of benzodiazepine hypnotics for insomnia
The first psychotropic drugs to be used for sedation were the bromides (1870s). By the turn
of the century these drugs were replaced with barbiturates following the introduction of
barbitone (1903). The first benzodiazepine marketed as a hypnotic was nitrazepam (1965).
Since the 1960s, benzodiazepines have remained the most widely prescribed drugs for sleep
problems. Whilst short-term use of benzodiazepine hypnotics are very effective in inducing
sleep, the sleep they induce is not the same as natural sleep. Benzodiazepines reduce sleep
onset, decrease nocturnal awakenings and therefore increase total sleep duration. However,
they alter normal sleep pattern (sleep architecture).
Stage 2 sleep (which is fairly light sleep) is increased and accounts for most of the increase
in sleep duration. However, stages 3 and 4 and REM sleep are reduced (Wheatley 1981).
These typical changes in sleep stages occur for most patients, although some variation is
observed according to dosage, the length of time an individual has been in receipt of
benzodiazepines, type of benzodiazepine and age.
A meta-analysis of benzodiazepine use in the treatment of insomnia carried out by Hobrook
et al (2000) analysed data from 45 trials, representing 2672 subjects. Analysis of sleep
records revealed that when compared with placebo, benzodiazepines reduced sleep latency
by 4.2 minutes (non-significant). This figure differed from the self-reported estimates of
sleep latency, in that the patients reported that sleep latency was reduced by 14.3 minutes
when benzodiazepines were used. Compared with placebo, benzodiazepines significantly
increased total sleep duration by 61.8 minutes. The meta-analysis also found that patients
receiving benzodiazepine treatment reported adverse effects, which included daytime
drowsiness, dizziness or light-headedness, in addition benzodiazepine use was associated
with cognitive impairment. However, these adverse effects did not translate into increased
discontinuation rates.
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In another meta-analysis (Smith et al 2002) pharmacotherapy was compared with behaviour
therapy for persistent insomnia; 21 studies representing 470 subjects were analysed. The
meta-analysis concluded, "overall, behaviour therapy and pharmacotherapy produce similar
short-term treatment outcomes in primary insomnia" (p.5). Comparison of outcome variables
found the following treatment effects:
• Sleep latency was reduced by 30 percent by pharmacotherapy compared with a 43 per
cent reduction by behavioural interventions.
• Both treatments reduced nocturnal awakenings by one.
• Wake time following sleep onset was reduced by 46 per cent with pharmacotherapy and
56 per cent with behaviour therapy.
• Pharmacotherapy increased total sleep duration by 12 per cent and behaviour therapy
increased total sleep duration by 6 per cent.
• Pharmacotherapy improved sleep quality by 20 per cent and behaviour therapy improved
sleep quality by 28 per cent.
(Smith et al 2002).
Tolerance to benzodiazepine hypnotics is reported to take place more quickly than the
anxiolytic drugs (Aston 1994). The decision to select long-term or short-term hypnotics has
been much debated as each has advantages and disadvantages over the other. Short half-life
hypnotics such as temazepam are less likely to leave a patient feeling "hung over" the next
morning, a common feature of nitrazepam, which has a long half-life. But the problem with
the more rapidly eliminated benzodiazepines such as temazepam is that of rebound effects.
Rebound effects can cause early morning wakening and anxiety during the following day
because the drug has been quickly eliminated from the body. It is not unusual to find patients
increasing their nightly dose of temazepam or taking another dose during the night when
they wake up. Problems with the longer-acting benzodiazepines such as nitrazepam include
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the residual effects, especially in older adults, which are associated with impairments of
performance tasks the next day. Residual effects arise because of incomplete elimination of
the drug and/or their pharmacologically active metabolites, in some cases resulting in
accumulation in the body.
The UK Committee on Safety of Medicines (1988) and the Royal College of Psychiatrists
(1988) recommend that benzodiazepines should only be prescribed for insomnia when "it is
severe, disabling or subjecting the individual to extreme distress". Nevertheless, prescribing
rates have remained fairly constant despite a reduction in the prescribing rates of anxiolytics.
Recommended dosage schedules are show below in Table 3.
Table 3: Rational use of benzodiazepines in insomnia
Type of insomnia Dosage and administration
Transient insomnia (e.g. disruption of
circadian rhythm)
1-2 nights only. Minimal dosage (usually not
more than diazepam 2-5 mg or equivalent)
Short term insomnia (e.g. temporary
environmental stress
Not for more than 2 weeks. Intermittent is
possible (1 night in 2 or 3 nights). Minimal
effective dosage (start with small dose,
increase if needed, usually not more than
diazepam 10 mg or equivalent)
Chronic insomnia (e.g. secondary to physical,
psychological or psychiatric causes)
Treat primary cause first. Intermittent
treatment if possible. Not more than 2 weeks
(course may be repeated after an interval).
Minimal effective dosage (as above)
(Source: Aston 1994)
Medical conditions and the effect on insomnia
Insomnia often develops as a result of medical conditions that cause pain and discomfort. In
addition, many physical conditions evoke an emotional response, which can give rise to
anxiety and depression. Emotional responses such as anxiety can further exacerbate
symptoms of a physical condition, as demonstrated in painful conditions such as arthritis or
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duodenal ulcer. Many medical conditions such as cardiovascular and pulmonary disorders
and thyroid dysfunction are shown to cause changes in sleep architecture (Kales and Kales
1984). In addition, a variety of medications can cause insomnia, either as a result of
administration or withdrawal. Certain drugs have a direct effect on the central nervous
system and others cause insomnia through their side-effects.
A study by Kuppermann et al (1995) examined the prevalence of sleep problems and their
correlates in a working population (mean age 36 years). Two groups were compared;
individuals reporting no current sleep problems and individuals reporting sleep problems (N
= 588). Of the range of physical conditions reported by respondents across both groups, four
conditions were found to feature at significantly higher prevalence rates in the group that had
sleep problems. In addition, a screening instrument for mental health problems (Mental
Health Index) revealed that the group with sleep problems also reported significantly higher
symptomatology indicative of mental health problems. Table 4 reports the prevalence of the
significant correlates of sleep problems.










8.5 per cent 16.2 per cent *
Headaches 15.2 per cent 43.7 per cent *
Muscle pain 18.8 per cent 37.0 per cent *
Neck or back pain 24.9 per cent 44.2 per cent *
Possible mental health
conditions 10.4 per cent 42.0 per cent *
(* Significantly higher than group one)
Source: Kuppermann et al (1995)
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The Kuppermann et al (1995) data highlight the predominance of pain or discomfort as a
feature of those physical conditions that contribute most to poor sleep.
Another study examined correlates of insomnia in patients with chronic illness (Katz and
McHorney 1998). In this study, the mean age of respondents (N = 3445) was 54 years. The
following list of conditions were found to be significantly associated with insomnia:
This study also reported that "there was no significant association between age and insomnia
after controlling for the presence of chronic conditions." (p.l 103).
In summary, it would appear that disruption to sleep arises from a complex interaction of
physical and emotional factors. According to the published research, the experience of pain
associated with many medical conditions can both exacerbate anxiety and depression or be
exacerbated by anxiety and depression, both of which add to sleep difficulties. In addition to
painful conditions there is a range of other chronic medical problems that can cause
disrupted sleep. The medications used to treat such conditions can further contribute to sleep
disruption. It would be reasonable, therefore, to postulate that with advancing age, health
problems will play an increasingly significant role in insomnia, because of the correlation















The role of psychiatric factors in insomnia
The relationship between insomnia and psychiatric disorders is well researched, especially as
diagnostic criteria for some psychiatric disorders are characterised by the inclusion of sleep
disturbance symptoms. It has also been proposed that psychiatric disorders are frequently
under-diagnosed in individuals presenting with insomnia (Tan et al 1984). Following an
examination of epidemiological data, Ford and Kramerow (1989) suggested that, of those
individuals reporting insomnia, up to 57 per cent may have a psychiatric condition or present
with a psychiatric condition, within a year.
The finding that chronic insomnia can be a causal factor in psychiatric disorders is explained
in terms of the presence of chronic insomnia becoming a stressor, a common precipitant in
the development of psychiatric problems. Table 5 reproduces data from a study by Breslau et
al (1996) which examined the prior history of sleep disturbance and subsequent onset (during
a 3A year follow-up period) of psychiatric disorders in a sample of young adults (TV =979).
Table 5: Incidence and gender adjusted odds ratios of new psychiatric disorders by prior
history of insomnia
Insomnia No insomnia OR (95 per centCI)
Major depression 15.9 per cent 4.6 per cent 3.95 (2.22-7.00)
Any anxiety* 13.7 per cent 7.1 percent 1.97(1.08-3.60)
Alcohol abuse 7.1 per cent 4.7 per cent 1.72 (0.85-3.52)
Drug abuse 4.1 per cent 0.6 per cent 7.18(2.13-24.17)
Nicotine dependence 17.8 per cent 8.2 per cent 2.41 (1.46-3.97)
(♦Any anxiety includes GAD, panic disorder, OCD and any phobia)
Source: Breslau et al 1996
One could speculate that the development of drug problems is a more likely outcome in a
younger population, from which these data were gathered.
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Mood disorders
The incidence of disturbed sleep in mood disorders is pervasive across all subtypes and is
therefore a diagnostic symptom for each. It is considered unusual to find a patient with mood
disorder who does not experience disrupted sleep-wake patterns, with the most commonly
reported being insomnia rather than hypersomnia.
Major depression is associated more often with early morning awakenings and dysthymic
disorder with frequent arousals and sleep onset difficulties (Walsh et al 1994). Not only is
insomnia a feature of depression, but also it has been shown to be a predictor of the
development of mood disorders. A study by Livingston et al (1993) sought to answer the
question - "Does sleep disturbance predict depression in elderly people?" The following
extract summarises the main finding of this study:
"The best predictor of future depression in elderly people who were not depressed was
current sleep disturbance. In the presence of current sleep disturbance, the traditional
predictors of depression - being a woman, having a disability, being unmarried, living alone
and being older - did not contribute further. This study has shown that sleep disorder is
associated with pathology." (p.445)
Anxiety disorders
The published research would appear to suggest that within samples of individuals with sleep
difficulties the prevalence of anxiety disorders is lower than for mood disorders. Walsh et al
(1993) argues that anxiety symptoms are frequently considered secondary to mood disorder
symptoms. He argued that when depressive symptomatology is present, the resulting
diagnosis will usually be one of affective disorder.
Nevertheless, two anxiety disorders include sleep disturbance as a diagnostic symptom.
Patients with generalised anxiety disorder often have sleep initiation difficulties. Patients
with post-traumatic stress disorder also report difficulty in sleep initiation but also
experience sleep maintenance problems, very often because of bad dreams or nightmares.
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Somatoform disorders
The most common somatic problems are reported to be insomnia, headache, irritable bowel
syndrome and hypochondriasis (Salkovskis 1999). The common feature in insomnia related
to somatisation is that of worry and subsequent increased arousal. There is a paucity of
published research reporting the prevalence of somatisation in insomnia and it is possible
that somatisation is often labelled as generalised anxiety. Mellinger et al (1985) reported that
37 per cent of patients with severe insomnia and 19 per cent of patients with mild insomnia
scored highly on a somatic anxiety scale, in contrast with 6 per cent of good sleepers.
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Chapter 3: Anxiety and the use of benzodiazepines
Anxiety comprises three systems: (i) physical symptoms (ii) cognitions and (iii) behavioural
changes. These three systems are closely inter-related, with each affecting the development
and maintenance of the others.
Anxiety states form a number of recognised anxiety disorders, each having their own
diagnostic criteria (found in DSM-IV and ICD-10). Generalised anxiety is the most common
of the anxiety disorders. Prevalence rates vary across published research, although some
consistency is observed. For example, from a general population survey, Weissman and
Merikangas (1986) reported 1-year prevalence rate for generalised anxiety disorder of 3-6
per cent and a 1-year prevalence rate for panic disorder in the range of 0.5-3 per cent.
Similarly, from a general population study, Uhlenuth et al (1983) estimated prevalence of
generalised anxiety disorder to be 6.4 per cent with prevalence of panic, agoraphobia and
other phobias to be 3.5 per cent.
In some disorders, such as post-traumatic stress disorder (PTSD), the precipitant to the
development of anxiety is clearly a major life event(s) or trauma. However, for others the
reasons for their development are less evident. Vulnerability to stress through genetic and
environmental factors can predispose individuals to anxiety problems and very often anxiety
symptoms can be traced back to childhood and young adulthood. However, there are
exceptions to this; for example, specific phobias often develop without any prior history of
anxiety.
The management and treatment of anxiety regardless of classification or cause is most
effectively carried out using psychological rather than pharmacological measures (Hackman
1993). Two anxiety disorders more frequently treated with benzodiazepines include
generalised anxiety disorder (GAD) and panic disorder (PD).
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Anxiety disorders and older adults
The average age of the participants in the current study is 72 years, therefore consideration
of anxiety in this age group is particularly relevant. Recent studies suggest that anxiety
disorders are the most common mental health disorders in older people (Blazer 1997, 2002).
Community based prevalence estimates of anxiety in older adults suggest that 11.4 per cent
of adults over 55 years meet the criteria for an anxiety disorder in 1 year (Flint 1994)
Woods (1996) argued that some specific phobias are particularly common to older adults.
For example, fear of crime, fear of dying and fear of falling. Fear of falling is the most
prevalent fear of older people (Howland et al 1993).
The use of benzodiazepines for anxiety
Prescribing recommendations for the use of benzodiazepines in the treatment or control of
anxiety are similar to the prescribing guidelines for benzodiazepine use with insomnia. The
Committee on Safety of Medicines (1988) advised that benzodiazepines "are indicated for
the short term relief (2-4 weeks only) of anxiety that is severe, disabling or causing
unacceptable distress". Aston (1994) suggested that this advice had been acted upon in the
United Kingdom, reporting that yearly prescriptions for anxiolytic benzodiazepines have
reduced from a peak of 18 million in 1978, to below 10 million by 1994.
Benzodiazepines, as in insomnia, provide only symptomatic relief in the treatment of
anxiety. The literature highlights the use of specific benzodiazepines for generalised anxiety
and panic disorder.
Many clinicians believe that the use of benzodiazepines in the long-term treatment of GAD
is justified because this disorder results in significant functional impairment (Rosenbaum and
Gelenberg 1991). The benzodiazepine of choice for GAD is one that provides a smooth onset
of action, with relatively slow absorption and elimination rates, so that fluctuations in plasma
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concentrations are minimised. However, as will be discussed in Chapter 4, this type of
benzodiazepine is potentially more problematic for older adults, because benzodiazepines
with a longer elimination half-life are more likely to be associated with cognitive
impairment, falls and road traffic accidents in the elderly.
A number of benzodiazepines have also been used in PD, as have tricyclic antidepressants
and monoamine oxidase inhibitors. Of the benzodiazepines used in the treatment of PD, the
literature reports that alprazolam is more successful than other benzodiazepines; alprazolam
is a high-potency benzodiazepine with a short elimination half-life. Nevertheless, according
to Sheeham et al (1984) as with other pharmacological treatments, cessation of medication in
PD is followed by relapse in 80 per cent of cases. This outcome leads to long-term use,
which can lead to dependence, tolerance and withdrawal symptoms. Psychological treatment
in the form of exposure work has been shown to reduce relapse and improve long-term
outcome in PD. However, it is important to be aware that there is evidence which
demonstrates that the simultaneous use of benzodiazepines can interfere with psychological
treatments (Marks and O'Sullivan 1989).
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Chapter 4: Older adults: relevant considerations
Reference to "older" adults in the current text uses the United Nations example, also adopted
by the World Health Organisation, of age 60 years to describe "older" people. However, it is
important to acknowledge that chronological age is not an absolute marker for the features of
ageing (WHO 2002).
Older adults are a growing section of society (Kinsella and Velkof 2001). Whilst this large
proportion of society should not be regarded as separate from younger adults, advancing age
brings particular challenges. These challenges include coping with general medical
conditions, the need for an increased amount of medication and psychosocial stressors such
as bereavement and isolation (WHO 2002). With regard to mental health problems, younger
and older adults are affected by many of the same disorders, although often prevalence, the
features of, and the course of mental health problems can differ.
Mental health problems in older adults
The Report of the Surgeon General (1999) reviewed mental health in older adults proposed
that the detection of mental illnesses is more difficult in older persons. The report stated:
"Many older individuals present with somatic complaints and experience symptoms of
depression and anxiety that do not meet the full criteria for depressive or anxiety disorders...
detection ofmental disorders in older adults is complicated further by high comorbidity with
other medical disorders." (p.340).
The published literature suggests that depressive symptoms are the most prevalent of mental
health problems (Report of the Surgeon General 1999). Beekman et al (1999) carried out a
review of community-based studies and reported an average prevalence of 13.5 per cent for
depressive symptomatology. However, the key issue in depression in older adults (as well as
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other psychiatric disorders) is that of under-diagnosis and under-treatment. Katon et al
(1992) examined the use of antidepressant medication for depression in older adults and
found that only 11 per cent received adequate antidepressant treatment, 34 per cent received
inadequate treatment and 55 per cent received no treatment.
In terms of the diagnosis of anxiety, a similar picture to that of depression is reported in that
many older adults present with anxiety symptoms that do not satisfy diagnostic criteria for
specific anxiety disorders, with the outcome that anxiety is left untreated. Katona et al (1997)
found such high rates of comorbid generalised anxiety with depression; they concluded that
depression should be considered whenever anxiety is observed in older adults.
Benzodiazepines and older adults
Despite the guidelines and the multinational trend towards reduced prescribing of
benzodiazepines, particularly anxiolytics, older adults continue to use prescribed
benzodiazepines at rates very similar to those they always have. Ticehurst (1995) said,
"After tobacco and alcohol, benzodiazepine consumption is associated with the greatest risk
of abuse and dependence in the elderly" (p. 187). According to Ancill and Carlyle (1993) the
most likely long-term benzodiazepine user is the elderly female.
Because anxiety in older adults can be difficult to differentiate from other conditions such as
depression, physical disability and cognitive dysfunction, it is of paramount importance that
the underlying cause of anxiety is established prior to commencing anxiolytic medication,
otherwise the cause may be masked and not adequately treated. However, it is in the
treatment of insomnia in older adults that benzodiazepines are most frequently prescribed.
Older adults are especially sensitive to the adverse effects of benzodiazepines and there are a
number of issues that are specific to the older adult population, which must be considered
when prescribing benzodiazepines to this group of patients.
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Drug metabolism
Drug absorption mechanisms change with ageing. In older adults higher brain
benzodiazepine levels are said to result from decreased protein binding and greater blood-
brain barrier permeability (Ancill and Carlyle 1993). In addition, drug accumulation arises
from declining lean body mass and slowed metabolism and excretion. However, it has been
shown that once tolerance has occurred, the extent of accumulation is not reflected by an
increase in sedation (Teboul and Chouinard 1990). This is a worrying feature of
benzodiazepine use with older adults because it allows accumulation to go unnoticed,
sometimes with serious consequences for this client group.
The effect of chronic illness
Kusserow (1989) reported that 80 per cent of adults over 65 years have one or more chronic
illnesses. Therefore, benzodiazepine prescribing in older adults should not occur in isolation
from their coexisting medical pathologies. Medical pathology and the medications used to
treat such conditions can have an impact on efficacy and toxicity of benzodiazepine
medication. According to Ancill and Carlyle (1993) cardiovascular, metabolic, hepatic and
renal pathologies can increase the risk of toxicity, but can also be an underlying cause of the
presenting anxiety.
The additive properties of benzodiazepines when used with other central nervous system
depressant drugs, is one of the most common forms of interaction between benzodiazepine
medication and other medications used to treat or control chronic illnesses in older adults.
Examples include alcohol, other hypnotic agents and some antidepressants, which can cause
varying degrees of sedation. In addition, benzodiazepines are also known to increase the
levels of certain drugs; one such example is digoxin, a medication prescribed for
cardiovascular problems (Bernstein 1988).
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Falls and hip fractures
A significant amount of published research has highlighted the problem of the increased risk
of falls (Sorok and Shimkin 1988), hip fractures (Ray et al 1989) and motor vehicle crashes
(Hemmelgarm et al 1997) in older people taking benzodiazepines. It is widely accepted that
the half-life of the benzodiazepine prescribed makes a significant contribution in this finding,
with longer half-life benzodiazepines believed to cause more accidents owing to longer
elimination times. Ray et al (1989) reported that the risk of fractures from falls when long
compared with short half-life benzodiazepines were used was 1.7 and 1.1 per cent
respectively. Falls in older age give rise to a higher risk of disability and death (WHO 2002).
Benzodiazepine use has also been linked to osteoporosis in older adults. It has been proposed
that benzodiazepines may act as chelators when combined with iron and this can affect
calcium intake, with the result that bone mineral reserves are depleted (Harrison and McNeill
1988).
Benzodiazepine choice
In summary, choosing which benzodiazepine to prescribe in the older adult client group is
complicated by the greater potential for adverse effects. As mentioned earlier the incidence
of hip fracture has been linked to the longer-acting benzodiazepines, such as nitrazepam and
flurazepam, owing to increased hang-over effects. The longer-acting benzodiazepines also
cause increased accumulation because of changes in drug metabolism with advanced age.
The use of short-acting benzodiazepines such as lorazepam and triazolam is not advisable on
a long-term basis following concerns of cognitive impairment and amnesic effects. Finally,
benzodiazepines can also interact with other medications used in the treatment of chronic
conditions.
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Therefore, Tinetti et al (1988) argued that the use of benzodiazepines warranted careful
consideration in the older adult population, especially if there was increased risk of
dementia, visual impairment, postural hypotension and neurological and musculoskeletal
disability.
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Chapter 5: The use of benzodiazepines in general practice
The general trend in prescribing rates for benzodiazepine medication by general practitioners
has shown a gradual decrease over the past 20 years (Simpson 1993). Nevertheless, despite
the magnitude of published evidence demonstrating the dependency potential of
benzodiazepines, the downward trend has been relatively slow. Wright (1991), in an editorial
about general practitioners and psychiatry, argued that the bulk of psychiatric and
psychological problems are seen and managed by general practitioners alone. He added that
many general practitioners have limited training in psychiatry and the problem of restricted
resources often afford them little recourse to make a referral to appropriate resources. This
does not excuse the over-prescribing of benzodiazepines but offers an explanation. Whilst
most general practitioners acknowledge that the use of benzodiazepine medication should be
avoided whereever possible, they often have little by way of alternative options.
Prevalence of long-term benzodiazepine use in community/general practice studies
A study by Rodrigo et al (1988) examined the health of long-term benzodiazepine users and
included prevalence rates of long-term use from a number of other studies. The Rodrigo et al
study reported prevalence of long-term use (mean 5 years) at 2.2 per cent in a practice
population of 3741. This finding was comparable to other studies reviewed by Rodrigo et al
which ranged from 1.6 per cent to 3.1 per cent; all were general practitioner samples.
However, these figures represent all adults in each general practice. Because the largest
group in receipt of benzodiazepines are older adults it is important to consider prevalence
rates in adults over 65 years.
Kirby et al (1999) reported a prevalence rate of benzodiazepine use in older adults of 17.3
per cent (N = 1701) in an Irish community sample. A longitudinal study by Taylor et al
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(1998) collected data from an urban sample in Liverpool on two occasions. Taylor et al
found that in the period 1982-83 the prevalence rate of benzodiazepine use in adults over 65
years was 12.8 per cent (,/V = 1070) and in the period 1989-91 the prevalence rate was found
to be 10.8 per cent (TV =5490).
Patient characteristics in primary care
Age
Simpson et al (1990a) reported the following age-band prevalence rates of long-term
benzodiazepine users, shown in Figure 3.













(Source: Simpson et al 1990a)
Physical health:
The Forth Valley GP Research Group (Simpson et al 1990b) examined three general
practices in central Scotland, comprising a total of 17,000 patients. A matched subsample
(age and sex) of long-term benzodiazepine users and controls were assessed for physical
morbidity, the authors concluded that:
"Patients receiving hypnotics only were older, had a history of more physical illness and had
received more non-psychotropic medication than patients receiving anxiolytics only." (p.22)
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The physical conditions found to be significantly more prevalent in long-term
benzodiazepine users were cardiovascular; gastrointestinal; genitourinary; respiratory;
central nervous; ear, nose and throat (Simpson 1990b), this finding reflects similar findings
reported in Chapter 2. However, it would appear that whilst physical morbidity is closely
linked to long-term benzodiazepine use across all ages, particular health problems across age
groups vary with the presence of a broader range of health problems found in older adults.
This is not particularly surprising when one considers that ageing is associated with the
development ofmore physical health problems.
There are occasions when benzodiazepines are indicated for a physical condition. The most
common example of which in the primary care setting would be in controlling muscle spasm
that causes pain or discomfort. However, as a psychotropic medication, it is in the treatment
of psychiatric and psychological problems that benzodiazepines are predominantly
associated.
Psychiatric problems
The two main problem areas for which benzodiazepines are prescribed in general practice
are anxiety and insomnia. As reviewed in Chapter 2 comorbidity with other psychiatric
disorders is common in long-term benzodiazepine users. Of particular significance is the
prevalence of depression, anxiety and somatisation which are often masked by insomnia.
The under-diagnosis of depression in general practice is common, particularly in older
patients (Unutzer et al 1999). The characteristics and problems associated with
benzodiazepine use in a primary care population are difficult to quantify because of the inter¬
relationship of causal factors. Research has also shown that sleep problems can predict
subsequent psychopathology, particularly depression. Faced with the range of possible
combinations of factors it is difficult to establish causal relationships when a patient presents
with more than one problem, such as anxiety, depression, insomnia, pain and discomfort, and
physical health anxiety. The use of benzodiazepine medication often serves to further
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complicate the relationship between these factors by masking symptomatology and creating
new symptoms by means of rebound, withdrawal and the effects of drug accumulation.
Reduction of long-term use of benzodiazepines in primary care
In a study of chronic benzodiazepine use in a primary care population, Bashir et al (1994)
asked general practitioners why they continued to prescribe benzodiazepine medication. The
two most commonly reported reasons given were (i) "because the patient wished to remain
on benzodiazepines" and (ii) "that it was too much of a struggle for the patient to come off
the tablets".
In a community survey of long-term daytime use of benzodiazepines, Wright et al (1994)
found that almost half their subject sample wished to continue taking their medication. In
addition, they found that the desire to stop using benzodiazepine medication varied across
age groups. A difference was demonstrated between patients over 60 years and those under
60 years, with those over 60 years significantly more likely to express a desire to continue
taking their medication. Similarly, Hawley et al (1994) found that patients from a general
practice population were "relatively old and exhibited a conspicuous lack of interest in
having any help with their chronic drug (benzodiazepine) use" (p.794). A further study by
Linden et al (1998) examined long-term, low-dosage use of benzodiazepines, and found that
two-thirds of a primary care sample (N= 122) rejected a drug-holiday proposal.
Although the published research reveals that benzodiazepine prescribing demonstrates a
downward trend, use of hypnotic benzodiazepines in the older adult population has remained
more static than the use of anxiolytic benzodiazepines in the general population. Morgan and
Clarke (1997) suggest the reason for this could be because benzodiazepines are used more
frequently as a hypnotic medication with older adults and the incidence of sleep problems is
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higher in older adults. Further evidence that anxiolytic use has reduced more rapidly than the
use of hypnotics, was demonstrated in a study by Taylor et al (1998). This longitudinal study
reported that during a 6-8 year period the prevalence of hypnotic benzodiazepine use in
adults over 65 years barely changed from 8.8 per cent to 8.5 per cent. The prevalence of
anxiolytic benzodiazepine use in adults over 65 years reduced from 5.5 per cent to 3.2 per
cent.
To conclude, despite well-established prescribing guidelines, which state that
benzodiazepines should not be used for more than 4 weeks, and then at only the lowest
possible dose to control symptoms, in 1995 Jago reported that 85 per cent of the 13.1 million
prescriptions written annually in the UK for hypnotic medication were for more than 28
days.
In summary, the research highlights that the largest cohort of benzodiazepine users in
primary care are older adults, of whom the vast majority take hypnotics for insomnia and
have done so for many years. This cohort is more likely to have diagnosed chronic health
problems for which they are in receipt of a range of medications. It is also likely that this
older cohort, as well as the rest of the benzodiazepine using population in primary care, will
have elevated levels of psychopathology. Finally, primary care recipients of benzodiazepine
medication would appear to be reluctant to reduce or stop taking benzodiazepines.
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Variables to be assessed in long term benzodiazepine users
The preceding chapters have endeavoured to introduce and review a proportion of the
breadth of research literature surrounding the benzodiazepines and have highlighted a range
of features and issues relevant to long-term benzodiazepine use in a primary care setting.
Based on this review, the prevalence and relationship of three key variables will be examined
in the context of long-term benzodiazepine use: dependence, psychopathology and insomnia.
In addition a fourth variable was selected which has not (to the author's knowledge) been
previously considered in relation to long-term benzodiazepine users: psychological
mindedness.
Dependency
Having established that benzodiazepine dependence is an important contributory factor in
patterns of benzodiazepine use, the consideration of dependency within the context of the
current study cannot be overlooked.
The participants in the pilot study frequently remarked that because their medication was
prescribed by a doctor it "must be safe" and that usually any suggestion that their
benzodiazepine medication could be "addictive" was rebuked. It would therefore be prudent
to avoid any use of the words "addiction" and "addict" in the present study.
In addition, because the daily benzodiazepines users in the pilot study reported that they had
never attempted to stop their benzodiazepine medication, it was quite likely that they had
never experienced withdrawal symptoms and would be unaware of the potential for this
occurrence. A measure of dependency that focused primarily on psychological dependence
and did not include items that emphasised withdrawal symptoms or questions about
tolerance was considered preferable. Also, because the participants might be defensive about
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the suggestion of dependency, these types of questions would need to be phrased in a non-
judgemental and non-threatening way.
Psvchopathology
The aim of the current study was to investigate the presence of a range of psychopathology
in benzodiazepine-using patients. This would include not only depression and general
anxiety but also other symptoms such as somatisation, which has rarely been considered in
previous studies of this type. Fuentes and Cox (2000) wrote that assessment of somatisation
was particularly relevant in anxious older adults "due to suggestions in the literature that
older adults may somatise their psychopathology" (p.301).
Insomnia
Insomnia is a key issue in the current study and is discussed at length in Chapter 2.
Assessment of sleep pathology is an important consideration.
Psychological mindedness
Psychological mindedness is introduced as a variable worthy of consideration in the current
study.
Chapter 5 examined benzodiazepine use in primary care and highlighted the finding that a
considerable proportion of long-term benzodiazepine users, usually older adults, are resistant
to consider cessation of their benzodiazepine medication. Similarly the pilot study, which
precedes this study, found that less than 50 per cent of participants were prepared to consider
stopping their benzodiazepine medication. Any one of a number of factors may explain an
individual's reluctance to reduce or stop using benzodiazepines, for example:
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• A belief that they would be unable to sleep without their sleeping tablets
• Psychological and/or physiological dependence
• Lack of awareness of the potential problems of long-term use
• Medication compliance
The pilot study also found that not all long-term benzodiazepine users took their
benzodiazepines every day, but that some users only took them when they felt they "needed
too".
The construct of "locus of control" may be relevant to the question of why some individuals
may decide to stop taking their benzodiazepine medication and others would not, and why
long-term benzodiazepine use does not necessarily mean daily use. Locus of control (Rotter
1966) is used to explain the extent to which a person perceives events/situations as being a
consequence of their own behaviour. In addiction research, the concept of locus of control
has been widely researched in an attempt to establish whether individuals high on internal
locus of control are better able to control their substance use than those individuals with high
external locus of control. The published literature in addiction research presents conflicting
reports regarding the usefulness of the Internal-External locus of control dimension (Davies
1992). However, the locus of control dimension does appear to have some value in
predicting behaviour change, especially in health settings. This has led to the development of
a number of different scales to measure perceived control and responsibility for individual
behaviour, with particular emphasis on health-related behaviours and beliefs.
A psychological variable that has at times been conceptualised in a similar way to locus of
control is that of psychological mindedness. For example, Rogawski (1982) states that "the
highest level of psychological mindedness is the ability to verbalise one's internal experience
as a product of one's own mind and passions and not as caused by, or the responsibility of,
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another" (p. 109). This description of psychological mindedness is similar to the way locus of
control has been conceptualised.
Psychological mindedness has long been considered relevant (by clinicians) in predicting
therapeutic outcome. However, it is a concept that has suffered from a lack of clear
definition and as such has given rise to a range of interpretation and has proved difficult to
operationalise. The origins of psychological mindedness are found in psychoanalytic
writings under "indications for psychoanalysis" (Appelbaum 1973). More recent attempts to
define psychological mindedness are reviewed by Hall (1992), who highlights the variation
in descriptive terminology. Nevertheless, the general theme is one of psychological
understanding of oneself.
Appelbaum's (1973) definition is probably the most frequently quoted definition in the
published literature on psychological mindedness, and is arguably the most comprehensive
yet succinct:
"A person's ability to see relationships among thoughts, feelings, and actions, with the goal
of learning the meaning and causes of his experiences and behaviour." (p.36).
Psychological mindedness was chosen for inclusion in the current study as, potentially, it
may explain differences in patterns of benzodiazepine use not otherwise explained by
psychopathology and insomnia. Contrary to the study of locus of control, psychological
mindedness has not been incorporated into studies of this type.
There are a limited number of measures to assess psychological mindedness, which have
been empirically tested. The author considered three of the better-known measures of
psychological mindedness (Conte and Ratto 1997), from which the Psychological
Mindedness Scale (PMS) was selected. The PMS was devised by Conte et al (1990) and
conceives psychological mindedness as the ability to access one's own and other's feelings




The introductory chapters of this thesis have endeavoured to introduce the main topic areas
associated with the long-term use of benzodiazepines in a primary care population. The
salient issues drawn from the published research include evidence that long-term use of
benzodiazepine medication results in dependence, tolerance, withdrawal symptomatology,
and reduced pharmacological efficacy. In addition, long-term use of benzodiazepines can
have adverse effects on cognitive, psychomotor and psychological functioning. As a result of
these problems, prescribing guidelines clearly discourage the long-term use of
benzodiazepines. However, whilst these guidelines have effected some reduction in long-
term use during the past 20 years, prevalence rates have reduced more slowly for hypnotic
benzodiazepine medication, especially in older adults, than for anxiolytic benzodiazepines.
This is particularly worrying when one examines the breadth of literature that reports the
potentially detrimental consequences of long-term benzodiazepine use with older adults.
In the primary care setting the most frequent use of benzodiazepine medication is found to be
with older adults that present with insomnia. The treatment of insomnia with hypnotics is
therefore considered in more detail than the use of anxiolytics for anxiety. In addition, the
evidence of significance physical health problems and psychiatric comorbidity in long-term
benzodiazepine users is an important and relevant issue.
Establishing causal and maintaining factors in long-term benzodiazepine use is beyond the
scope of this study. However, the intention of the study is to explore a number of hypotheses
derived from the issues highlighted in the literature review. These hypotheses seek to
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demonstrate a common psychological profile for this cohort, which could be used to inform
treatment options and future prescribing practice with primary care patients.
This research study differs from existing published studies because it incorporates a number
of different but potentially related variables. Previous studies have focused on a narrow
range of psychopathology associated with benzodiazepine use and have neglected the
possibility of confounding elements comprising long-term benzodiazepine use. This study
considers a wider range of variables involved in long term benzodiazepine use, including
insomnia, benzodiazepine dependence and relevant psychiatric disorders such as anxiety,
depression and somatisation. The study also examines the demographic features of the
sample in relation to each variable and acknowledges the potential influence of chronic
medical health problems and chronic pain.
In addition, the concept of drug "dependence" arising from the long term prescription of
benzodiazepines has rarely been considered in either older adult samples or primary care
samples, the current study combines both these cohorts.
Finally, the study aims to interpret the findings in terms of informing treatment options, in
particular the study introduces a relatively novel psychological variable with regard to
research in this area, that of psychological mindedness. In the current study psychological
mindedness is considered in relation to dependence and in relation to benzodiazepine users
willingness to consider treatment.
Hypotheses
Hypothesis 1:
(a) Those individuals in receipt of long-term repeat prescriptions for benzodiazepine
medication will show evidence of psychopathology, as measured by the Brief Symptom
Inventory.
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(b) Furthermore, psychopathology will predict benzodiazepine dependence, as measured by
the Severity of Dependence Scale.
Hypothesis 2:
Those individuals in receipt of long-term repeat prescriptions for benzodiazepine medication
will show evidence of poorer sleep quality, as measured by the Pittsburgh Sleep Quality
Index.
Hypothesis 3:
Those individuals exhibiting poorer sleep quality, as measured by the Pittsburgh Sleep
Quality Index, will have increased levels of psychopathology, as measured by the Brief
Symptom Inventory.
Hypothesis 4:
Those individuals exhibiting greater dependence on benzodiazepine medication as assessed






The aim of the study was to establish whether a common psychological profile prevails
among individuals in a primary care population who have been taking prescribed
benzodiazepine medication for longer than the recommended period of time. The study
included patients who were prescribed benzodiazepines by their general practitioners for
either anxiety or sleep problems. Detailed information was gathered with regard to the
psychopathology (including anxiety, depression, somatisation, phobic anxiety, inter-personal
sensitivity, insomnia and benzodiazepine dependence) of this patient group.
It was anticipated that these data would be beneficial for two reasons. First, they would
inform the psychological treatment of those individuals in the study, should they request help
to stop using benzodiazepines. Second, these data could suggest alternative treatment options
for future patients, that present to their general practitioners with difficulties that may lead to
the repeat prescription of benzodiazepine medication.
Study design
The research design employed was a cross-sectional survey of an identified population using
standardised questionnaires. The design therefore utilised between-subject measures to
examine the relationships between subjects on a number of variables.
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The purpose of the enquiry was to portray an informed psychological profile of this patient
group.
The study involved administering a number of psychological questionnaires to each
participant. The questionnaires that were used have well-established validity and have been
widely used for both research purposes and in clinical practice.
Participants
In total, 84 participants took part in the study; Table 6 gives demographic details according
to sex for age, employment status and whether participants lived alone or with another
person.
Table 6: Characteristics of the sample: age, sex, employment and whether living alone
Female (A=56) Male (A =27)
Age in years Mean 73.03* 70.77*
SD 12.65 13.48
Range 36-93 41-92
% of total sample
Employment Employed 6 2 9.5
Status Unemployed 7 7 16.7
Retired 44 18 73.8
Living alone Alone 31 7 45.8
or with Not alone 25 20 54.2
someone




A semi-structured interview was carried out with each participant. The purpose of the
interview was to gather information from the participants about their history of
benzodiazepine use, pattern of use and the factors that might have influenced their
benzodiazepine use. The interview also provided an opportunity for the researcher to collect
selected demographic details. (The interview schedule can be found in Appendix 2.)
Questions about the history of benzodiazepine use:
• "What was the original reason you were prescribed benzodiazepine medication?"
• "Can you remember who gave you your first prescription? (Ifyes) "Who?"
• "How long have you been in receipt of your prescription?"
Questions pertaining to a participant's pattern of benzodiazepine use:
• "What is the current reason(s) for your use of benzodiazepine medication?" (If the
participant gave more than one reason they were asked to rate them)
• "Do you take your tablets as prescribed by your doctor?" "For example is that everyday
or just at certain times?" "If at certain times when would that be?"
• "Would you like to stop or reduce your BZD tablets?" (Ifyes) "What help do you think
you would need?" "For example who do you think could help?" (Ifno) "What are your
reasons for not wanting to change you current use ofBZD?"
Questions pertaining to factors that might have influenced a participant's benzodiazepine use
or demonstrate a dependence on another substance:
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• "Do you have any medical health problems?" (Ifyes) "Are you taking any medication?"
• Do you have any painful conditions? (Ifyes) "What?" "How long?" "Pain relief?"
• "Do you drink alcohol?" (Ifyes) "How much?" "For example what would you drink in
an average week?" "If you drank more alcohol in the past was it ever a problem?" "For
example do you think you ever drank too much?"
• "Do you smoke cigarettes?" (Ifyes) "How many?" "How long have you smoked?" "If
you smoked in the past, when and why did you stop?" "How long did you smoke for?"
Demographic information:
Information elicited from the participant during the interview included employment status
and marital status. If a participant was not working they were asked how long they had not
been in work or had been retired. If a participant lived alone they were asked how long this
had been the case.
The remaining demographic details were collected from the practice GPASS1 database.
These included:
• Sex
• Date of birth
• The length of time the participant had been in receipt of their benzodiazepine
prescription.
• The type of benzodiazepine medication and the prescribed dose (this might differ from
actual dose consumption reported in the semi-structured interview).
Finally, at the end of the semi-structured interview participants were asked if they would like
to stop or reduce their use of benzodiazepine medication. If they said that they would like to
change their benzodiazepine use they were asked what help they thought they would need to
make this change. If they answered that they did not want to change their benzodiazepine
use, they were asked for their reasons for this decision. Participants were also asked if they
had anything else that they would like to add, or if they felt that the researcher should have
asked them anything else.
Questionnaire measures
Four questionnaires were selected for the study. The rationale behind the selection of each
questionnaire and a description of each questionnaire is given below. (A copy of the
combined questionnaire can be found in Appendix 2)
The Severity of Dependence Scale (SDS)
The SDS was devised by Gossop et al (1995) to provide a short and easy to administer self-
report questionnaire with which to measure dependence for different types of drugs. The
SDS items are explicitly concerned with psychological components of dependence, with no
reference made to physical symptomatology such as withdrawal symptoms. Bailie (1996)
has argued that relying on withdrawal symptoms, as an indicator of dependence is not
adequate. The items in the SDS are intended to examine an individuals control over their
drug use and their preoccupation and anxieties about their drug use.
The SDS was adapted by De Las Cuevas et al (2000) for use as a screening instrument for
benzodiazepine dependence. Quite simply the word "drug" in the original SDS was
substituted with the word "tranquilliser".
1 GPASS - The General Practitioner Administration System for Scotland was established in 1984, using software originally
developed by a Glasgow GP. GPASS is a national computerised Primary Care system and is now used in over 84% of general
practices in Scotland.
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The SDS validation study (De Las Cuevas et al 2000) suggests a cut-off score of >7 to
indicate benzodiazepine dependence. This cut-off score predicts overall sensitivity of 97.9
per cent and specificity of 94.2 per cent. However, this finding was based upon a validation
study, which used a sample drawn from attendees of a mental health outpatient service.
Therefore, the cut-off score of >7 may not be definitive when the SDS is used with other
client groups.
The authors of the SDS validation study propose that the adapted form is an "extremely"
useful scale with the following uses:
• In surveys requiring a screening test for benzodiazepine dependence.
• A measure of the severity of benzodiazepine dependence.
• For use as a quantitative measure to examine the correlation with other measures.
• For use as an indicator or the prevalence of benzodiazepine dependence.
The SDS was particularly suitable for use in the current study because of its brevity. A more
comprehensive measure such as The Benzodiazepine Dependence Questionnaire (Baillie
1996) was considered but was felt to be too long for the purpose of the current study. The
length of the SDS questionnaire was an important consideration because it was to be
combined with three other questionnaires.
Structure: The SDS comprises five items, each with a choice of four responses. The items are
scored on a four-point scale (0-3) producing a total score with a range from 0-15, with
higher scores indicating greater severity. The referent time-period provided to the respondent
is "during the last month". (The SDS items can be located in the combined questionnaire in
Appendix 2 labelled "Severity of Dependence Scale")
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The Brief Symptom Inventory (BSI)
The BSI is a subset of the Symptom Checklist-90-R (SCL-90-R) and was devised by
Derogatis in 1975. The instrument assesses a broad range of psychological problems and
symptoms of psychopathology, including symptom intensity. The BSI has been used in
mental health, medical and educational settings as well as for research purposes. It is
effective in the initial evaluation of patients as well as for monitoring progress and treatment
outcome.
The BSI comprises nine symptom dimensions, but for the purpose of the current study only
five of the dimensions were used. The decision to exclude four dimensions arose because
they assessed extraneous symptomatology as far as the requirements of the current study.
Excluded dimensions
Obsessive Compulsive Disorder OCD - This has a relatively low prevalence rate in older
adults of whom the current subject sample mostly comprised. Therefore, it was reasonable to
predict that this dimension would be the least useful of the three "anxiety" dimensions
included in the complete BSI. In addition, the author felt that some of the six items that
comprise this dimension were not specific to OCD, particularly in the current cohort, and
may not simply assess OCD but also other difficulties. Examples of two such items include
"Trouble remembering things" and "Trouble concentrating".
Hostility - According to the authors of the BSI, the hostility items were devised to assess
anger and included items such as "Having urges to beat, injure or harm someone" and
"Having urges to break or smash things". Because "anger" does not represent a psychiatric
disorder, this dimension was not included in the current study.
Paranoid Ideation and Psychoticism - Clinical judgement was brought to bear in the decision
not to include paranoid ideation and psychoticism items in the current study. The author felt
that it would be unlikely that participants from a primary care cohort would endorse such
54
items and may find them off-putting. Potential participants with a diagnosis of dementia or
psychotic illness had already been excluded from the study.
Dimensions of the BSI selected for the current study
The definitions given by Derogatis (1975) for each of the five dimensions selected from the
BSI are reproduced in Table 7 below:
Table 7: Description of five BSI dimensions
Somatisation "The somatisation dimension reflects distress arising from perceptions of
bodily dysfunction. Items focus on cardiovascular, gastrointestinal and
respiratory complaints; other systems with strong autonomic medication are
included as well. Pain and discomfort of the gross musculature and additional
somatic equivalents of anxiety are also components of somatisation."
Interpersonal
Sensitivity*
"The interpersonal sensitivity dimension centres on feelings of personal
inadequacy and inferiority, particularly in comparison with others. Self-
deprecation, self-doubt and marked discomfort during interpersonal
interactions are characteristic manifestations of this syndrome."
Depression "The symptoms of the depression dimension reflect a representative range of
the indications of clinical depression. Symptoms of dysphoric mood and
affect are represented as are lack of motivation and loss of interest in life."
Anxiety "General signs such as nervousness and tension are included in the anxiety
dimension, as are panic attacks and feelings of terror. Cognitive components
involving feelings of apprehension and some somatic correlates of anxiety are
also included as dimensional components."
Phobic
Anxiety
"Phobic anxiety is defined as a persistent fear response to a specific person,
place, object or situation that is irrational and disproportionate to the stimulus
and leads to avoidance or escape behaviour. The items of this dimension focus
on the more pathognomic and disruptive manifestations of phobic behaviour."
* As with the hostility dimension, interpersonal sensitivity is not regarded as a psychiatric
disorder. However interpersonal sensitivity was included because it was felt that as a concept
it was closely linked to anxiety, particularly social anxiety, and could be endorsed by those
individuals that were found to be anxious.
The BSI also has the added advantage that normative scores have been developed for its use
with adults aged 60 years and over. Male and female normative scores on the BSI were
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published by Hale et al (1984) derived from a large sample (N= 565) that had a mean age of
73 years.
Structure: The number of questions for each of the five selected dimensions of the BSI are as
follows (total 28 questions): Depression six questions; Anxiety six questions; Phobic
Anxiety five questions; Somatisation seven questions; Interpersonal Sensitivity four
questions. Respondents were required to indicate their experience of each symptom on a
five-point scale of increasing severity from "not at all" to "extremely". A mean score for
each dimension is derived from each set of raw scores. The referent time-period provided to
the respondent is "during the past 7 days including today". (The BSI items can be located in
the combined questionnaire in Appendix 2 labelled "Brief Symptom Inventory")
The Pittsburgh Sleep Quality Index (PSQI)
The PSQI (Buysse et al 1989) is a comprehensive self-report sleep questionnaire designed to
assess areas such as sleep latency, sleep efficiency, daytime dysfunction and overall sleep
quality.
In considering the applications of the PSQI, the authors state that it can be used to study...
"...the relationship between sleep quality and other variables, such as age, gender, health
status, medical and psychiatric conditions, and performance on other psychological
variables." (p.207). The authors of the PSQI recommend a global PSQI score of greater than
5 to distinguish "poor" sleepers from "good" sleepers. This cut-off was found to yield a
sensitivity of 89.6 per cent and specificity of 86.5 per cent.
The PSQI is used to assess sleep quality over a 1-month interval. The questionnaire
comprises 19 items; however, for the purpose of the current study, item 19 was excluded
because it consists of questions for clinical information only which are not tabulated in the
scoring of the PSQI.
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Structure: With the exception of the first four items the PSQI questions utilise forced-choice
responses on a four-point scale of increasing severity. The 18 self-rated items are combined
to form seven "component" scores which are allocated a score with a range of 0-3:
subjective sleep quality; sleep latency; sleep duration; habitual sleep efficiency; sleep
disturbances; use of sleep medication; daytime dysfunction. The seven component scores are
added together to yield a global score, with a range of 0-21. Higher scores indicate severity
of sleep problem. (The PSQI items can be located in the combined questionnaire in
Appendix 2 labelled "Pittsburgh Sleep Quality Index")
The Psychological Mindedness Scale (PMS)
The PMS was chosen because the questionnaire items appeared to be relatively easy to
understand and more applicable to the proposed sample, than questionnaire items in the other
psychological mindedness questionnaires. However, the author was unable to locate any
published research that had used the PMS in any studies similar to the current study, its
suitability in the current setting was therefore untested.
In an examination of the factor structure of the PMS, Conte et al (1996) found five principle
factors, which were labelled as follows:
• Willingness to try to understand oneself and others
• Openness to new ideas and capacity for change
• Access to one's feelings
• Belief in the benefits of discussing one's problems
• Interest in meaning and motivation of own and others behaviour
Although only 27 of the 45 items account for this factor structure the authors did not shorten
the scale, arguing that the remaining items still contributed to the scale.
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Structure: The PMS comprises 45 statements to which the respondent rates their strength of
agreement or disagreement. The statements are worded both positively and negatively and
are answered by means of a four-point Likert scale. The scale generates a total score that can
be converted to a percentile rank. (The PMS items can be located in the combined
questionnaire in Appendix 2 labelled "Psychological Mindedness Scale")
The four questionnaires were combined to give appearance of one long questionnaire. With
the exception of the first four PSQI items, all items offered closed fixed-alternative
responses that required the respondent to place a tick in the corresponding box. Print was
enlarged as much as space would allow to assist respondents with poor eyesight.
Questionnaires were not counterbalanced (see discussion of order effects below).
Pilot study
The pilot study described in Appendix 2, involved collecting qualitative and audit data which
was used to inform the design of the main study. Without the pilot study it would have been
difficult to decide upon which measures to use in the main study. For example, the pilot
study revealed that the predominant reason for benzodiazepine use in the target subject
population was because of sleep difficulties. This prompted the selection of an appropriate
measure to assess sleep quality.
The pilot study found that the majority of potential participants were aged over 65 years.
This gave rise to the consideration of questionnaire factors such as comprehensibility and
length, because many older adults may have been less familiar with the process of
completing questionnaires. It was also important to check whether a potential questionnaire
was restricted to particular age groups.
The participants in the pilot study were found to be resistant to any suggestion that they
might be dependent or addicted to their benzodiazepine medication. Therefore, the
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questionnaire measure of dependency for the main study was carefully selected, avoiding the
use of such words.
The pilot study also highlighted the requirement for the researcher to be available to visit
participants in their own homes, as many of the potential participants were quite elderly and
would have mobility or transport difficulties. The need to visit participants in their own
homes would require more time and this was allowed for when planning the time-scale of the
main study.
Power calculation
The author located a paper by Marsden et al (2000) which used multiple regression analysis
to examine the predictors of psychiatric symptoms. The study used both the SDS and the
BSI, along with other variables. However, in contrast to the present study Marsden et al
sought to establish predictors of psychiatric symptoms, as measured by the BSI, therefore
BSI scores formed the dependent variable and SDS score was one of the independent
variables. The current study aimed to examine whether psychopathology (using the BSI)
predicted severity of dependence (SDS).
Using Cohen's (1992) formula for calculating effect size (for multiple regression analysis),
the Marsden et al study was found to demonstrate a large effect size (d = 0.58). This was not
surprising when one considered the heterogeneous features of the study cohort, which were
drawn from a range of community and residential settings. The present study would consist
of a more homogeneous group of participants (compared with the Marsden et al study),
therefore, it would be prudent to select a more conservative effect size. A medium effect
size was selected. Based on Cohen's (1992) estimate of sample size (setting power at 0.8 and
alpha at 0.05) multiple regression analysis would require that N = 91 (for five independent
variables).
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For correlational analysis and testing differences between two independent means, assuming
medium effect size (setting power at 0.8 and alpha at 0.05), N = 85 and N = 64 respectively.
Therefore, recruitment of 91 subjects would provide a reasonable chance of rejecting the null
hypothesis and allow testing of sub-hypotheses using correlational and t-test analyses.
Ethical approval
Ethical approval was sought from the Borders Research
granted without any amendments requested. A copy of the
Appendix 3.
Procedure
Data collection consisted of three stages. Stage one involved postal recruitment of potential
participants by general practitioners. Stage two involved follow-up postal or telephone
contact with potential participants by the researcher to arrange the interviews. Stage three
consisted of data collection, which involved a single face-to-face contact with each
participant. This process was carried out over a four-month period.
Recruitment of participants
The study was carried out in the Scottish Borders. Eighty three per cent of the participants
recruited for the study were recruited from one general practice. Although the study was
originally planned to focus on one general practice, because of the shortfall in participants
required for the study (based on the original power calculation) a second smaller general
practice, also in the Scottish Borders, was approached and agreed to participate. Both
Ethics Committee (BREC) and
BREC approval can be found in
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general practices are situated in rural communities, geographically 15 miles apart. They
could be considered similar in terms of socio-economic status.
The first stage of the recruitment process involved each general practitioner contacting all
their registered patients who were in receipt of a repeat prescription for benzodiazepine
medication for more than three months. This included all adult patients (over 18 years) who
were prescribed one of the following: temazepam, diazepam and nitrazepam.
This information was collected using a GPASS database search. The search results were
grouped according to individual general practitioners so that a patient list could be circulated
to each doctor. The general practitioners were asked to consider each patient on their own
list for their suitability to participate in the study. The exclusions that the general
practitioners were asked to screen out are given below.
Exclusion Criteria
The study was not concerned with people taking benzodiazepines obtained from an illicit
source (i.e. black-market use of benzodiazepines). In addition, the study did not include
patients prescribed benzodiazepines for alcohol withdrawal, epilepsy or psychiatric
conditions such as dementia and psychotic illness. Persons with a learning disability were
also excluded.
The total number of potential participants following the application of the exclusion criteria
was 161.
A letter to patients was composed by the general practitioners collectively, it contained
information introducing the proposed study and requested that they consider taking part. The
general practitioners were given guidelines by the author to ensure that certain essential
points were made in the letter. For example, the general practitioners were advised that
potential participants must be made aware that participation in the study would be
anonymous and all information they disclosed to the researcher would be confidential. Each
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general practitioner signed the letter sent to their own patients. A copy of the letter can be
found in Appendix 4.
Potential participants were asked to return the slip enclosed with the letter in the stamped
envelope addressed to their own general practitioner. The return slip requested that the
potential participant indicate a response to two questions. Firstly, the respondent was asked if
they would be willing to be contacted by the researcher about the study: (i) yes or (ii) no.
This question was qualified by the following statement: "Note: ticking yes does not mean
that you are agreeing to take part, just that you are willing to be approached." Secondly, the
respondent was asked whether they would be happy to be contacted by (i) letter or telephone
or (ii) just by letter.
Returned slips that indicated that the potential participant would be willing to be contacted
about the study were forwarded to the author.
The second stage of the recruitment process was executed once a potential participant had
given their permission to be approached by the author. The majority (77 per cent) of
respondents ticked the box on their return slip indicating that they did not mind whether they
were contacted by telephone or by letter. The author telephoned all these individuals and
explained to each of them further details of the study. They were then asked if they would be
happy to participate and if they agreed a convenient time was arranged.
Contacting potential participants by telephone at this stage proved to be a more successful
method than by postal letter. Of the 70 individuals that were telephoned and asked to
participate 66 agreed.
Those individuals that returned their slip indicating that they agreed to be contacted about
the study but would prefer to be contacted by letter were sent another letter (see Appendix
4). This second letter gave the potential participant further information about the study and
included another return slip which offered a choice of three appointment times and the
choice of venue (local health centre or home). The respondent was asked to complete the slip
and return it in the stamped addressed envelope provided. Of the 21 individuals that were
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contacted a second time by letter, 18 returned their slip having selected an appointment time.
Unlike the larger group of participants that were contacted by telephone, most of this group
chose to come into the health centre to be seen.
The decision to contact potential participants by telephone was made for two reasons. Firstly,
this method was quicker and cheaper. Secondly, it was felt that having a conversation with a
potential participant provided a better opportunity to explain to the potential participant what
would be involved if they agreed to participate in the study and address any concerns they
might have.
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Of the 161 patients (across the two GP practices) that were contacted to participate in the
study 52 per cent took part in the study.
Data collection
Data collection involved a single meeting with each participant, usually in their own home.
(Eighty two per cent of participants agreed to be seen in their own home and 18 per cent of
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participants requested to be seen at the health centre.) The semi-structured interview was
carried out first, using a prepared interview schedule. This was followed by the
administration of the questionnaire.
Interview procedure
The researcher began by reiterating the information contained in the introductory letter used
to recruit participants for the study. The purpose of the research was explained to each
participant and each was reassured of complete confidentiality and the respect for
anonymity.
The researcher then outlined how the interview would proceed, i.e. a brief "chat" about the
participants use of benzodiazepine medication, followed by the completion of a
questionnaire. Once the researcher had elicited from the participant that they were happy to
proceed they were asked to sign two copies of a consent form. The researcher kept one copy
and the participant kept the other copy.
The interview schedule was adhered to with each participant, thus providing some
consistency in terms of the order in which the questions were asked. Some participants
volunteered a lot of additional information; therefore completion of the interview took a
variable amount of time.
The inclusion of open-ended questions in the semi-structured interview allowed an
opportunity for rapport-building with the participant, because these types of questions
allowed greater freedom for the participant to talk about what was relevant to them. Whilst
much of the information reported in response to an open-ended question was not relevant to
the research questions, it afforded an opportunity for the participant to express their point of




The interviewer remained with the participant during completion of the questionnaire, to
clarity any confusion surrounding how to fill in the questionnaire or interpret the questions.
The majority of the participants requested that the researcher filled in the questionnaire with
them. In theory, the questionnaire should have been relatively easy to complete because the
process merely involved ticking a choice of boxes. However, many of the more elderly
participants were found to deliberate over the alternative choices and required a prompt to
select a response. The last section of the questionnaire, which consisted of the psychological
mindedness questions, proved to be the most difficult and time-consuming to answer.
Younger participants were found to complete the questionnaire more easily; one could
speculate that older adults are less familiar with answering questionnaires and they appeared
to be more worried about making sure they "got it right".
Many participants commented on the repetition found in the psychological mindedness
questionnaire.
At the end of the meeting, participants were thanked for their participation and given an
information leaflet about benzodiazepine medication. It was explained to each participant
that should they decide that they would like to stop taking benzodiazepine medication they
would be given help to do this involving both their general practitioner and the author. It was
emphasised to them that they should not stop their medication without first consulting their
general practitioner (this advice is also stated clearly on the leaflet). The leaflet contained a
return slip that could be handed in to the health centre by the participant, indicating that they
wished to be contacted about stopping their benzodiazepine medication.
Interviewing participants in their own home was considered preferable to the health centre
because the home environment is generally considered less anxiety provoking. The home
environment was also found to contribute to rapport building, for example participants
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visited in their own homes frequently offered the researcher tea/coffee and engaged in
general "chit-chat" before and after the interview. In addition, when an appointment was
arranged with a participant to be seen in their own home there was more likelihood that the
participant would attend.
Order effects
The decision to proceed first with the interview followed by the questionnaire is supported
by evidence that indicates that a questionnaire, by virtue of its structured questions, can
become a "learning exercise", thus creating an agenda for the participant, which can spill
over into the subsequent interview and influence their discourse (Best et al 1995). It also
made sense in this study to begin with the semi-structured interview, as the first few
questions elicited demographic information that a participant would expect to be asked of
them first. The open-ended interview questions provide an opportunity to build rapport with
the participant.
Although the questionnaire was presented as a single questionnaire with all questions
following on continuous pages, it consisted of four distinct questionnaires, thereby creating
the potential for order effects. However, because each questionnaire focused on different
topics, which bore very little relation to each other, the author felt the potential for "cueing"
across the questionnaire items was low. For example, it seemed unlikely that answering
questions about sleep quality before answering questions about psychiatric symptomatology
would influence how the questions about psychiatric symptoms were answered. Therefore,
the order in which the four questionnaires were presented was not counterbalanced.
The four questionnaires were presented as one questionnaire in the following order:
(i) Pittsburgh Sleep Quality Index
(ii) Brief Symptom Index
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(iii) Severity of Addiction Scale
(iv) Psychological Mindedness Scale
The sleep quality questions were placed first because sleep problems were the most salient
issue for the majority of participants. Therefore, questions about sleep met with the
participant's expectation and could be viewed as easing the participant into the
questionnaire. The psychological mindedness questions were placed at the end of the
questionnaire, because they were the most difficult to answer and could be viewed as
somewhat discouraging.
Preparing raw data for analysis
The questionnaire was divided into its four composite questionnaires and each was scored
according to its own scoring mechanism. Information collected from the semi-structured
interview was collated to form a large number of additional variables. Information pertaining
to medical health problems and reasons for benzodiazepine use were categorised as
described below. All benzodiazepine dosages were expressed in terms of diazepam
equivalents using British National Formulary (BNF) conversion tables (2002) for use in
statistical analysis. Diazepam equivalent doses were calculated as follows: 5 mg of
diazepam is equivalent to 5 mg of nitrazepam and 10 mg of temazepam.
Reasons for benzodiazepine use
Participants gave a total of 10 different reasons for their original or current use of
benzodiazepines. These data were therefore assigned to one of the 10 alternative categories
(if during data collection a participant gave more than one answer in response to these two
questions, they were asked to select the primary reason).
67
Medical conditions
Almost every participant in the study had one or more medical conditions for which they
were prescribed medication. It therefore seemed that the most manageable way of
categorising participants' medical health problems was to allocate each participant to one or
more categories according to their medication. A record was collected of the repeat
prescription issued to every participant.
The BNF groups all medications according to the condition they are used to treat; this system
comprises 11 main categories of health problems. Each participant's medication was
recorded according to these categories. Eight of the 11 BNF health categories were relevant
to the participants' in the study; cardiovascular; gastro-intestinal; central nervous system;
respiratory system; musculoskeletal; endocrine system; malignant disease and
immunosuppression; obstetrics, gynaecology and urinary tract disorders. Recording these
data in this way allowed for the prevalence for each medical category to be calculated and
gave rise to a total number of medical categories per participant. However, it is noted that
this method affords only a crude system of recording the medical health problems of the
current sample.
All data were entered in to SPSS (Statistical Package for the Social Sciences) version 10.
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Chapter 8; Results
Preparation of data for analysis
Requirements for parametric tests: The distributional assumptions of the variables to be
analysed using parametric statistics were considered. The five BSI variables were found to
be positively skewed and therefore a natural logarithm (x+1) transformation was carried out
on each variable. The distribution of total scores for the remaining three measures (PSQI,
PMS, SDS) did not depart significantly from normality. Additional dichotomous and ordinal
variables were analysed using nonparametric tests. Data was analysed using SPSS
(Statistical Package for the Social Sciences) version 10. The significance level of test
results, unless otherwise stated, was set atp- .05 (two-tailed).
Descriptive statistics: characteristics of the sample
The information gathered by means of the semi-structured interview was collated and is
presented descriptively below. A number of these variables were analysed further using
inferential statistics.
Prevalence rate
Using GPASS data for the first practice from which participants were recruited for the study,
the following prevalence rates were calculated. In the total practice population of adults over
18 (N = 4857) the number of patients in receipt of a long-term repeat prescription for
benzodiazepine medication was found to be 136; this amounted to a total practice prevalence
rate of 2.8 per cent.
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Prevalence rates according to age and sex were computed: 3.1 per cent ofmales >= 60 years;
9.4 per cent of females >= 60 years; 0.9 per cent of males under 60 years; 1.1 per cent of
females under 60 years.
Type of benzodiazepine used: dosage and number of years taken
Across all benzodiazepines the mean number of years that participants had been in receipt of
their benzodiazepine medication was 10.8 (SD 8.19) years, the modal number of years was
20.
Table 9 below shows the mean daily dose for each benzodiazepine and the BNF (British
National Formulary 2002) recommended doses for "elderly" patients. The table also includes
the mean number of years each benzodiazepine was prescribed.
Table 9: Dose and length of time in receipt of benzodiazepines
N Mean dosage BNF Mean years in
Type of BZD (%) (SD) Recommended receipt of BZD*
dose (SD)
Diazepam 20 5.40 mg 7.5 - 15 mg 10.95
(28.80) (3.83) (8.05)
Temazepam 37 14.59 mg 10 mg 8.56
(44.04) (11.86) (6.39)
Nitrazepam 27 5.78 mg 2.5 - 5 mg 13.88
(32.14) (3.38) (9.66)
*A significant difference was found between the mean number of years in receipt of BZD across type;
(F(2,81) = 3.498; p =0.035). Post hoc analysis revealed that participants in receipt of nitrazepam had
been taking it significantly longer than participants who were in receipt of temazepam.
Length of time in receipt of benzodiazepine medication and association with age
Participants were grouped into three age groups: adult (<60 years); young older adults (60-69
years); old older adults (70+ years).
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Distribution of participants across the three groups was as follows: Adults - N = 16, mean
age 51.7 (SD 6.39); Young older adults -N= 16, mean age 65.6 (SD 3.3); Old older adults -
N = 52, mean age 80.6 (SD 5.9).
Figure 3 below shows the mean age at which benzodiazepines were commenced and mean
number of years participants were in receipt of benzodiazepines according to age group. The
graph illustrates that on average the older group (over seventy years) and young old (sixty to
seventy years) have been taking their benzodiazepines for a similar period of time. This
suggests that older age does not necessarily mean that benzodiazepines have been used for a
longer period of time. In addition, no statistical relationship was observed between age and
the length of time in receipt of a benzodiazepine.
Pearson's correlational analysis demonstrated that there was a significant positive correlation
between age and age when commenced benzodiazepine {r = .816, p = <0.001, n = 84). This
would suggest that older adults are as likely to be commenced on benzodiazepine medication
as younger adults.
Figure 3: Graph to show mean age at which BZD were commenced and mean number of
years in receipt of BZD according to age group
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Figure 4 below shows that of those patients commenced on a benzodiazepine in the last 5
years nearly 50 per cent were over 70 years old.
Figure 4: Age distribution of patients who commenced benzodiazepine in last 5 years
Age
Is there a relationship between living alone and benzodiazepine use
Of the 84 participants, 39 participants lived alone. The mean number of years lived alone
was 12.6 years (SD 12.6) after one outlier was removed from the calculation. These 38
participants were all widowed.
A significant positive correlation was found between the number of years in receipt of
benzodiazepines and the number ofyears lived alone (r = .483, p = 0.002, N = 38). When
this relationship was explored further, it was found that the significant relationship between
the number ofyears in receipt of benzodiazepines and the number ofyears lived alone was
only significant for the thirteen participants who commenced benzodiazepines following a
bereavement (r = .871,/> = <0.001, N = 13). Therefore, with the exception of individuals
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commenced on benzodiazepines as a result of bereavement, there does not appear to be an
association between living alone and benzodiazepine use.
Medical conditions and benzodiazepine use
Eighty-three out of 84 participants were in receipt of a repeat prescription for medication(s)
for a comorbid physical medical condition, in addition to their benzodiazepine. (See
Appendix 5(a) for medical conditions)
Using Spearman's rank correlation analyses no significant association was found between
the number of health problems and sex, age, anxiety, depression, inter personal sensitivity,
phobic anxiety, SDS score, and PQSI score.
A significant association was found between increased number of health conditions and
higher somatisation scores (r = .240,/? = 0.028, N= 84).
Pain
The presence or absence of painful conditions and use of prescribed pain reliefmedication
were correlated with PSQI score using a Point-biserial correlation. The presence of painful
conditions (rph = .344, = 0.002, N = 81) and use of prescribed pain relief (rpb = 0.340,/? =
.002, N= 81) were associated with increased sleep disturbance. Participants formed two
groups; participants that experienced pain (N= 45) and participants who did not experience
pain (A =36). Analyses found that there were significantly higher PSQI score (t - 3A64,df=
79, p = 0.002), and significantly larger dose of benzodiazepines used (t = 2.294, df= 79, p =
0.024) in the group who experienced pain, compared with the group who did not experience
pain.
In addition, the group who experience pain were significantly more likely to use
benzodiazepines daily (z = 3.109,/? = 0.002).
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Use of pain relief was associated with two categories of medical problem: musculoskeletal
(X2 = 6.431, df = 1, p = 0.011) and gastro-intestinal (X2 = 5.063, df = 1, p = 0.024).
Participants with these two types of conditions used significantly more pain relief.
Do participants wish to stop their benzodiazepine medication
Seventy-four percent of the total sample said that they did not wish to stop their
benzodiazepine medication. Table 10 below shows that female participants were less willing
to consider stopping their benzodiazepine medication than males. This difference was found
to be statistically significant using chi-square analysis (X2 = 12.220, df= 1 ,p = <0.001).
Table 10: Crosstabulation of sex and desire to stop benzodiazepine medication
would like to stop bzd

























In addition, participants who use benzodiazepines less frequently were found to be more
likely to consider stopping them (X2 = 12.157, df= \,p = <0.001).
Reasons given for benzodiazepine use
With the exception of participants who gave "anxiety" (N = 6) as their reason for
commencing benzodiazepine medication, "problem sleeping" was the primary reason given.
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Bereavement (N = 13) and stress and worry (N = 12) were the most commonly reported
reasons for sleep problems leading to commencement of benzodiazepine medication. (See
Appendix 5(b) for a more detailed examination of the reasons given for benzodiazepine use.)
Table 11 below cross-tabulates the original reason given by participants for commencing
benzodiazepines with the current reason for taking benzodiazepines. These data demonstrate
that a large number of patients continue to use benzodiazepines for sleep, despite the original
reason for their sleep problem being no longer valid.
A surprisingly large proportion of the sample (38 per cent) could not identify a reason for
their original presentation to their general practitioner with a sleep problem.
Seventy six per cent of the sample reported that their continued use of benzodiazepines was
due to sleep problems for which they were unable to identify a reason.
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Total CR* 64 3 0 1 7 0 4 2 3 84
Total OR = total number for each original reason
Total CR = total number for each current reason
Severity of Dependence Scale
The SDS questionnaire comprises five items, which require a response on a 4-point Likert
scale. As shown in Figure 5 below the first four items utilise the same Likert scale. SDS item
five (see Figure 6) has a different choice of responses.
Responses to SDS items 1-4 are positively skewed, although some more so than others.
Response to the first SDS item "Did you think your use of tranquillisers was out of control?"
(SDS1) demonstrate poor discrimination; responses to this question were very positively
skewed. The distribution of responses across item 3 "Did you worry about your use of
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tranquillisers?" (SDS3) were also found to be very skewed. Items 2, 4, and 5 appear to give
rise to a more useful range of responses.




















































out of control worry miss a dose worry use of wish could stop
SDS questions 1-4
Figure 6: The distribution of responses to item 5 on the SDS










The relationship between the SDS items was explored using Spearman's rank correlation
analyses (see Appendix 5(c) for the correlation matrix)
With the exception of three significant correlation coefficients, there were poor relationships
between the five SDS items. The two items which appear to be most closely related were
"How difficult would you find it to stop your tranquillisers?" (SDS5) and "Did the prospect
ofmissing a dose make you anxious or worried?" (SDS2).
The results of the Cronbach alpha reliability analysis using covariance matrix found an alpha
value of 0.299 (standardised item alpha: 0.335). This result compared unfavourably with the
result of the reliability analysis reported in the SDS validation study by De La Cuevas et al
(2000), which reported an alpha value of 0.813 (standardised alpha: 0.814).
During the semi-structured interview participants were asked about the frequency of their
benzodiazepine use. This information was coded simply as "daily" or "not daily" usage.
Sixty-one participants (72.6 per cent) used their benzodiazepine medication daily; 23
participants (27.4 per cent) did not use benzodiazepines daily. It was possible that frequency
of benzodiazepine use might serve as a crude estimation of dependency, against which to
evaluate responses to the SDS. The five SDS items and the SDS total score were correlated
with frequency of use using Spearman's rank correlation analyses. A higher total SDS score
(rs = .396, p = < 0.001, N- 84); greater endorsement of "difficulty to stop" (rs = .460,p - <
0.001, N= 84) and "worry about missing a dose" (rs = .389, p = < 0.001, N= 84) correlated
significantly with increased frequency of use.
To conclude, the five items comprising the SDS appear to lack internal consistency. Two
SDS items "difficulty to stop" and "worry about missing a dose", seem to demonstrate a
more valid measure of dependency, in the current sample, than the other items in the SDS.
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The discriminative power of items 1 and 3 is low. This raises the question of the
appropriateness of using the recommended cut off score.
An appropriate cut-off score for the SDS
The "cut-off score as recommended by the authors of the SDS scale is: >= 7. Using this cut¬
off with the current sample found that only 17.9 per cent of participants (N = 15) were
classified as dependent on benzodiazepines. It seemed likely that this was an under
estimation of dependence in the sample when one considered participants responses to SDS
item 5 (Figure 6). For example, responses to SDS item 5 found that only 15.5 per cent of
participants reported that they would not find it difficult to stop their benzodiazepines. A
further 56 per cent of participants reported that they would find it either "very difficult" or
"impossible" to stop their benzodiazepines.
Closer examination of individual item scores highlights a pattern of responses which may
explain the finding that 82.1 per cent of participants (N= 69) had a relatively low total SDS
score. For example, 90.5 per cent of participants endorsed "never" in response to SDS item 1
"Did you think your use of tranquillisers was out of control"(Figure 5), thus scoring zero for
this item. Participants were found to remark that because they took their benzodiazepine
medication as prescribed by their general practitioner, they "believed" that their use of
benzodiazepines "could not be out of control". Similarly, for SDS item 3, 65.5 per cent of
participants reported that they "never" worried about their use of benzodiazepines. Again
participants attributed this response to their prescribed use of benzodiazepines.
It would therefore appear that because the individuals in the current sample were prescribed
their medication by a general practitioner, this feature of the sample changed the relevance of
these two SDS questionnaire items (SDS item 1 and SDS item 3). The author would argue
that in the current sample SDS items 1 and 3 add very little to the measurement of
benzodiazepine dependency. For example, the mean SDS total score (N = 84) derived from
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the five SDS items was found to be 4.28 (SD 2.35). If SDS items 1 and 3 are excluded from
this calculation the mean SDS total score (N = 84) derived from the remaining three SDS
items is found to be 3.72 (SD 2.11), a difference of only 0.56.
To conclude, SDS items 1 and 3 make very little contribution to the total SDS score and it
could be argued that in the current sample benzodiazepine dependency is more accurately
measured by only three SDS items. Therefore, a cut off SDS score of 7 based on 5 items is
not appropriate for a sample for whom only 3 items appear to be salient.
Figure 7: Frequency distribution of SDS total score
total SDS
total SDS
The proposed cut off score for dependence as measured by the SDS is normally 7, which is
just below the half-way point on the potential scale of 0-15. As Figure 7 illustrates, SDS
scores in the current sample range from 0-10, therefore, 4 represents just below the half-way
point in this sample.
In order to decide upon an appropriate SDS cut-off score to measure dependency, a well-
established method used in signal detection theory was employed (Green and Swets 1966). A
Receiver Operating Characteristic (ROC) curve was generated to determine an optimum
decision threshold (cut off point) using sensitivity and specificity values. The state variable
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selected was frequency of use. Examination of the coordinates of the curve revealed that a
cut off of 4 optimised sensitivity and specificity. The ROC graph and table coordinates of the
curve can be found in Appendix 6(a).
The Pittsburgh Sleep Quality Index
The PSQI comprises 18 items that combine to form seven "component" scores, from which a
global score is calculated. The mean global score for the total sample was found to be 11.07
(SD 4.05). The PSQI cut-off score (>5) proposes to distinguish between "poor" and "good"
sleepers. In the current sample 90.5 per cent fell into the "poor sleepers" category.
Sleep latency represents the amount of time taken to fall asleep. The mean amount of time
taken by participants to fall asleep was 38.1 minutes (SD 28.8). Mean sleep duration was
found to be a total of 6.2 hours (SD 1.39) per night.
A greater sleep efficiency percentage represents more hours spent asleep whilst in bed. Mean
sleep efficiency in the current sample was found to be a relatively poor 64.9 per cent (SD
16.02). The mean number of hours spent in bed by participants was found to be 9.08 hours
(SD 1.70). Therefore, on average, participants appear to be spending one-third (about 3
hours) of their time in bed awake. (See Appendix 5(d) for details of PSQI component
scores.)
Participants found to be dependent on benzodiazepines (using SDS cut off of 4) were found
to have a significantly higher PSQI score than non dependent benzodiazepine users (t =
3.839, df= 82,p = <0.001). However, no difference in PQSI score was found between daily
and non daily benzodiazepine users.
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Psychological Mindedness Scale
The PMS questionnaire scores can range from <= 102 (percentile 0) to >= 170 (percentile
99). The mean PMS score in the current sample was found to be 121.4 (SD 13.34). The mean
percentile score was 27.9 (SD 27.68). Psychological Mindedness in the current sample
would therefore appear to be below average.
A small but statistically significant correlation was found between age and PMS score (r = -
.277, p = 0.011, N = 84). This suggests that older persons are likely to be less
psychologically minded. The PMS scores did not correlate with the following variables: sex,
dose ofBZD, length of time in receipt ofBZD, number ofhealth conditions or pain.
A significant difference was observed between PMS score according to age group (F (2,81)
= 9.818; p = <0.001). Post hoc analysis revealed that adults were significantly more
psychologically minded than "young" older adults and "old" older adults. There was no
difference between PMS scores for "young" older adults and "old" older adults. Figure 8
illustrates the boxplots of the PMS scores according to age group (after removal of one
extreme value).
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The BSI dimensions each comprise between 7 and 4 questionnaire items, from which a mean
score is derived. A larger mean represents more symptomatology.
Figure 9 below plots the mean scores for (i) male and female participants aged 60 years and
over (N = 68) and (ii) normative scores for an elderly population (=>60). Figure 10 below
plots the mean scores for (i) male and female participants aged below 60 years (N= 16) and
(ii) normative scores for an adult population. It was not possible to plot the comparison
between the sample mean and population means on a single graph because the BSI
population norms vary across age group.
Mean BSI dimension scores appear to be higher for the second group of participants below
60 years (Figure 10).
Participants were divided in to two groups: under 60 years old and 60 years and above. No
significant differences were found between the two groups on a number of variables: dosage,
frequency of usage, individual medical health conditions and total number of health
conditions, painful conditions, PSQ1 score and SDS score.
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Figure 9: Graph to show comparison between sample mean scores and normative scores in
participants 60+ years
BSI dimension scores for participants =>60 years
0.8 j
Anxiety Inter-personal Somatisation Depression Phobic
Figure 10: Graph to show comparison between sample mean scores and normative scores in
participants less than 60 years































To explore the relationship between BSI dimension scores, age and sex a three-factor mixed
factorial anova was computed (N= 84):
Three-factor mixed ANOVA
Within-Subjects Effects
BSI dimensions - F(4,80) = 2.269; p = .062
Interaction between BSI dimensions X Age - F(4,80) = 3.825; p = 0.005
Interaction between BSI dimensions X Sex - F(4,80) = .711; p = 0.585
Interaction between BSI dimensions X Age X Sex - F(4,80) = .538; p = 0.708
Between-Subjects Effects
Sex - F(1,80) = .087; p = 0.769
Age - F(1,80) = 11.266; p = 0.001
Interaction between Age X Sex - F(4,80) = 1.308; p = 0.256
The results show a significant main effect for age and a significant interaction between age
and BSI dimensions. The BSI dimensions do not demonstrate a significant main effect
although the F value was approaching statistical significance. Sex does not have a main
effect or have any interaction effects.
It seemed likely from viewing Figure 9 above that in the over 60 age group differences
according to sex may exist. Therefore, a two-factor mixed factorial anova was computed for
this age group (N= 60).
Two-factor mixed ANOVA
Within-Subjects Effects
BSI dimensions - F(4,66) = 10.099; p = < 0.001
Interaction between BSI dimensions X Sex - F(4,80) = .165; p = 0.956
Between-Subjects Effects
Sex - F(1,66) = 2.856; p = 0.096
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In summary, the anova results reveal a significant relationship between age and level of
psychopathology. Younger adults exhibit higher levels of psychopathology than older adults,
but greater variation between individual psychopathologies exists within the older adult
sample. The effect of sex on level of psychopathology is greater in the older adult group, but
not statistically significant. (See Appendix 6(b) for SPSS output.)
Testing the hypotheses
Hypothesis 1(a)
In order to demonstrate significant levels of psychopathology in long-term benzodiazepine
users, BS1 dimension scores were compared with BS1 population norms using a Wilcoxon
paired samples test.
Table 12 shows the mean scores for each BSI dimension and the normative cut-off as
determined by age and sex. With the exception of anxiety in older females and anxiety and
interpersonal sensitivity in older males, all BSI mean dimension scores in the current sample
were found to be higher than the corresponding normative cut-off score.
















Anxiety Mean .47 (SD .63) .29 (SD .46) .99 (SD 1.13) 1.23 (SD .55)
Norm cut-off .48 .30 .37 .22
Interpersonal
sensitvity
Mean .49 (SD .50) .28 (SD .38) .94 (SD .89) .82 (SD .59)
Norm cut-off .40 .32 .35 .25
Somatisation Mean .73 (SD .45) .53 (SD .41) .82 (SD .80 .95 (SD .59)
Norm cut-off .50 .45 .43 .29
Depression Mean .68 (SD .88) .55 (SD .68) .72 (SD .76) .80 (SD .54)
Norm cut-off .53 .43 .46 .28
Phobic
anxiety
Mean .38 (SD .32) .23 (SD .46) .95 (SD .79) .94 (SD 1.21)
Norm cut-off .25 .17 .19 .08
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The Wilcoxon test was used to compare each participants BSI dimension score with its
corresponding normative score (determined by age and sex as shown in Table 12). A
Wilcoxon test was used because the distribution of the normative scores was too negatively
skewed (because of the high proportion of older females who had the same normative score).
Table 13 below shows the z-value and significance for each BSI dimension (N= 84).
Table 13: Results of the Wilcoxon paired samples test
Test Statistics!5
Anxiety Interpersonal Somatisation Depression Phobic
mean- mean- mean- mean- mean-
Anxiety Interpersonal Somatisation Depression Phobic
norm norm norm norm norm
1 -458a -1.309a -3.620a -.714a -1.7773
Asymp. Sig.
(1-tailed)
.323 .095 .000 .237 .037
a. Based on negative ranks.
b. Wilcoxon Signed Ranks Test
Out of the five BSI dimensions, somatisation and phobic anxiety demonstrated significantly
higher levels than normal levels of somatisation and phobic anxiety in the general
population.
Rejection of the null hypotheses: The results found that those individuals in receipt of a long-
term repeat prescription for benzodiazepines demonstrated statistically significant levels (in
descending order of significance) of somatisation and phobic anxiety (p=<.05). Hypothesis
1 (a) is therefore upheld.
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Hypothesis 1(b)
In order to test the hypothesis that psychopathology will predict benzodiazepine dependence
a regression analysis was computed.
There were two options for regression analysis. The first was to select multiple regression
analysis, using total SDS score as the dependent variable and BSI dimensions as the
independent variables. This option examined whether psychopathology (i.e. scores across the
five BSI dimensions) predicts scores on the SDS.
The second option involved the use of logistic regression analysis in order to examine
whether psychopathology predicts benzodiazepine dependence. In this example the
dependent variable is a dichotomous one (dependence/no dependence). The author felt that
to predict category membership would be a more useful procedure. However, the results of a
logistic regression analysis using the current data set would need to be interpreted with
caution, because as previously discussed the reliability of the SDS as a measure of
benzodiazepine dependence with the current subject sample was questionable. The finding
that the original cut off score for benzodiazepine dependence did not detect dependence in
the current cohort prompted the cut off score to be reduced to 4. For this reason a multiple
regression analysis was computed first to establish whether psychopathology could
significantly predict SDS scores. Had this analysis not been statistically significant it could
have been considered somewhat questionable to analyse the data further using logistic
regression to predict category membership.
Multiple regression
Multiple regression casewise diagnostics found no outliers. A scatter plot found no
discernible pattern, confirming that the assumptions of linearity and homogeneity of variance
had been met.
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Table 14 reports the results of a stepwise regression analysis. Only two BS1 dimensions
achieved the entry criterion: anxiety and somatisation. The best model fit would appear to be
model 2, which includes anxiety and somatisation as both of these coefficients are
statistically significant. Model 2 accounts for 20.1 per cent of the variance in the dependent
variable (F (1,82) = 11.432; = <0.001).
Table 14: Results of the Multiple Regression Analysis for dependent variable SDS score
Model Summary
Adjusted Std. Error of
Model R R Square R Square the Estimate
1 .417a ,174 .164 2.1507
2 ,469b .220 .201 2.1025
a- Predictors: (Constant), LNANX
b- Predictors: (Constant), LNANX, LNSOM
ANOWf
Sum of
Model Squares df Mean Square F Sig.
1 Regression 79.868 1 79.868 17.268 ,000a
Residual 379.275 82 4.625
Total 459.143 83
2 Regression 101.070 2 50.535 11.432 ,000b
Residual 358.073 81 4.421
Total 459.143 83
a. Predictors: (Constant), LNANX
b. Predictors: (Constant), LNANX, LNSOM




















2 (Constant) 1.989 .639 3.112 .003
LNANX .766 .289 .298 2.650 .010
LNSOM .919 .420 .246 2.190 .031
a. Dependent Variable: total SDS
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Logistic regression
The result of the logistic regression analysis found that the BSI dimensions together explain
43 per cent of the variance in the dependent variable (benzodiazepine dependence using a
SDS cut off of 4). This result is statistically significant as illustrated by the Chi-square value.
However, the use of the backward stepwise option in logistic regression allowed for closer
examination of the relative importance of each of the BSI dimensions. This consideration
was relevant in order that the "best model" to explain the variance found in the dependent
variable could be posited.
See Appendix 6(c) for SPSS print out for all regression analyses
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Table 15: Results of the Logistic Regression Analysis for dependent variable BZD
dependence
Omnibus Tests of Model Coefficients
Chi-sauare df Siq.
Step 1 Step 32.350 5 .000
Block 32.350 5 .000
Model 32.350 5 .000
Step 7? Step -.004 1 .951
Block 32.346 4 .000
Model 32.346 4 .000
Step y Step -2.557 1 .110
Block 29.789 3 .000
Model 29.789 3 .000
Step 43 Step -2.450 1 .118
Block 27.339 2 .000
Model 27.339 2 .000
a- A negative Chi-squares value indicates that the
Chi-squares value has decreased from the
previous step.
Model Summary
-2 Log Cox & Snell Nagelkerke
Step likelihood R Square R Square
1 77.146 .320 .439
2 77.149 .320 .439
3 79.706 .299 .410
4 82.156 .278 .381









Step ANXMEAN -43.278 9.411 1 .002
1 INTMEAN -39.804 2.463 1 .117
SOMEAM -40.156 3.167 1 .075
DEPMEAN -41.195 5.244 1 .022
PHOBMEAN -38.575 .004 1 .951
Step ANXMEAN -43.318 9.488 1 .002
2 INTMEAN -39.879 2.609 1 .106
SOMEAM -40.184 3.219 1 073
DEPMEAN -41.259 5.368 1 .021
Step ANXMEAN -43.544 7.382 1 .007
3 SOMEAM -41.082 2.459 1 .117
DEPMEAN -41.517 3.327 1 .068
Step ANXMEAN -46.425 10.695 1 .001
4 DEPMEAN -43.093 4.030 1 .045
a. Based on conditional parameter estimates
Table 15 shows that anxiety and depression offer the best model for predicting the dependent
variable (38.1 per cent of the variance). Inclusion any of the others BSI dimensions, or any
first order interaction, does not significantly increase variance accounted for. Examination of
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the "change in -2 Log likelihood" statistic in Table 15 found that anxiety makes the
strongest contribution to the model, as to remove anxiety as a predictor increases the -2 Log
likelihood statistic significantly more than the removal of any other predictors. (See
Appendix 6(c) for the SPSS printout)
Rejection of the null hypotheses: Anxiety and depression were found to explain a significant
proportion of the variance in the dependent variable (38 per cent). On the basis of these
results it is posited that anxiety and depression are significant predictors of benzodiazepine
dependence. Therefore Hypothesis 1(b) which states that psychopathology will predict
benzodiazepine dependence is upheld.
Hypothesis 2
Hypothesis 2 predicted that long-term users of benzodiazepine medication would show
evidence of poorer sleep quality, as measured by the Pittsburgh Sleep Quality Index.
This hypothesis was tested using a one sample t-test. The authors of the PSQ1 (Buysse et al
1989) published mean global and component scores, across four diagnostic groups including
controls. Controls were described as "healthy control subjects without sleep complaints"
(p. 195).
The mean global PSQI score for healthy controls was reported as 2.67, this figure was
selected as the test value for a one sample t-test (N= 84).
One-Sample Test
Test Value = 2.67







global score 18.970 83 .000 8.4014 7.5205 9.2823
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The results of the one sample t-test demonstrate a very significant difference between the
mean global PSQI score found in the current sample and the mean global PSQ1 score for
healthy controls.
Rejection of the null hypotheses: The results found that long-term users of benzodiazepine
medication demonstrated significantly poorer sleep quality than healthy controls therefore
Hypothesis 2 is upheld.
Hypothesis 3
Hypothesis 3 predicted that those individuals exhibiting poorer sleep quality would have
increased levels of psychopathology.
Table 16 below shows that each BSI dimension correlates significantly with global PSQI
score demonstrating that increased levels of psychopathology is associated with poorer sleep
quality.
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global score Pearson Correlation 1.000
Sig. (2-tailed)
N 84
total raw bsi Pearson Correlation .515"
Sig. (2-tailed) .000
N 84
ANXIETY Pearson Correlation .502"
Sig. (2-tailed) .000
N 84
INTERPERSONAL Pearson Correlation .232*
Sig. (2-tailed) .033
N 84
SOMATISATION Pearson Correlation .443"
Sig. (2-tailed) .000
N 84
DEPRESSION Pearson Correlation .408"
Sig. (2-tailed) .000
N 84
PHOBIC ANXIETY Pearson Correlation .334*
Sig. (2-tailed) .002
N 84
•* = p=< 0.01 level
*
= p=< 0.05 level
A multiple regression analysis was computed to explore which of the BSI dimensions best
predict poorer sleep. Table 17 reports the results of a stepwise regression analysis. Only two
BSI dimensions achieved the entry criterion: anxiety and somatisation. The best model fit
would appear to be model 2, which includes anxiety and somatisation as both of these
coefficients are statistically significant. Model 2 accounts for 28.7 per cent of the variance in
the dependent variable (F (1,82) = 17.718;/? = <0.001).
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Table 17: Results of the Multiple Regression Analysis for dependent variable PSQI global
score
Model Summaryc
Adjusted Std. Error of
Model R R Square R Square the Estimate
1 ,502a .252 .243 3.5312
2 552b .304 .287 3.4271
a. Predictors: (Constant), LNANX
b. Predictors: (Constant), LNANX, LNSOM




Squares df Mean Square F Sig.
1 Regression 345.102 1 345.102 27.676 ,000a
Residual 1022.470 82 12.469
Total 1367.571 83
2 Regression 416.203 2 208.102 17.718 ,000b
Residual 951.368 81 11.745
Total 1367.571 83
a Predictors: (Constant), LNANX
b. Predictors: (Constant), LNANX, LNSOM




















2 (Constant) 6.587 1.042 6.323 .000
LNANX 1.668 .471 .376 3.542 .001
LNSOM 1.683 .684 .261 2.460 .016
a. Dependent Variable: global score
Rejection of the null hypotheses: The results found (in descending order of significance) that
anxiety, somatisation, depression, phobic anxiety and inter-personal sensitivity are
significantly correlated with poorer sleep. Anxiety and somatisation were found to
significantly predict poorer sleep. Hypothesis 3 was therefore upheld.
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Hypothesis 4
Hypothesis 4 predicted that individuals exhibiting greater dependence would be less
psychologically minded. Table 18 below shows that the difference between mean PMS
scores for dependent and non dependent groups is not statistically significant. Therefore the
null hypothesis can not be rejected.
However, a statistically significant difference in PMS score was found between those
individuals who used their benzodiazepines every day and those individuals who chose not
to take them every day.










Dependent 119.66 12.27 1.606 82 0.056
Not dependent 124.50 14.77
Frequency of
Benzodiazepine use
Daily 119.18 11.60 2.556 82 0.006
Not daily 127.26 15.96
SUMMARY OF HYPOTHESIS TESTING
• The results found that those individuals in receipt of a long-term repeat prescription for
benzodiazepines demonstrated significantly higher levels of somatisation and phobic
anxiety than the normal population. Hypothesis 1(a) was therefore upheld.
• The results found that anxiety and depression were found to be significant predictors of
benzodiazepine dependence. Hypothesis 1(b) was therefore upheld.
• The results found that the long-term use of benzodiazepine medication does not relieve
insomnia. Hypothesis 2 was therefore upheld.
• The results found that anxiety, somatisation, depression, phobic anxiety and inter¬
personal sensitivity are significantly correlated with poorer sleep; with higher levels of
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psychopathology found to accompany poorer sleep. Anxiety and somatisation were
found to significantly predict poorer sleep. Hypothesis 3 was therefore upheld.
SUMMARY OF ADDITIONAL SIGNIFICANT RESULTS
• Significant differences were found in the mean number of years in receipt of
benzodiazepines according to type.
• Living alone and benzodiazepine use only demonstrates a significant relationship when
benzodiazepines are commenced following bereavement.
• Pain was found to be significantly associated with poorer sleep, higher dose of
benzodiazepine and increased frequency of benzodiazepine use.
• Participants who use benzodiazepines less frequently are significantly more likely to
consider stopping them.
• Males are significantly more likely than females to consider stopping benzodiazepines.
• Older benzodiazepine users are significantly less psychologically minded than younger
benzodiazepine users.
• Younger benzodiazepine users exhibit significantly more psychopathology than older
benzodiazepine users. More variation across different types of psychopathology was
found in older benzodiazepine users.
• Daily benzodiazepine users were found to be significantly less psychologically minded
than infrequent benzodiazepine users.
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Chapter 9; Discussion
This final chapter discusses the results of the study and examines their significance and
clinical implications. Limitations of the research study are considered.
Relating the findings of the current study to the published research on long-term
benzodiazepine use
Prevalence rates of benzodiazepine use vary considerably. Chapter 1 reported that general
prevalence rates range from 2.2 per cent to 17.6 per cent. However, focusing more closely on
long-term use in primary care samples, the literature highlights a much higher proportion of
older adults in receipt of long-term benzodiazepines, with the rate of benzodiazepine users
per 1000 rising steadily across age bands (Chapter 5). Published prevalence rates in older
adults were rarely found to be less than 10 per cent. The literature also indicates that whilst
the prescribing of anxiolytics has reduced, the use of hypnotics with older persons has
remained fairly constant (Taylor et al 1998). In the present study, a small percentage of long-
term benzodiazepine users were in receipt of anxiolytics for anxiety disorders, although
diazepam which is an anxiolytic, was being used for sleep and associated medical health
problems. Whilst the general prevalence rate in the practice population studied was relatively
low (2.8 per cent) compared with other published studies, when this figure was examined
more closely prevalence rates in older adults were found to be considerably higher,
especially older females. Therefore, the study reflects the current prescribing trend with
respect to benzodiazepine use (i.e. higher levels of prescribed hypnotics with older adults).
It is clear from the data presented in the Results section that recommended prescribing
guidelines for benzodiazepines have not been adhered to with regard to participants in the
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current study. Almost 20 per cent of the sample was taking more than the BNF
recommended dose. More worrying was the finding that participants had been taking their
benzodiazepines for an average of 10 years; this figure far exceeds the recommendation of 4
weeks. In addition, over half the sample was prescribed a longer-acting benzodiazepine,
which, as discussed in the introductory chapters, is more likely to give rise to adverse effects
over time, particularly with older patients for whom the specific risk factors have been well
publicised. The literature proposes that the long-term use of hypnotics is likely to produce
tolerance. Whilst one can only speculate as to the presence of tolerance in the current
sample, it would not be unreasonable to suggest that a significant proportion of the sample
will have developed tolerance to their benzodiazepine medication, in view of the length of
time that they have been using it. It is therefore probable that these participants will no
longer gain any physiological benefit from using benzodiazepines. This is one possible
explanation for the significantly high PSQ1 scores, which demonstrate that despite the use of
"sleeping pills" 90 per cent of the sample report insomnia. This finding is in line with the
Committee on the Review of Medicines (1980) and the White House Office of Drug Policy
and National Institute on Drug Abuse (1979), who reported on the loss of efficacy of
hypnotics with continuous use. What is troubling about the finding that long-term hypnotic
use is ineffective in treating insomnia, is the fact that this information was reported over 20
years ago, yet the current study demonstrates that individuals are still being commenced on
long-term repeat prescriptions for hypnotics.
The age distribution of the sample showed that the largest group (35 per cent) in receipt of
benzodiazepines was over 80 years old. This finding is in line with prevalence rates reported
in Chapter 5 by Simpson et al (1990). The general perception of long-term benzodiazepine
use in older samples is that the most elderly persons are likely to have been taking their
benzodiazepines for the longest period of time. In the current sample no association was
found between age and the length of time a patient had been prescribed benzodiazepines. In
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addition, of those patients commenced benzodiazepines in the past 5 years nearly 50 per cent
were over the age of 70 years. Therefore, despite the evidence that older persons are most at
risk of adverse effects from benzodiazepine use, it would appear that they are still the most
likely group to be commenced on long-term repeat prescriptions.
The PSQI identified 90 per cent of the sample to be poor sleepers. Sleep efficacy was found
to be the most problematic of the seven sleep components comprising the PSQI. Participants
spent a mean of 9 hours in bed per night but slept an average of 6 hours; this amounts to poor
sleep efficiency. However, as reported in Chapter 2, ageing affects sleep requirement and by
the age of 60 years most individuals will only require around 6 hours sleep. Therefore, the
majority of participants were actually meeting their sleep requirement. Changes in sleep
duration and sleep architecture are a normal part of the ageing process, which means that an
increase in nocturnal awakenings and reduced sleep duration are a normal, not abnormal
feature of sleep as one gets older.
It is possible that sleep problems within the sample were, to some extent, related to
unrealistic expectations of sleep rather than actual sleep deficiencies. It has been suggested
that older adults prefer to spend more time in bed, not because they are tired but because of
boredom, social isolation and lack of purposeful activity. Therefore, retiring to bed "early"
contributes to poor sleep efficacy, but closer examination of the raw data reveals that for
many older participants sleep duration was adequate. This feature of the participants sleep
habits is further confirmed by the finding that sleep latency (time taken to fall asleep) was
the second most problematic component. Furthermore, the prevalence of daytime
dysfunction was relatively low in the sample; of the seven PSQI component scores daytime
dysfunction was the lowest. This would suggest that lack of sleep was not considerable
enough to impair daytime functioning. Instead, as psychopathology was found to
significantly correlate with daytime dysfunction, it was possible that in the current sample
psychopathology played a bigger part in daytime dysfunction than did lack of sleep.
100
In addition, it has been shown that a mismatch exists between subjective and objective
measures of sleep duration. Schneider-Helmert (1988) found that patients given
benzodiazepines overestimated their sleep duration by an average of 72 minutes as measured
by EEG recordings. In the same sample, when benzodiazepines were withdrawn the patients
underestimated the duration of their sleep by an average of 1 hour. It is possible that within
the current sample many participants "believe" themselves to be poor sleepers and this had
been reinforced by their long-term use of benzodiazepines. This belief may have
inadvertently influenced their self-report on the sleep measure.
In contrast to previous research evidence, some of the demographic features of insomnia
were not replicated in the current study. For example, as cited in the Introduction, insomnia
has been reported to be associated with older age, living alone and being female. The study
found no difference in PSQI scores across these groups. However, as PSQI scores were high
throughout the sample comparative analysis was self-limiting.
Each BSI dimension significantly correlated with total PSQI global score. Somewhat
surprisingly (because sleep problems are a diagnostic indicator of depression) although
depression correlated with poorer sleep it was not found to be a significant predictor of poor
sleep. In the current sample anxiety and somatisation were found to be significant predictors
of poorer sleep. Not surprisingly participants who were found to be dependent on
benzodiazepines had a significantly higher PSQI score. However there was no significant
difference in PQSI score between daily and less frequent benzodiazepine users. This is
further evidence that in this sample long-term use of benzodiazepines does not assist sleep.
The results found that participants gave a range of different reasons for commencing
benzodiazepines. With the exception of six participants that reported anxiety as the primary
reason for their benzodiazepine use, the sample reported that sleep difficulties had prompted
their original presentation to their general practitioner. However 38 per cent of this group
were unable to identify a reason or precipitant for their sleep problems. Very few participants
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seemed concerned about the length of time they had been taking their benzodiazepines and
belief in the efficacy of their benzodiazepines was very strong. Participants for whom the
original reason for commencement on benzodiazepines was no longer pertinent seemed to be
unconcerned that years later they were still taking them. Typical responses to the question of
"What is the current reason for your use of benzodiazepine medication?" were: (i) "I've
always been a bad sleeper"; (ii) "I would get even less sleep than I do already if I didn't take
a sleeping pill"; (iii) "I'm a light sleeper, the pills give me a better sleep". Most participants
said that without benzodiazepines their amount of sleep would be considerably less than it
currently was, and some participants reported that they were convinced that they would not
sleep at all.
Bereavement, stress or worry and pain were the three most common reasons for commencing
repeat prescription benzodiazepines. The "medical" reasons for commencement of
benzodiazepines, for example, pain, muscle spasms and tinitus remained constant over time.
Psychological reasons for commencing benzodiazepines, for example, worries, depression
and bereavement, were found to disappear over time. Nevertheless, these participants
continued to use their benzodiazepines, as they believed they would not be able to sleep
without them.
Although research has shown that older persons who live alone to be more likely to use long-
term benzodiazepines (Pinsker and Suljaga-Petchel 1984). No relationship was found
between the length of time in receipt of benzodiazepines and the length of time that an
individual had lived alone, unless benzodiazepines were commenced following bereavement.
Similarly, there was no difference in the reasons given for commencing benzodiazepines
according to whether a patient lived alone or with a partner, when bereavement was excluded
from the analysis.
Fifteen per cent of the sample were commenced on benzodiazepines following the loss of
their spouse; for most of these participants their bereavement was over 10 years previously.
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The usual features of bereavement normally include crying and sadness, anxiety, insomnia
and loss of appetite (Institute of Medicine 1998). However, using benzodiazepines, which
may provide relief in the short term with such symptoms, is not helpful long term.
Bereavement is a risk factor for depression (and therefore suicide), with between 10 and 20
per cent of widowed people developing clinically significant symptoms of depression within
the first year following bereavement (Report of the Surgeon General 1999). The institution
of benzodiazepines may mask a diagnosis of either adjustment disorder or depression with
the result that an individual would not receive appropriate treatment.
One of the surprising findings of the study was the lack of impact that medical conditions
appeared to have on the participants sleep and psychopathology. Chapter 2 presented
evidence that insomnia is frequently linked to a number of medical conditions and/or the
drugs used to treat such conditions (Kales and Kales 1984). Zanocchi et al (1999) found that
in an elderly sample, number of medications significantly correlated with poor sleep as
measured by the PSQ1. However, whilst the participants in the current study experienced
most of the medical conditions and used the medications reported by Kales and Kales, no
statistical association was found between the number of health conditions and poorer sleep.
Nevertheless, it was not possible to compare poor sleepers/good sleepers with medical
problems/no medical problems because almost the whole sample were poor sleepers with
medical conditions, therefore the effect on sleep of medical conditions may well have existed
in the sample but was not measurable. As one might predict a small but statistically
significant relationship was found between increased health problems and higher
somatisation scores. In addition, participants experiencing more health problems were also
found to take higher doses of benzodiazepines.
The study did find a significant relationship between pain, poorer sleep and increased use of
benzodiazepines. The two medical categories that were significantly associated with the use
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of pain relief were musculoskeletal conditions and gastro-intestinal conditions; most
commonly reported painful conditions included rheumatoid arthritis, osteoarthritis, ulcers of
the digestive tract or stomach cramps. This finding is in line with the Kupperman et al (1995)
research, cited in Chapter 2, which proposed that it is the painful feature of many medical
conditions that contributes most to sleep problems.
A large proportion of the sample did not wish to stop using benzodiazepines; females were
significantly less likely to want to stop than males. In addition, participants that used
benzodiazepines less frequently were significantly more likely, than daily users, to want to
stop taking them. The average participant that did not wish to stop taking their
benzodiazepine medication was older, took a higher dose and had been taking them for
longer, than the average participant who wanted to stop taking them.
As reviewed in Chapter Five older adults have been found to be much less likely to want to
stop benzodiazepine medication (Wright et al 1994). In view of the mean age of the current
sample (72), it is not surprising that this finding was replicated. One possible explanation for
the lack of interest within the sample to stop their benzodiazepine medication may lie with
the concept of psychological mindedness.
Psychological mindedness and psychological treatments with older people
Although, scores on the PMS were well below the population average (mean percentile rank
of 28), participants who reported that they used their benzodiazepines less frequently were
found to have significantly higher scores on the psychological mindedness scale.
Analysis found a significant association between age and PMS scores, with older adults
found to be less psychologically minded. The authors of the PMS described individuals low
on psychological mindedness as representing "a group one would not expect to be insightful
nor be open to, motivated for, or have the capacity for change" (p. 18) What the present study
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cannot tell us (because it did not include a control group) is whether being less
psychologically minded is a feature of older long-term benzodiazepine users or a general
feature of older age. Nevertheless, this is a significant finding as it suggests that
psychological mindedness could be a key determinant in the willingness to stop
benzodiazepine medication. It is therefore an area that warrants consideration in the search to
find ways to encourage long-term benzodiazepine users to stop their benzodiazepine
medication.
Of the three psychological mindedness scales reviewed for the current study it would appear
that none has been tested specifically on an older population. The normative data for
psychological mindedness scales derives from students and young adult samples and is a
limitation of using the PMS with older adults. Normative data for this age group would allow
a more accurate assessment of psychological mindedness in older adults.
Anther problem with the PMS was the length of the questionnaire. For individuals not used
to filling in questionnaires, or individuals with less education and literacy skills, the 45
"difficult" items were found to be tedious and time consuming. Participants commented that
they found the PMS items "hard to understand" and that they were repetitive. In addition,
eight of the PMS items asked the respondent about trying out new behaviours, one such
example "I like to try new things even if it involves taking risks". The more elderly members
of the sample remarked that due to frailty or current health problems, trying new things and
taking "risks" was not an option for them. More meaningful responses might have been
elicited from respondents if the items had not been worded in the present tense, but in such a
way that did not allow current health and other difficulties to restrict the way an older person
could respond.
The issue of psychological mindedness bears some relation to a much-debated topic in the
older-adult research literature regarding the efficacy of psychological therapies with older
adults. Older adults are often overlooked in terms of access to psychological treatments and a
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number of reasons for this situation have been proposed. Many older adults present with sub¬
clinical conditions, or with atypical symptomatology that makes assessment and diagnosis of
mental health problems more difficult. In addition, diagnosis of mental health problems in
older adults is often further complicated by high comorbidity with other medical disorders
(Report of the Surgeon General 1999). There are also stereotypes about normal ageing, for
example the "understandability phenomenon" (Blanchard 1996), which suggests that
depression and hopelessness are to be expected in older age as a consequence of losses or
bereavement and the common misconception that an older person is not capable of change
(Stanley and Averill 1999). These factors can serve as a barrier to psychological treatment
with the result that older adults are not referred for psychological therapies. This situation
creates a "vicious circle" whereby older people do not get the opportunity to learn about and
benefit from psychological input. This maintains the belief that psychological approaches are
less appropriate for the older person, which denies the older person the opportunity to
develop more psychological ways of thinking.
This is not to say that sometimes a different approach might need to be adopted when
working psychologically with older adults. However, this is usually little more than careful
socialisation to psychological ways of approaching emotional problems and dispelling the
misconceptions or cohort beliefs an older person may have about therapy.
If an older person has had a limited experience of psychological ways of thinking about and
approaching problems, this would explain poorer scores on a measure such as the PMS. For
example a common theme in the PMS is the notion that talking about worries and problems
can be helpful. However, if an individual has never been encouraged, or had the opportunity
to do this, they would be less likely to view talking about problems as potentially beneficial.
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Measuring benzodiazepine dependence in primary care
An important feature of the current study, which proved to be difficult to evaluate, was the
issue of benzodiazepine dependency. The prevalence of benzodiazepine dependency,
whether dependency was physiological or psychological and how best to measure it, all
proved to be difficult factors to assess.
The SDS was originally developed as a short self-report scale for measuring drug
dependency across a range of drugs. Adapted by De la Cuevas et al (2000) for use with
benzodiazepine users, the authors claimed that its items were "explicitly concerned with
psychological components of dependence" (p.246).
The pilot study (see Appendix 1) established that the sample population was reluctant to
consider that they could be "dependent" on benzodiazepines. The use of the word "addicted"
was forcefully denied by all the participants in the pilot study. Therefore, a questionnaire that
did not use such terminology was considered to be most appropriate. In addition, it appeared
that those individuals who took their benzodiazepines every day rarely missed a dose. This
gave rise to a situation in which symptoms of withdrawal, recurrence or rebound had not
been experienced to any significant degree. In addition, over 60 per cent of the sample were
prescribed a benzodiazepine with a long half-life. This meant that should a single dose be
missed, owing to the cumulative effects of the longer-acting benzodiazepines, withdrawal
symptoms are not immediately in evidence. Therefore, to have asked participants about
withdrawal symptomatology would not have been very productive because, for this sample,
withdrawal was not a salient issue.
That is not to say that participants would not experience withdrawal if they suddenly stopped
their benzodiazepines. Chapter 1 reviewed the prevalence of withdrawal reactions following
discontinuation of benzodiazepines. It is highly likely that owing to their long-term usage, a
large proportion of the sample would experience some degree of withdrawal if they stopped
their benzodiazepines, particularly in the absence of a gradual taper regime.
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In view of participants' limited experience of withdrawal (which is frequently used as a
measure of physiological dependence), the selection of a questionnaire that measured
psychological dependency had seemed most appropriate. However, the psychological
components of the SDS items focus on "impaired control over drug taking" and "anxieties
about drug use". It was found that these aspects of benzodiazepine use were not considered
to be a problem by the participants in the current sample and consequently only a small
amount of dependency was detected in the sample when the SDS was used with the
suggested cut off score of seven.
It is proposed that this finding is best explained by consideration of the context in which
long-term benzodiazepine use occurs for this cohort of users. Long-term repeat prescribing
of benzodiazepines is most commonly seen in primary care settings. In this context a patient
usually has a well-established and trusted relationship with their general practitioner. In
addition, older patients are reported to be more compliant about taking psychoactive
medications than other types ofmedication (Cooper et al 1982). Under these circumstances it
is unlikely that patients would question the appropriateness of their benzodiazepine
medication, especially if they take other medications for more serious medical conditions. In
such cases it is probable that the importance of compliance and adherence has been
impressed upon them. For many older persons, taking medications every day is a well-
established and unquestioned behaviour.
When participants were asked if they had ever questioned the use of their benzodiazepines,
they responded with comments such as "My doctor wouldn't give me them if they weren't
safe" or "I've been taking them for years and they've not done me any harm".
The procedure of repeat prescribing, which does not involve frequent patient doctor
consultation, could give the patient the impression that there is very little to be concerned
about with regard to the use of benzodiazepines. This attitude was reflected in the responses
to the question in the SDS that asked if the respondent had any worries about using
benzodiazepines ("Did you worry about the use of your tranquillisers?"). Similarly, when
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asked if they thought their benzodiazepine use was out of control ("Did you think your use
of tranquillisers was out of control?") participants overwhelmingly said that it was not,
because they took their tablets as prescribed. The two SDS items that appeared to measure
benzodiazepine dependence more reliably were "perceived difficulty to stop
benzodiazepines" and "concern about missing a dose". Although these concerns were
because the participants were worried about not sleeping, not about withdrawal.
The SDS therefore proved to be less than satisfactory in identifying dependence in the
current cohort. Despite having face validity in practice the SDS items demonstrated poor
internal consistency, as they did not correlate well with each other (range 0.04-0.44). The
Results section presented evidence to support a reduced cut-off SDS score in the current
sample in order to increase the sensitivity of the measure. Ideally, to select an appropriate cut
off score on the SDS for this sample, the study should have included another standardised
measure of dependency with normative data for older adults, against which to assess the
SDS. Instead frequency of benzodiazepine use was selected as a "rough guide" to gauge the
presence or absence of dependency. It was not the intention to suggest that the frequency of
use variable was "better" than the SDS in detecting benzodiazepine dependence, rather that it
was useful in highlighting the rationale underpinning the decision to reduce the SDS cut-off.
Poor reliability demonstrated by both the PMS and SDS with this sample could be partly
attributable to the cohort beliefs found within the sample. Thus highlighting the problem of
using measures that have been developed with other types of client group. The (older)
primary care sample in the current study held beliefs that were incongruent with the themes
being measured by the SDS questionnaire. In particular, the notion of dependency was not
regarded as relevant by the participants, who appeared to hold stereotypical views about
"drug addicts" as very distinct from themselves. Alternatively, if the PMS did reliably
measure psychological mindedness, thus demonstrating that older people are less
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psychologically minded, this could explain why the SDS (designed to measure the
psychological component of dependency) was not a useful measure with the current sample.
The problems observed with the use of the SDS in the current setting emphasise the need for
a dependency measure specifically designed for older people. In addition, the PMS could be
made more applicable for older adults by rewording items to account for limitations that
accompany normal ageing, as these may have affected the ways in which respondents
answered the questions.
Psychopathology in long-term benzodiazepine users
The BSI was used to measure anxiety, depression, somatisation, phobic anxiety and
interpersonal sensitivity. Psychopathology was examined in relation to insomnia and
benzodiazepine dependency. Elevated levels of pyshopathology were found across the total
sample, with the prevalence of somatisation found to be greater than the other
psychopathologies. This was not a surprising finding as the literature suggests that older
adults are more likely to report somatic symptoms (Blazer 1996) and that somatisation has
been found in up to 37 per cent of patients with severe insomnia (Mellinger et al 1985).
Chapter 3 reported that generalised anxiety was more prevalent than other anxiety disorders,
however, the combined prevalence of phobic disorders (agoraphobia, simple phobia and
social phobia) in older adults has a reported prevalence rate of 10 per cent (Lindesay et al
1989). This may explain the higher scores for phobic anxiety rather than anxiety, as
measured by the BSI in the current sample. Although older women were found to exhibit
higher levels of symptomatology than did older men, this difference was not significant.
Previous research has found that, in general, women are more likely to experience higher
levels of psychopathology than men. However, this finding is less consistent in older adult
samples, with a number of published studies presenting conflicting results (Hale and
Cochran 1983). In the current study, as psychopathology appears to be associated with
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benzodiazepine use, this is likely to offset potential sex differences and, indeed, no
significant sex differences were found.
While both somatisation and anxiety were found to significantly predict sleep difficulties,
anxiety was shown to be a much stronger predictor. A similar result was found for severity
of dependence in that somatisation and anxiety were found to be significant predictors, but
again anxiety demonstrated a larger effect. When dependence was measured as category
membership, anxiety and depression were significant predictors, but yet again anxiety was
the main predictor. Because sleep difficulties and benzodiazepine use are associated in this
study, it is not possible to determine whether the relationship between anxiety and sleep, and
anxiety and dependency, are independent of one another, or whether they are the same
relationship. To tease out the relationship between dependency, sleep and anxiety would
have required a further comparison including participants that used benzodiazepines but did
not still have a sleep problem.
The key finding, therefore, is that of the psychopathologies investigated, the prevalence of
somatisation was greater than other psychopathology, but that anxiety was the most
significant feature of sleep difficulties and long-term benzodiazepine dependence, although it
is not possible to establish the causal factors in this association.
Some studies have shown that significant levels of anxiety and depressive symptomatology
are to be found in those individuals that have been using benzodiazepines long term. When
such individuals were successfully withdrawn from their benzodiazepines, many were shown
to have significantly improved anxiety and depression scores. The conclusion from this
finding was that long-term benzodiazepine use might worsen anxiety and depression
(Schweizer et al 1990). Therefore, whilst the institution of benzodiazepines is likely to
provide some relief in the short term, in the long term the patient is not helped by their
continued use and may even feel worse. This could be due to either physiological effect such
as tolerance and rebound effects and or the psychological effects of psychological
dependence.
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Psychological treatment approaches for anxiety and insomnia in older adults
The results of the present study suggest that it may make more sense for insomnia to be
viewed as an anxiety problem. The treatment of anxiety has moved on since the 1960s and
1970s when Valium was readily prescribed, and this is reflected in the drop in anxiolytic
prescriptions. The preferred choice for the treatment of anxiety is now a psychological
approach (Nathan and Gorman 1998). What remains unclear is why the treatment of
insomnia has not seen a similar shift in approach from the use of pharmacological to
psychological intervention. Could this be because the treatment of insomnia mainly concerns
older adults who, as mentioned previously, are less likely to be referred for psychological
therapies?
Psychotherapeutic interventions for anxiety disorders in older adults have not been as well-
researched as in younger populations, for whom a well-established body of evidence has
found psychological interventions to be efficacious (Sunderland et al 1991). In contrast, the
study of depression in older adults has received more attention with regard to the efficacy of
psychological treatment, with a number of meta-analyses reporting significant results in
favour of psychological treatments for late-life depression, particularly the use of cognitive
behaviour therapy (Laidlaw 2002). Nevertheless, non-pharmacological anxiety treatments
for older adults have shown that the use of psychological interventions can be effective, for
example the use of relaxation techniques (DeBerry et al 1989; Scogin et al 1992) and
cognitive behaviour therapy (King and Barrowclough 1991; Stanley et al 1996; Gorenstein et
al 2000). With growing evidence to support the use of cognitive behaviour therapy (CBT)
for late life depression there does not appear to be any reason why the use of CBT for
anxiety in older adults could not prove to be equally effective.
Approaches to the psychological treatment of insomnia with older adults include anxiety
management techniques such as relaxation training (Bootzin and Perlis 1992) and the use of
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CBT to target maladaptive cognitions (Morin et al 1995). Other efficacious behavioural
approaches used to treat insomnia include stimulus control therapy, sleep restriction therapy
and sleep hygiene education (Nowell et al 1998).
"No systematic data support the idea that elderly patients are too old for psychological
change. Most experts agree that, provided cognitive function is intact, elderly patients
respond well to psychotherapeutic interventions." (p.45 Small 1997).
Therefore, if effective psychological treatments for anxiety and insomnia are available, why
then within the older adult population are they not more widely employed. This brings the
discussion back to the issues raised earlier regarding the use of psychological therapies with
older people.
In terms of approaches to benzodiazepine withdrawal, psychological input such anxiety
management and support with gradual-taper regimes have also been found to be beneficial.
Jones (1991) reported a randomised controlled trail in a primary care setting (N = 200) in
which twice as many patients in the treatment group reduced their benzodiazepines
compared with control group. Treatment consisted of counselling and relaxation therapy by a
practice nurse and a clinical psychologist.
In summary, whether the problems of insomnia are caused by basic misconceptions about
sleep requirements in old age, as a result of underlying anxiety owing to psychological
distress or health problems or anxieties about discontinuing benzodiazepines, the research
evidence shows that psychological approaches offer a safer and more effective treatment
option than long-term benzodiazepine use.
The Department of Health made the following statement in a Health of the Nation strategy
document " Further effort is needed to review the use of benzodiazepines and replace them,
as necessary, with behavioural, cognitive and psychotherapeutic methods." (1992).
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Methodological issues
Meeting the required sample size was found to be a problem with this study. The projected
number of participants required for the study was 91. The study ran into difficulties
recruiting this number from the original general practice in which the study was based,
which prompted the need to recruit from a second general practice and cost more time.
Despite access to a second practice population subject numbers fell short of the estimated
requirement (the total number of participants that took part in the study was 84). Fortunately,
statistically significant results were achieved despite the shortfall in number.
Although the pilot study had given some indication of the time required for data collection, it
proved impossible to predict accurately the amount of time data collection would take. The
study was set in a rural setting, with the average home visit involving a return journey of 45
to 50 miles. Therefore visiting the majority of participants in their own homes was very time
consuming. One alternative would have been to compose a questionnaire to collect the
demographic information, which could have been posted along with the study questionnaire,
thus removing the need to visit each participant. Although response rates to postal
questionnaires are usually low, because of the time-saving feature of this method more
general practices could have been included in the study, which may have resulted in similar
total of participants. However, it is questionable whether all participants would have filled in
the questionnaire without help, as the PMS questions were reported to be challenging to
complete. Also, without the interview the depth of qualitative data would have been absent.
The discussion has already highlighted the problems with the PMS and SDS in an older adult
sample. The use of the PSQI was found to identify 90 per cent of the sample as poor
sleepers, as this was such a large proportion it raised the question of whether the cut-off of
five was set too low for an older sample. A study was located that used a cut-off score of
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eight for the PSQI (Fichtenberg et al 2001); however, this was with a sample of brain-injured
patients. A further study was found in which the authors of the PSQI examined subjective
sleep quality in "healthy" older adults (>80 years). Using the cut-off score of five the results
found that "overall sleep quality for the majority (68.1 per cent) of 80-yr-olds fell within a
categorically defined range for "good" sleepers" (p.331 Buysse et al 1991). This would
suggest that the PSQI cut-off score used was indeed satisfactory.
Participation in the study was voluntary. Forty-eight per cent of the individuals invited to
take part chose not to. Unfortunately therefore, the characteristics of these benzodiazepine
users remain unknown. A common theme elicited from the individuals that did take part was
suspicion about whether they would continue to be prescribed benzodiazepines. This concern
was met with reassurance from the researcher in that regardless of the information they gave
during their participation in the study, their prescription would not be altered in any way.
Most participants appeared genuinely relieved following this reassurance. It is possible that
this suspicion prevented a number of potential participants from taking part in the study.
An additional component to the study that had to be omitted due to time constraints was to
have included an investigation of the general practitioners views on, and their criteria for
prescribing long-term repeat benzodiazepine prescriptions. It would also have been
interesting to establish how familiar general practitioners were with the specific problems
associated with long-term benzodiazepines in older adults.
A further component to the study originally considered was to utilise the information from
the study to inform alternative treatment options. This would have involved helping
participants to withdraw from their benzodiazepine medication, using the information
gathered from each individual patient to inform their own treatment package. For example, if
a participant was found to be experiencing elevated levels of anxiety, an approach
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incorporating anxiety management would be more suitable, if on the other hand the sleep
problem was due to poor sleep habits, sleep hygiene work may be most appropriate.
Unfortunately, very few participants came forward expressing an interest in discontinuing
their benzodiazepines.
The main difficulty with the data collected in this study lie with the interpretation of the
complex relationships between the principle variables measured. It was not possible to
control for the interactions between benzodiazepine dependency, sleep problems and
psychopathology. These interactions between the variables prohibit speculation regarding
causal relationships. In addition, two further variables, medical health problems and pain, are
likely to have confounded these relationships further.
Future directions
The important question that remains unanswered is why do general practitioners continue to
prescribe long-term repeat prescription benzodiazepines when all the evidence clearly
contraindicates their long-term usage. One answer could be the lack of alternative treatment
options available to general practitioners. Whilst the research points to psychological
approaches as being the way forward in the treatment of anxiety and insomnia, inequity of
access to clinical psychology services continues to be a problem. Referrals to psychology
continue to increase, resulting in longer waiting lists as supply does not match demand.
General practitioners are therefore faced with a situation in which they have to prioritise
which patients they refer to psychology.
Although non-pharmacological treatments inevitably cost more than the price of
benzodiazepine medication, there are more cost-effective ways of helping people to
discontinue using their benzodiazepines, which can be achieved without recourse to
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expensive one-to-one therapy from a clinical psychologist. Within the multidisciplinary
setting, clinical psychologists are being increasingly called upon to supervise and support
other professionals, such as practice nurses and assistant psychologists, in carrying out basic
anxiety management work, sleep hygiene and psychoeducation, which can be carried out
individually or in groups. A study by Holden et al (1996) found that general practitioners
want to help their patients withdraw from benzodiazepines, therefore clinical psychologists
could work together with general practitioners to support them in this objective.
Is it fair, however, to place all the responsibility for the current situation, in which older
adults are continuing to use benzodiazepines, despite their lack of efficacy and potentially
harmful effects, solely with general practitioners? Participants in the current study were all
given the opportunity to discontinue their benzodiazepines with support from their general
practitioner and a clinical psychologist. Each participant was given an information leaflet
about their benzodiazepine medication, which highlighted the possibility of adverse effects
with long-term use. To date, only 7 per cent of the sample has expressed an interest in
stopping their benzodiazepines.
Doctors that prescribe benzodiazepines more frequently to older patients than to younger
patients may be accused of ageism. However, the issue of ageism is a broader problem based
on societal perceptions of old age, to which older people themselves have been found to
contribute. Many older people hold the same negative ageist assumptions as do younger
people, typically that they are "too old to change". This was a reccurring theme encountered
in the current study. Fortunately, society's attitudes to old age are changing as shown by the
concept of active ageing (WHO, 2002), which is described as the process of optimising
opportunities for older people in order to extend healthy life expectancy, productivity and
quality of life in older age. This philosophy is at odds with the long-term use of
benzodiazepines in older adults.
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Conclusion and clinical implications
To conclude, the study found that despite all the evidence contraindicating the use of long-
term benzodiazepines, the practice of long-term prescribing of benzodiazepines is still found
to be taking place in primary care. Whilst patients present to their general practitioners
complaining of sleep difficulties, for many the underlying problem is one of anxiety. The
study shows that neither anxiety or insomnia benefit from long-term use of benzodiazepines
and it is postulated that over time the disadvantages of long-term usage outweigh any short
term benefit.
In order to avoid commencing their patients on benzodiazepine medication general
practitioners require an alternative option. It is suggested that psychological approaches offer
the most effective alternative to pharmacology.
Recommendations for a proactive strategy based in the primary care setting should include:
• Improved access to psychological treatment approaches.
• Provision of specialist older adult psychology services.
• Increased use of clinical psychologists in their consultancy role.
• Implementation of a treatment protocol which would include a policy of comprehensive
assessment.
This research study has shown that the majority of primary care patients on long-term
benzodiazepine prescriptions have significant psychopathology and that they are reluctant to
consider discontinuation of their benzodiazepines. Therefore, a more proactive strategy
incorporating psychological approaches may provide the only realistic option to address the
problem of reducing long-term benzodiazepine use in the future.
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PILOT STUDY
Introduction
A pilot study was carried out in order to gather information, which would inform the design
of the larger research study.
The pilot study consisted of collecting qualitative and quantitative data relating to patterns of
benzodiazepine use in an identified general practice. This general practice comprised four
general practitioners with a total of 4988 registered patients over the age of 16 years.
Method
Data collection was undertaken in two stages. Stage one involved auditing existing patient
records, using the Health Centre's computerised system of recording patient information.
Stage two involved the researcher collecting information directly from a small number of
patients who were identified as being in receipt of a repeat prescription for benzodiazepine
medication by their general practitioners.
Stage One
The General Practitioner Administration System for Scotland (GPASS) was established in
1984 using software originally developed by a Glasgow general practitioner. GPASS is a
national computerised primary care system and is now used in over 84 per cent (N= 855) of
general practices in Scotland. It allows access to patients' prescription records, for example,
which medication a patient is in receipt of, prescribed dose, and frequency of collection of
repeat prescriptions. GPASS data was used to answer the following questions:
1
1. How many patients within the identified practice had been in receipt of a repeat
prescription for more than 3 months?
2. Which of the benzodiazepine drugs were most frequently prescribed by the general
practitioners? How many patients were prescribed each of the different benzodiazepines?
3. What is the ratio of male to female patients in receipt of a repeat prescription for
benzodiazepine medication?
4. Are different benzodiazepine drugs prescribed according to sex?
5. How many patients and what type of benzodiazepine medication is prescribed according
to age group?
6. How many patients are in receipt of a repeat prescription according to individual general
practitioner?
7. How long have patients been in receipt of repeat prescription?
Stage Two
Participants
Nine participants took part in stage two of the pilot study. Of the nine participants three were
female. The age of participants ranged from 52 to 83 years (mean 73.1years, SD 9.30).
Length of time in receipt of a repeat prescription for benzodiazepine medication ranged from
1 to 17 years (mean 9.44, SD 5.10).
Materials
A semi-structured interview was conducted with each participant and each participant filled
in the Hospital Anxiety and Depression Scale (HADS) (Snaith & Zigmond 1994). The
HADS is a 14-item questionnaire that is widely used as a screening instrument. It provides a
2
measure of symptomatology for anxiety and depression, with cut-off scores based on
normative population data.
In addition, participants also filled in two questions from the Pittsburgh Sleep Quality Index
(Buysse et al 1989). The two questions form one component score, labelled "Daytime
dysfunction". Scores for the "Daytime dysfunction" represent a continuum with a range from
0 to 3; a higher score indicates more daytime dysfunction due to lethargy.
Procedure
Twelve patients registered with the identified practice were approached by their general
practitioners and asked if they would consent to being contacted by the researcher to answer
a number of questions about their use of benzodiazepine medication.
During a 4 to 6-week period the first three patients attending each general practitioner (for
any reason), who were in receipt of a benzodiazepine prescription, were invited to participate
in the pilot study; the selection process, therefore, was not strictly random. However, as the
general practitioners were under instructions to approach the first three patients they
encountered during the identified period of time, this helped to minimise selection bias. In
addition, the general practitioners were blind to the exact questions that would be asked of
their patients.
Of the twelve patients that were asked by their general practitioners to participate in the pilot
study, nine agreed to meet with the researcher. Once consent had been given the researcher
contacted each patient and arranged a home visit.
3
The amount of time spent with each participant varied from 40 to 60 minutes and was
dependent on the volume of information volunteered by a participant during the semi-




1. Number of patients (>16 years) registered with the identified practice who were in
receipt of a repeat prescription for more than 3 months.
A =147
2. Type of benzodiazepine drug most frequently prescribed by the general practitioners and
the number of patients prescribed each type.
Nitrazepam = 49 Lorazepam = 2
Temazepam = 59 Diazepam = 37
3. The ratio of male to female patients in receipt of benzodiazepine medication.
Females = 105 Males = 42
Ratio 2.5:1
4. Type of benzodiazepine medication prescribed according to sex.
Table 1 reports the number of patients prescribed each type of benzodiazepine medication
according to sex. Because over twice as many females as males were prescribed
4
benzodiazepine medication, these figures are also presented as a percentage of the total
number in each sub-group, this allows for comparison across the two groups.
Table 1: Distribution of four types of benzodiazepine medication according to sex
Females Males
N % of females N % of males
Diazepam 25 23.8 12 28.57
Temazepam 42 40 17 40.47
Nitrazepam 37 35.23 12 28.57
Lorazepam 1 0.95 1 2.38
Total 105 42
There would appear to be no significant difference with regard to the distribution of each
type of benzodiazepine prescribed across the two groups.
Figure 1: Graph to show the percentage of each benzodiazepine (excluding lorazepam)
prescribed according to female and male sub-groups
% of the 3 most commonly prescribed
BZD in female and male sub-groups
5
5. Number of patients and type of benzodiazepine medication prescribed according to age
group.
Table 2 reports the number of patients prescribed each type of benzodiazepine medication
according to age group. Total number of patients represented in Table 2 = 145; lorazepam
data excluded.
Table 2: Distribution of the three most commonly prescribed benzodiazepine medication
according to age range
Age range (years)
30-39 40-19 50-59 60-69 70-79 80-89 90-99
No of patients on
Diazepam
2 5 10 7 6 5 2
No of patients on
Temazepam
1 2 11 10 12 18 5
No of patients on
Nitrazepam
1 0 5 7 19 16 1
Total 4 7 26 24 37 39 8
Figure 2: Graph to show the number of patients prescribed benzodiazepine medication
(excluding Lorazepam) according to age range
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6. Number of patients in receipt of a repeat prescription according to individual general
practitioners.
Table 3 reports the number of patients prescribed each type of benzodiazepine medication
according to individual general practitioners. Data are also presented as a percentage of the
total number of patients per doctor; this allows for comparisons between the four doctors.
There are a number of obvious problems when comparing the prescribing patterns of
individual general practitioners; these are highlighted in the discussion. Nevertheless, the
purpose of examining these data was simply to consider (i) whether the general practitioners
were all prescribing benzodiazepine medication to a similar extent, and (ii) whether
individual general practitioners favoured certain benzodiazepine medication to the exclusion
of other types.
Table 3: Distribution of each benzodiazepine medication according to individual general
practitioner
Doctor A Doctor B Doctor C Doctor D
N % N % N % N %
Diazepam 7 17.5 10 27.07 16 32 4 20
Temazepam 22 55 13 35.13 13 26 11 55
Nitrazepam 9 22.5 14 37.83 21 42 5 25
Lorazepam 2 5
Total 40 37 50 20
Doctors' A and D have a greater percentage of their patients in receipt of temazepam
medication. Doctors' B and C have a greater percentage of their patients in receipt of
nitrazepam medication. Nevertheless, it does not appear that any of the general practitioners
favour the prescribing of one benzodiazepine to the exclusion of all others.
7. Length of time patients (N= 147) have been in receipt of repeat prescription.
Mean no. of years = 5.30 (SD 4.65)
7
Figure 3: Graph to show the length of time patients have been in receipt of their BZD
prescription.
Number of years in receipt of BZD
Number of years
Figure 3 illustrates that the largest grouping: 35 per cent of the sample have been taking their
benzodiazepine medication for between 6 and 10 years. The second largest grouping are
those patients who have been taking their benzodiazepine medication for between 1 and 5
years; this group forms 31 per cent of the sample.
Stage Two
Questionnaire
Table 4 reports participants' questionnaire scores for HADS and the Pittsburgh Sleep Quality
Index (PSQI) - daytime dysfunction score.
The P1ADS provides both an anxiety score (range 0-21) and a depression score (range 0-21);
with higher scores indicating the presence of more symptomatology. HADS scores for each
condition are grouped in four categories of severity:
0-7 = normal 8-10 = mild 11-14 = moderate 15-21= severe
8
Table 4 also includes each participants' daytime dysfunction score (range 0-3) derived from
two questions in the PSQI. A higher score indicates an increase in daytime dysfunction due
to lethargy.
Table 4: HADS and PSQI scores for nine benzodiazepine users
Participant Anxiety Depression Day-time
score score dysfunction score
1 8* 7 1
2 3 6 0
3 5 1 0
4 5 2 0
5 5 5 1
6 8* 4 1
7 4 1 1
8 20* 8* 1
9 9* 7 2
(* = above cut off)
Table 4 shows that four of the nine participants had significant scores for either anxiety or
depression. Three participants demonstrate mild anxiety and participant number 8
demonstrated severe anxiety and mild depression. With the exception of participant 9,
daytime dysfunction appears to be minimal.
Semi-structured interview data
The purpose of the semi-structured interview was to collect a range of qualitative
information from the nine long-term benzodiazepine users. Information volunteered by the
participants varied considerably in content and was therefore difficult to quantify and
categorise.
However, each participants discourse included responses to a number of predetermined
questions. A brief synopsis of these individual responses can be found in the Pilot study
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appendix. Below, a general summary of the nine individual synopses found in the Pilot study
appendix is given.
Bereavement, health anxiety and stress were the most commonly reported problems which
led to the patient consulting their general practitioner. In almost every case the patient
presented to their general practitioner as having sleep difficulties as a result of these
problems and a repeat prescription for a benzodiazepine medication was given.
Four patients were in receipt of temazepam, three patients were in receipt of nitrazepam and
two patients were in receipt of diazepam. Interestingly the three patients taking nitrazepam
each reported experiencing the "hangover effect". Two of the three had found this had
previously interfered with their work performance (they were still in employment at the
time) and they had subsequently revisited their general practitioners which had resulted in a
dosage reduction. Following participation in the research, the third patient (Participant 9 in
Table 4) consulted his general practitioner about feeling "sleepy" in the mornings and was
transferred on to a prescription for temazepam. With the exception of one patient, who found
that benzodiazepine medication affected bowel movement, there were no other reported side-
effects.
Only one patient reported that the effectiveness of their medication reduced over time.
However, two patients described their use of benzodiazepine medication to be "infrequent"
(one or two nights a month) and another patient said that he deliberately chose to take his
benzodiazepine on alternate nights to avoid "getting too used to it"
With the exception of participant 5, all participants reported sleeping an average of 4-5
hours per night. The sample divided equally into two groups; those that fell to sleep easily
and those that found that it took them a long time to fall asleep. There was no association
between length of time taken to get to sleep and psychopathology, as measured by the
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HADS. Also, there did not appear to be a link between difficulty in falling to sleep and
length of time on benzodiazepine medication. For example, of the four participants that
reported it took them a long time to get to sleep, two had been taking benzodiazepine
medication for over 10 years; in contrast, the other two participants had been taking
benzodiazepine medication for 1 year. This is a worthwhile line of inquiry because
prescribing guidelines suggest that the efficacy of benzodiazepine medication diminish over
time. Despite half the sample complaining that it took them a long time to get to sleep, they
did not appear to perceive this as an indication that their medication was not very effective.
Instead, they all believed that without any medication at all they would sleep for fewer hours.
Of those four participants that reported less difficulty in getting to sleep, three did not take
their benzodiazepine medication every day and the fourth participant (participant 7) in this
group exceeded his prescribed dosage most nights. Interestingly these four participants were
all using temazepam. The remaining five participants in the sample (of whom four reported
difficulty in getting to sleep) were all prescribed nitrazepam or diazepam medication.
When the participants were asked how much they felt that they needed to take their
medication they all denied "addiction" with regard to their benzodiazepine use. The three
"infrequent" users each suggested that they could not be dependent/addicted because they did
not take their tablets every night. Of the remaining six participants that took their medication
every day, three said that they "must be dependent" because they needed their tablets to get
to sleep. A further two participants said that they "needed" to take their tablets every night to
get to sleep, but that they were not "dependent" or "addicted" to them. Finally, one
participant said that their benzodiazepine was a "habit" but that she was not "dependent on
them"
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Five participants said that they did not want to consider stopping or reducing their
benzodiazepine use. Of the four that said they would consider stopping their benzodiazepine
use, two said that they would not seek help with this - they said that they would prefer to
stop by themselves. Two participants said that they thought the first step if they decided to
stop taking their benzodiazepine would be to speak to their general practitioner.
Discussion
In summary, audit of repeat prescriptions for benzodiazepine in a small rural practice found
2.94 per cent of the total practice population over the age of 16 years to be in receipt of a
prescription for benzodiazepine medication. Approximately two-thirds of this sample were
over 65 years old.
In line with the claim made by Hawley (1994) who said that there has been a decline in the
prescribing of anxiolytic medication, whilst prescribing rates for hypnotics have remained
constant, the vast majority of the sample would appear to be prescribed benzodiazepines for
sleep difficulties.
The audit found the ratio of female to male prescribed benzodiazepines was two and a half
females per male. This is a predictable finding for two reasons, firstly it is generally felt that
women are far more likely than men to present to their general practitioners and talk about
their worries (Butler & Hope 1995). Secondly, as women tend to live longer than men, the
ratio of females to males is naturally higher in the elderly population.
With the exception of two cases, where lorazepam was prescribed, the general practitioners
used the same three benzodiazepine drugs for all cases requiring an anxiolytic or hypnotic.
Prescribing patterns of individual general practitioners did not significantly differ. It is also
important to bear in mind that some general will have "inheritied" patients already in receipt
of a repeat prescription. Also, of the four general practitioners only one was female (part-
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time). It is therefore possible that she would have a higher proportion of female patients, who
as mentioned already, are more likely to present with problems that lead to the general
practitioners prescribing benzodiazepine medication. In addition, one of the general
practitioners had been with the practice considerably longer than the other three. This
general practitioner was more likely to have a greater number of elderly patients.
Questionnaire data and semi-structured interviews with nine long-term benzodiazepine users
found the following features. Almost half the sample (45per cent) were found to demonstrate
a significant degree of anxiety and or depression, as measured by the HADS. A higher
incidence of anxiety compared with depression was found, although caution should be
exercised because, with the exception of one participant, scores were "borderline" with
regard to clinical significance.
Participants that were prescribed the longer-acting benzodiazepine, nitrazepam, reported
"hang-over" effects.
With the exception of one participant, those participants prescribed temazepam took their
medication less frequently than the rest of the sample (who used their medication every day).
These three participants reported that they were prepared to accept some sleeplessness when
they did not take their tablets, as they knew they could "fall back on" their medication when
they felt they "really needed it". It was interesting to note that of the six participants' that
took their medication every day, only one was using a short-acting benzodiazepine
(temazepam), the other five participants were prescribed the long-acting benzodizepines
nitrazepam and diazepam.
In general, the sample were reluctant to consider that they were "dependent" or "addicted",
although a small number volunteered the word "dependent", the word "addicted" was
vigorously denied by all participants.
Of the sample of participants that were asked if they would like to stop using their
benzodiazepine medication, less than 50 per cent were prepared to consider the option. This
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finding is comparable with published research (Wright et al 1994, Linden et al 1998). The
only reason participants gave for this was because they felt that they would not get any sleep
without their tablets.
Implications for the main study
It is not possible to draw definitive conclusions from the information gathered in the pilot
study. Nevertheless, the data collected informed the choice of standardised measures chosen
for the larger study.
Firstly, as a result of the pilot study, it was felt that the HADS might not be a sensitive
enough measure for use with the larger sample. This was because the audit information
revealed that the potential sample for the larger study would consist of a large majority of
older adults. There exists some research evidence which argues that the HADS is a less
accurate measure of anxiety and depression in older adults (Kenn et al 1987, Flint and Rifat
1996, Davies et al (1993). However, the use of the HADS with the nine participants in the
pilot study, did elicit the presence of some anxiety and depressive symptomatology in the
sample and therefore confirmed the validity of assessing for depression and anxiety in this
group of patients.
Secondly, the pilot study demonstrated that individual use of benzodiazepine medication was
mostly attributed to sleep difficulties. Therefore, the use of a comprehensive measure of
sleep quality would be important for use with the larger sample. Also, dialogue with the
small sub-sample revealed that whilst sleep difficulties were found to be the common
presenting problem, which prompted the prescription for benzodiazepine medication, the
participants disclosed a range of different problems as the "cause" of their sleep difficulties.
This finding informed the decision to include a standardised measure that was designed to
screen for a number of clinical disorders.
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Thirdly, the pilot study revealed an interesting and potentially important difference within
the sample. A proportion of those patients in receipt of a repeat prescription did not take their
medication on a daily basis. These participants reported that they preferred not to take their
tablets unless they felt it was completely necessary, for example if they had not had
"enough" sleep in the preceding nights. One participant described his tablets as an "insurance
policy". An important part of the larger study would be to explore what (if any) is the
difference between patients that choose not to take their tablets daily and those that do take
them every day. It would therefore be meaningful to include measures that would assess
subject variables in addition to psychopathology. One option might be to consider a patient's
use of alternative resources to that of pharmacology, for example psychological resources
(psychological mindedness). A further variable to consider is that of (perceived) dependence
on benzodiazepine medication.
In summary, the pilot study used both audit data (N = 147) and qualitative data (N=9): these
data provided a good starting point with regard to informing which variables would be
important to consider in the larger study.
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1. How long been taking BDZ >10 years
2. Type of BZD? Temazepam
3. Frequency? Infrequent use - as required
4. What problems were you having prior to the receipt of your prescription?
Clinical depression
7. What was the initial effect of your BZD medication? Good sleep
8. What is the current effect? Still helps with sleep although used infrequently
9. Have you noticed any side effects? No side effects
V
10. Do you need to take your BZD every
day?
I'm not addicted to them because I don't
use them every night
11. Do you have sleep difficulties?
I fall asleep quickly but wake after 4
hours, I always awake at 5am
12. Do you smoke?
No
13. Do you drink?
No
15. Who would you like to help you, if you would like to stop taking your BZD?
I could stop by myself
14. Would you like to stop taking your BZD?
Yes, I don't want to be dependent on them
Participant 2
1. How long been taking BDZ >10 years
2. Type of BZD? Diazepam
3. Frequency? Every night
V
4. What problems were you having prior to the receipt of your prescription?
Family stress
V
5. What was the original reason for 6 Do yQU stj|| {ake them for thgt
your BZD prescription. reason or some other reason?
>
No, I take them for sleep now
Stress
V
7. What was the initial effect of your BZD medication? They made me feel calm
8. What is the current effect? Help me to get to sleep
9. Have you noticed any side effects?
V
10. Do you need to take your BZD every
day?
I think I must be dependent on them, I
wouldn't sleep at all if I didn't have them
<-
12. Do you smoke?
I've smoked for 50 years
13. Do you drink?
No
_ __ * V
15. Who would you like to help you, if you would like to stop taking your BZD?
11. Do you have sleep difficulties?
\l usually fall asleep reading, usuallyaround 2o'clock. Then I wake up at
7am
14. Would you like to stop taking your BZD?
No
Participant 3
1. How long been taking BDZ >10 years
2. Type of BZD? Nitrazepam
3. Frequency? Every night
4. What problems were you having prior to the receipt of your prescription?
A disrupted sleep pattern due to working continental shifts
V
V
5. What was the original reason for
your BZD prescription?
Sleep problems due to shift work ->
6. Do you still take them for that
reason or some other reason?
I've retired now, but still have
problems sleeping
V
7. What was the initial effect of your BZD medication? Good sleep
8. What is the current effect? Still helps but not as good
9. Have you noticed any side effects? Hangover effect -1 went to work feeling
sleepy
10. Do you need to take your BZD every
day?
I think I was dependent on them,
couldn't sleep without them
11. Do you have sleep difficulties?
I find it difficult to get to sleep, then I
sleep for 4 or 5 hours
12. Do you smoke?
I stopped smoking 20
years ago
13. Do you drink?
I'm a social drinker, I have
a couple of pints most
nights
.>
14. Would you like to stop taking your BZD?
Yes, because they are not having the same effect
anymore
V
15. Who would you like to help you, if you would like to stop taking your BZD?
I think I can stop by myself
Participant 4
1. How long been taking BDZ 17 years
2. Type of BZD? Nitrazepam
3. Frequency? Every night
4. What problems were you having prior to the receipt of your prescription?
Car crash resulting in head injury and loss of daughter (bereavement)
Work stress
7. What was the initial effect of your BZD medication? Good sleep but it made me too
sleepy so I had to have the dose reduced
8. What is the current effect? Well it helps me sleep but not enough
9. Have you noticed any side effects? Not now, but I used to get a hangover effect
W
10. Do you need to take your BZD every
day?
I think it's force of habit but I'm not
dependent on them
11. Do you have sleep difficulties?
I take my tablet at 8pm, go to bed at
9.30pm, I lie awake until 12am.
I always wake at 4.30am
12. Do you smoke?
No
13. Do you drink?
No
14. Would you like to stop taking your BZD?
No, I wouldn't get any sleep
V
15. Who would you like to help you, if you would like to stop taking your BZD?
Participant 5
1. How long been taking BDZ >10 years
2. Type of BZD? Temazepam,
3. Frequency? Infrequent use - as required




5. What was the original reason for
your BZD prescription?
Sleep problems due to work stress
6. Do you still take them for that
reason or some other reason?
More or less the same reason, I take
them when I'm worried, because if I'm
worried I don't sleep
V
7. What was the initial effect of your BZD medication? Good sleep
8. What is the current effect? Still the same
9. Have you noticed any side effects? No side effects
V
10. Do you need to take your BZD every
day?
I never take them every night, therefore
I'm not dependent
11. Do you have sleep difficulties?
I get to sleep quickly and sleep for 7
hours unless worried
12. Do you smoke?
Smokes a pipe
13. Do you drink?
I have 2 or 3 glasses of gin
a night
14. Would you like to stop taking your BZD?
Not really as I don't use them frequently
15. Who would you like to help you, if you would like to stop taking your BZD?
Participant 6
1. How long been taking BDZ? 15 years
2. Type of BZD? Temazepam
3. Frequency? Several nights per week
4. What problems were you having prior to the receipt of your prescription?
Heart by-pass operation
V
7. What was the initial effect of your BZD medication? Helped with sleep but
effectiveness soon wore off
8. What is the current effect? Not that helpful
9. Have you noticed any side effects? Interfered with bowel movement
V
10. Do you need to take your BZD every
day?
I've never felt addicted, because I try not
to take them every day.
11. Do you have sleep difficulties?
I get to sleep quickly but wake after 2
or 3 hours. I lie awake until 5am when
I fall back to sleep for 2 or 3 hours
<
12. Do you smoke?
No
13. Do you drink?
I have an occasional drink
\/
15. Who would you like to help you, if you would like to stop taking your BZD?
I suppose my GP
14. Would you like to stop taking your BZD?
Yes, I would like to be able to get to sleep without
them
Participant 7
1. How long been taking BDZ? 11 years
2. Type of BZD? Temazepam
3. Frequency? Every night
4. What problems were you having prior to the receipt of your prescription?
Bereavement (wife)
V
5. What was the original reason for
your BZD prescription?
Sleep problems due to bereavement ->
6. Do you still take them for that
reason or some other reason?
Well I still take them for sleep
V
7. What was the initial effect of your BZD medication? Good sleep
8. What is the current effect? If I wake up I need to take another to get back to sleep
9. Have you noticed any side effects?
V
10. Do you need to take your BZD every
day?
I think I must be dependent on them, as
I wouldn't sleep without them
No side effects
11. Do you have sleep difficulties?
I take 1 or 2 tablets at 12am and fall to
sleep quickly. I sleep for 4 or 5 hours,
then I wake up and sometimes I take
another one -1 doze and then get up
at 7 or 8am
12. Do you smoke?
No




14. Would you like to stop taking your BZD?
No, I would like a stronger one
V
15. Who would you like to help you, if you would like to stop taking your BZD?
Participant 8
1. How long been taking BDZ?
2. Type of BZD?
1 year
Diazepam & Nitrazepam
3. Frequency? 2 or 3 times daily
V
4. What problems were you having prior to the receipt of your prescription?
Heart attack - subsequent cardiac problems
V
5. What was the original reason for
your BZD prescription?
Anxiety due to health worries ->
6. Do you still take them for that
reason or some other reason?
Same reason
V
7. What was the initial effect of your BZD medication? Helped to calm me down
8. What is the current effect? Same
9. Have you noticed any side effects? No side effects
V
10. Do you need to take your BZD every
day?
I'm not dependent, but at the moment I
need to take them most days
11. Do you have sleep difficulties?
I find it difficult to get to sleep, I lie
awake for hours. I sleep about 5 hours
with the sleeping tablet
12. Do you smoke?
Yes
13. Do you drink?
No
14. Would you like to stop taking your BZD?
No, I think I need them too much at the moment
V
15. Who would you like to help you, if you would like to stop taking your BZD?
Participant 9
1. How long been taking BDZ 1 year
2. Type of BZD? Nitrazepam
3. Frequency? Every night
4. What problems were you having prior to the receipt of your prescription?
Bereavement (wife) and worry
V
7. What was the initial effect of your BZD medication? Helps me to get to sleep, stops
me worrying in bed
8. What is the current effect? Not as good
9. Have you noticed any side effects?
V
10. Do you need to take your BZD every
day?
I need them to get to sleep but I'm not
addicted to them
Hangover effect, I don't like to drive
in the mornings
11. Do you have sleep difficulties?
It takes me a while to get to sleep, I lie
awake worrying
12. Do you smoke?
No
13. Do you drink?
No
14. Would you like to stop taking your BZD?
Yes, if I could get to sleep without them
V
15. Who would you like to help you, if you would like to stop taking your BZD?





D.O.B Marital status (If living alone ask for how long)
Employment status (If not working ask when stopped)
How long have you been in receipt of your prescription?
Do you take your tablets as prescribed by your doctor? For example is that everyday or just at
certain times? If at certain times when would that be?
What was the original reason you were prescribed benzodiazepine medication?
Can you remember who gave you your first prescription? Yes □ No □
If yes - who?
What is the current reason(s) for your use of benzodiazepine medication? (If more than one reason
rate)
Do you drink alcohol? Yes □ No □
If yes - how much? For example what would you drink in an average week.
If you drank more alcohol in the past was it ever a problem? For example do you
think you ever drank too much?
Do you smoke cigarettes? Yes □ No □
Ifyes - how many?
How long have you smoked?
If you smoked in the past when and why did you stop?
How long did you smoke for?
Name
Do you have any medical health problems?
If yes - are you taking any medication?
Do you have any painful conditions?
Ifyes - what? how long? pain relief?
Would you like to stop or reduce your BZD tablets? Yes □ No □
If yes - what help do you think you would need? For example who do you think
could help?
If no - what are your reasons for not wanting to change you current use of BZD?
Is there anything else I should have asked you? Is there anything you would like to add?
Give info leaflet then sav: After you have had a chance to read the leaflet you might decide you
would like to find out more about stopping your tablets. Please return the slip in the leaflet if you like
to find out more.
PLEASE ANSWER ALL QUESTIONS.
X
w The following questions relate to your usual sleep habits during the past month only. Your












During the past month, when have you
usually gone to bed at night?
Usual bed time
During the past month, when have you
usually got up in the morning?
Usual getting up time.
During the past month, how long (in minutes)
has it usually taken you to fall asleep each
night?
Number of minutes.
During the past month, how many hours of
actual sleep did you get at night? (This may be
different to the number of hours you spend in
bed.)
Hours of sleep per night.
For each of the remaining questions, tick the one best response.
During the past month, how often have Not Less than Once or Three or
you had trouble sleeping because during the once a twice a more
you past week week times a
month week
Cannot get to sleep within 30 minutes
Wake up in the middle of the night or early
morning
Have to get up to go to the bathroom
Cannot breathe comfortably




















How often during the past month have you
had trouble sleeping because of this other
reason
During the past month, how often have you
take medicine (prescribed or "over the
counter") to help you sleep?
During the past month, how often have you
had trouble staying awake while driving,
eating meals, or engaging in social activity?
PLEASE ANSWER ALL QUESTIONS.
Very good Fairly good Fairly bad Very bad
During the past month, how would you rate












During the past month, how much of a
problem has it been for you to keep up
enough enthusiasm to get things done?
Below is a list of problems people sometimes have. Please read each one carefully, and tick the
O response that best describes HOW MUCH THAT PROBLEM HAS DISTRESSED OR















Nervousness or shaking inside
Fainting or dizziness
Pains in heart or chest
Feeling afraid in open spaces or in the streets
Thoughts of ending your life
Suddenly scared for no reason
Feeling lonely
Feeling blue
Feeling no interest in things
Feeling fearful
Your feelings being easily hurt
Feeling that people are unfriendly or dislike you
Nausea or upset stomach
Feeling inferior to others
Feeling afraid to travel on buses, subways or trains
Trouble getting your breath
Hot or cold spells
Having to avoid certain things, places or activities
because they frighten you
Numbness or tingling in parts of your body
Feeling hopeless about the future
Feeling weak in parts of your body
Feeling tense or keyed up
Feeling very self-conscious with others
Feeling uneasy in crowds, such as shopping
Spells of terror or panic
Feeling nervous when you are left alone
Feeling so restless that you couldn't sit still
Feelings of worthlessness
PLEASE ANSWER ALL QUESTIONS.
3 Please place a tick next to the response which best describes how you have felt during the
PAST MONTH about your tranquillisers (benzodiazepine medication).
Never/ almost
never
Sometimes Often Always/ nearly
always
Did you think your use of tranquillisers
was out of control?
Did the prospect of missing a dose
make you anxious or worried?
Did you worry about your use of
tranquillisers?






How difficult would you find it to stop
or go without your tranquillisers?










1 would be willing to talk about my personal
problems if 1 thought it might help me or a member
of my family.
1 am always curious about the reasons people
behave as they do.
1 think that most people who are mentally ill have
something physically wrong with their brain.
When 1 have a problem, if 1 talk about it with a
friend, 1 feel a lot better
Often 1 don't know what I'm feeling.
1 am trying to change old habits to try a new way of
doing things.
There are certain problems which 1 could not
discuss outside my immediate family.
1 often find myself thinking about what made me act
in a certain way.
Emotional problems can sometimes make you
physically sick.









When you have problems, talking about them with
other people just make them worse.
Usually, if 1 feel an emotion, 1 can identify it.
If a friend gave me advice about how to do
something better, I'd try it out.
1 am annoyed by someone, whether he is a doctor
or not, if they want to know about my personal
problems.
1 find that once 1 develop a habit it is hard to
change, even if 1 know there is another way of
doing things that might be better.
1 think that people who are mentally ill often have
problems that begin in their childhood.
Letting off steam by talking to someone about your
problems often makes you feel a lot better.
People sometimes say that 1 act as if I'm having a
certain emotion (anger for example) but 1 am
unaware of it.
1 get annoyed when people give me advice about
changing the way 1 do things.
It would not be difficult for me to talk about personal
problems with people such as doctors and
clergymen.
If a good friend of mine suddenly started to insult
me, my first reaction might be to try to understand
why he was so angry.
1 think that when a person has crazy thoughts, it is
often because he is very anxious or upset.
I've never found that talking to other people about
my worries helps much.
Often, even though 1 know that I'm having an
emotion, 1 don't know what it is.









1 like to do things the way I've done them in the
past. 1 don't like to try and change my behaviour
much.
There are some things in my life that 1 would not
discuss with anyone.
Understanding the reasons you have deep down
for acting in certain ways is important.
At work, if someone suggested a different way of
doing a job that might be better, I'd give it a try.
I've found that when 1 talk about my problems to
someone else. 1 come up with ways to solve them
that 1 hadn't thought of before.
1 am sensitive to the changes in my own feelings.
When 1 learn a new way of doing something, 1 like
to try it out to see if it would work better than what 1
have been doing before.
It is important to be open and honest when you talk
about your troubles with someone you can trust.
1 really enjoy trying to figure other people out.
1 think that most people with mental problems have
probably received some kind of injury to their head.
Talking about your worries to another person helps
you to understand your problems better.
I'm usually in touch with my feelings.
1 like to try new things, even if it involves taking
risks.
It would be very difficult for me to discuss upsetting
or embarrassing aspects of my personal life with
people even if 1 trust them.
If 1 suddenly lost my temper with someone, without
knowing exactly why, my first impulse would be to
forget about it.
1 think that a person's environment (family etc) has
very little to do with whether he develops mental
problems.
When you have some troubles, talking about them
to someone else just makes you more confused.
1 frequently don't want to delve too deeply into what
I'm feeling.









1 don't like doing things if there is a chance that
they won't work out.
1 think that no matter how hard you try, you'll never
really understand what makes people tick.
1 think that what goes on deep down in a person's
mind is important in determining whether he will
have a mental illness.
Fear of embarrassment or failure doesn't stop me
from trying something new.
(Note: The format and font size of this questionnaire has been reduced to fit margins)
APPENDIX 3
BORDERS RESEARCH ETHIICS COMMITTEE
Response for a local research proposal
Copy to be sent to the local researcher
1. LREC name and address Borders Research Ethics Committee
Trust Management




2. Title of study Benzodiazepine use in a primary care population
3. Name of local researcher April Quiglev, Trainee Clinical Psychologist, Psychological Therapies
Sendees, Borders Primary Care NHS Trust
4. LREC reference number 02/BREC/03
Borders Research Ethics Committee has considered the above application with a view to recommending
whether the research should go ahead locally.
5. Borders Research Ethics Committee considered the following issues:
approve defer reject
Suitability of researcher and support staff M □ □
Suitability of site , 13 □ □
Suitability of research for local subject population 13 □ □
Patient information sheet and consent form (please state) 13 □ . □
If any of the above are deferred or rejected, please state reason.
6. Borders Research Ethics Committee wishes to offer the following comments for information
Copies of the GP letter and information sheet must be forwarded to the Committee once they have been
finalised.
7. Borders Research Ethics Committee wishes to raise the following significant concerns
Date application considered 17th January 2002
Process by which application was considered locally: full committee
The decision of Borders Research Ethics Committee
[X] Borders Research Ethics Committee recommends the research go ahead. Please read the conditions of approval
attached to this form
Borders Research Ethics Committee does not recommend the research go ahead for the local reasons set out in i
7.
| | Borders Research Ethics Committee has deferred making a decision and is awaiting clarification from the research
Signed Chairman/Representative of
Borders Research Ethics Committee rw.. 0 n ,Uate l~ I ' ( • o 2
Print name Mr A.C.H. Watson. Chairman
APPENDIX 4
Copy of recruitment letter from GP's
Copy of return slip









We are fortunate to have as part of the team in the Practice at the moment Dr April
Quigley who is a trainee Clinical Psychologist. She is interested to do some research in
to the use of Benzodiazepine medication.
Benzodiazepine tablets include Diazepam, Temazepam and Nitrazepam tablets. These
tablets are usually prescribed for sleep and anxiety problems. As you have a
prescription for this type of medication she would very much like to meet with you (even
if you are not currently taking them).
Dr Quigley is happy to arrange a meeting with you either at the Health Centre or at
your home and obviously involvement in the study is entirely voluntary. This meeting
will involve answering a few questions about your tablets and filling in a questionnaire.
May we reassure you that participation in this study will not affect your prescription in
any way and also that any information gathered will be kept entirely confidential and
will be destroyed after the study is completed.
Should any patient decide that they would like to stop or reduce their Benzodiazepine
tablets Dr Quigley will be able to offer some psychological help with this.
You will find enclosed with this letter a return slip, we would very much appreciate it if
you could fill this in and return it in the S.A.E. provided.
Trusting that you will consent to be contacted, in receipt of your reply Dr Quigley will be
in touch in due course. You will then have the opportunity to ask any questions you
might have and if you choose to participate Dr Quigley will arrange a meeting with you.
If you agree to participate in this study it will not affect you current prescription
and the study will ensure complete anonymity and confidentiality.
At any time you may change your mind and withdraw from the study.
Many thanks for your help in this valuable piece of research.
Yours sincerely
Dr (relevant GP)
This study has been approved by the Borders Research Ethics Committee
Benzodiazepine study
Name




(Note: ticking "yes" does not mean you are agreeing to take part, just
that you are willing to be approached.)
I am happy to be contacted by:
Tick one
Letter or telephone □
Just by letter □









You may remember receiving a letter from your GP asking you to take part in a
study we are currently undertaking in Jedburgh which is looking at
Benzodiazepine medication. First of all I would like to thank you for returning
your slip on which you indicated that you would prefer to be contacted by letter.
If you would agree to meet with me I would like to visit you at home or you may
chose to come along to the Health Centre.
The meeting would involve answering some questions about your tablets, for
example, do they help and in what way, and questions about your sleep and
any health problems or worries you might have.
The study is like a survey and all the information we gather from the people we
speak to remains anonymous. I have seen a number of people so far who have
all said that the questions were not intrusive and that they had been pleased to
help.
Could I ask you to return the enclosed slip in the S.A.E. provided, which offers a
choice of times when one of us could meet with you.




This study has been approved by the Borders Research Ethics Committee
APPENDIX 5: ADDITIONAL RESULTS
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Table 1: Prevalence ofmedical conditions according to sex
Appendix 5 (b)
Reasons given for benzodiazepine use
Figure 1: Reason given for original benzodiazepine prescription
Figure 2: Reason given for current use of benzodiazepine
Appendix 5 (c)
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Appendix 5 (d)
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Figure 4: Sleep latency: distribution of number of minutes taken to fall asleep
Figure 5: Sleep duration: total number of hours slept per night
APPENDIX 5: ADDITIONAL RESULTS
Appendix 5 (a)
Medical conditions and benzodiazepine use
Table 1 below reports the number of participants in receipt of medication for each of the 8
categories of medical conditions grouped according to BNF categories (see chapter 7).
Table 1: Prevalence ofmedical conditions according to sex
Male Female
BNF groupings of medical conditions N = 27 % N = 56 %
Cardiovascular 25 92.6 41 71.9
Gastro intestinal 13 41.1 33 57.9
Central nervous system 23 85.2 48 84.2
Respiratory system 9 33.3 17 29.8
Musculoskeletal 10 37 34 59.6
Endocrine system 6 22.2 17 29.8
Malignant & immunosuppression 1 3.7 6 10.5
Obstetrics, gynaecology, urinary tract 3 11.1 12 21.1
Pain
Self report painful conditions 18 66.7 38 66.7
Prescribed pain relief 12 44.4 33 57.9
Mean SD Mean SD
Number of health categories per participant 3.33 1.38 3.68 1.62
Appendix 5 (b)
Reasons given for benzodiazepine use
With the exception of participants who gave "anxiety" (N = 6) as their reason for
commencing benzodiazepine medication, "problem sleeping" was the primary reason given.
Fifty five percent of participants were able to give a reason for their sleep difficulty. Thirty
eight percent were unable to give a precipitant to their sleep problem. It is possible that a
number of the 12 participants who reported "stress and worry" as the reason that they could
not sleep, could have been experiencing an anxiety disorder such as generalised anxiety
disorder (GAD).
Figure 1: Reason given for original benzodiazepine prescription











Figure 2 below gives the current reason for participants use of benzodiazepine medication.
The majority of participants did not report a reason for their current sleep problem.
Only three participants reported that their continued use of benzodiazepines was still for
anxiety, these participants took their benzodiazepines during the daytime. The remaining 81
participants took their benzodiazepine at night.
Figure 2: Reason given for current use of benzodiazepine








The 13 participants who reported bereavement as their original reason for commencing
benzodiazepines, reported sleep as their current reason for benzodiazapine use. The mean
length of time since commencing a benzodiazepine, and therefore an indication of time since
their bereavement was 10.9 years (mode = 14 years).
Of the three participants who commenced benzodiazepine medication due to shift work, one
participant (aged 56) continues to work shifts and had been using benzodiazepines for 3
years. The other two participants commenced benzodiazepines at the age of 52 and 61, they
continued to take them following their retirement and have now been taking them for 20
years each.
Twelve participants who commenced benzodiazepines because pain (N=6), muscle spasms
(N=4) or tinitus (N=2) was impairing their sleep, report the same reason for their current use
of benzodiazepines.
After bereavement, stress and worry was the most commonly reported reason for sleep
problems leading to commencement of benzodiazepine medication. Of the twelve
participants who gave this reason, three said that they currently still had worries. These three
participants had been taking their benzodiazepines for a mean duration of 3.6 years. The
remaining nine participants said that the original stresses and worries had gone but that they
still required benzodiazepines to sleep. This group of nine had been taking their
benzodiazepines for an average of 10 years.
Appendix 5 (c)
Correlation matrix for SDS items
worry wish
out of miss a worry could how total
control dose use of stop difficult SDS
out of control Correlation Coefficient 1.000
Sig. (2-tailed)
N 84
worry miss a dose Correlation Coefficient .061 1.000
Sig. (2-tailed) .583
N 84 84
worry use of Correlation Coefficient .124 -.163 1.000
Sig. (2-tailed) .263 .138
N 84 84 84
wish could stop Correlation Coefficient .246* -.070 .380" 1.000
Sig. (2-tailed) .024 .529 .000
N 84 84 84 84
how difficult Correlation Coefficient -.047 .444" -.105 .059 1.000
Sig. (2-tailed) .671 .000 .341 .596
N 84 84 84 84 84
total SDS Correlation Coefficient .298" .599" .350" .598" .624" 1.000
Sig. (2-tailed) .006 .000 .001 .000 .000
N 84 84 84 84 84 84
*■ Correlation is significant at the .05 level (2-tailed).
**• Correlation is significant at the .01 level (2-tailed).
Note that in terms of the correlation of each item with the total SDS score, each item
contributes to the total SDS score, this means that a proportion of the correlation coefficient
is determined by its correlation with itself.
Appendix 5 (d)
The Pittsburgh Sleep Quality Index
Figure 3 below illustrates the mean score for each of the seven PSQI components. As one
would expect questions regarding the "use of sleep medication" were the most highly
endorsed. It would appear that "sleep latency" and "sleep efficiency" are also more
problematic than other components.
Figure 3: Error bar chart to show mean scores on 7 components of PSQI & 95% CI
Figure 4: Sleep latency: distribution of number ofminutes taken to fall asleep
20.0 60.0 100.0 140.0
Minutes taken to fall asleep
Figure 5: Sleep duration: total number of hours slept per night
length of time asleep in hours
Table 2 below shows that a number of the BS1 dimensions scores correlate with the PSQI
component scores, demonstrating a relationship between increased sleep difficulty and
higher levels of psychopathology. Daytime dysfunction demonstrates the strongest
relationship with the BSI dimension scores. This is predictable on the basis that increased
symptomatology is likely to lead to poorer general functioning, which could well be
reflected in daytime dysfunction.
Sleep disturbance correlates significantly with all dimensions except interpersonal
sensitivity. Interpersonal sensitivity is the dimension least associated with the sleep
component scores, but this is not surprising because whilst this dimension is linked to
anxiety and phobic anxiety, it is not a specific diagnosable condition.
Reduced sleep duration is associated with the "anxious" dimensions; anxiety, somatisation
and phobic anxiety, suggesting that worry could be reducing total sleep time. Surprisingly
however, sleep latency appears less of a problem for the anxious participants, instead it
would appear to be those participants who scored more highly for depression who have more
of a problem getting to sleep.
Table 2: Correlation matrix to show the relationship between BSI dimension scores and
PSQI component scores
Anxiety Depression Somatis¬ Inter¬ Phobic Total




Subjective rs = .339 .343 .165 .202 .286 .311
sleep quality P = .002 .001 .134 .066 .008 .004
Sleep latency rs = .177 .221 .172 .033 .125 .197
P = .107 .043 .117 .763 .257 .073
Sleep duration rs = .458 .211 .261 .115 .270 .316
P = .000 .054 .016 .300 .013 .003
Sleep rs = .344 .238 .277 .143 .142 .290
efficiency P = .001 .029 .011 .194 .197 .007
Sleep rs = .315 .306 .376 .113 .257 .362
disturbances P = .004 .005 .000 .305 .018 .001
Use of sleep rs = .195 .130 .275 .059 .086 .193
medication P = .076 .239 .011 .594 .439 .079
Daytime rs = .344 .259 .472 .345 .237 .458
dysfunction P = .001 .018 .000 .001 .030 .000




General Linear Model: Three-Factor mixed ANOVA
General Linear Model: Two- Factor mixed ANOVA
Appendix 6 (c!
Regression Analysis for dependent variable SDS score
Logistic Regression for dependent variable BZD
Regression Analysis for dependent variable PSQI score









Larger values of the test result variable(s) indicate
stronger evidence for a positive actual state.





0.00 .25 .50 .75 1.00
1 - Specificity
Diagonal segments are produced by ties.
Area Under the Curve






Lower Bound Upper Bound
.754 .059 .000 .640 .869
The test result variable(s): total SDS has at least one tie between the
positive actual state group and the negative actual state group. Statistics
may be biased.
a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5
Coordinates of the Curve
Test Result Variable(s): total SDS
Positive if
Greater Than












The test result variable(s): total SDS has at least one tie
between the positive actual state group and the negative
actual state group.
a- The smallest cutoff value is the minimum
observed test value minus 1, and the largest cutoff
value is the maximum observed test value plus 1.
All the other cutoff values are the averages of two
consecutive ordered observed test values.
Appendix 6 (b)












SEX 1.00 male 27
2.00 female 57
age group 1.00 over 60 68
2.00 under 60 16
Descriptive Statistics
SEX age group Mean Std. Deviation N
pho mean + 1 male over 60 .1574 .3002 20
transformed under 60 .5452 .4854 7
Total .2580 .3876 27
female over 60 .2657 .3302 48
under 60 .5902 .4360 9
Total .3169 .3646 57
Total over 60 .2338 .3233 68
under 60 .5705 .4429 16
Total .2980 .3708 84
dep mean + 1 male over 60 .3669 .3754 20
transformed under 60 .5549 .2835 7
Total .4156 .3586 27
female over 60 .4335 .3958 48
under 60 .4608 .4226 9
Total .4378 .3964 57
Total over 60 .4139 .3883 68
under 60 .5019 .3602 16
Total .4307 .3826 84
int mean +1 transformed male over 60 .2184 .2569 20
under 60 .5433 .3823 7
Total .3026 .3210 27
female over 60 .3541 .3029 48
under 60 .5673 .4735 9
Total .3877 .3394 57
Total over 60 .3142 .2949 68
under 60 .5568 .4221 16
Total .3604 .3341 84
som mean +1 transform male over 60 .3971 .2667 20
under 60 .6308 .3019 7
Total .4577 .2896 27
female over 60 .5193 .2576 48
under 60 .5470 .3376 9
Total .5237 .2685 57
Total over 60 .4834 .2643 68
under 60 .5837 .3148 16
Total .5025 .2754 84
anx mean +1 transform male over 60 .2128 .2952 20
under 60 .7759 .2623 7
Total .3588 .3778 27
female over 60 .3228 .3515 48
under 60 .5647 .5157 9
Total .3610 .3868 57
Total over 60 .2905 .3375 68
under 60 .6571 .4255 16
Total .3603 .3817 84
Mauchly's Test of Sphericity1'
Measure: MEASURE_1
Epsilon3





BSI .893 8.901 9 .447 .941 1.000 .250
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
a' May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the
Tests ofWithin-Subjects Effects table.
b.
Design: Intercept+SEX+AGEGROUP+SEX * AGEGROUP





of Squares df Mean Square F Sig.
BSI Sphericity Assumed .506 4 .127 2.269 .062
Greenhouse-Geisser .506 3.765 .135 2.269 .066
Huynh-Feldt .506 4.000 .127 2.269 .062
Lower-bound .506 1.000 .506 2.269 .136
BSI* SEX Sphericity Assumed .159 4 3.967E-02 .711 .585
Greenhouse-Geisser .159 3.765 4.215E-02 .711 .577
Huynh-Feldt .159 4.000 3.967E-02 .711 .585
Lower-bound .159 1.000 .159 .711 .402
BSI * AGEGROUP Sphericity Assumed .854 4 .213 3.825 .005
Greenhouse-Geisser .854 3.765 .227 3.825 .006
Huynh-Feldt .854 4.000 .213 3.825 .005
Lower-bound .854 1.000 .854 3.825 .054
BSI * SEX * AGEGROUP Sphericity Assumed .120 4 3.002E-02 .538 .708
Greenhouse-Geisser .120 3.765 3.189E-02 .538 .697
Huynh-Feldt .120 4.000 3.002E-02 .538 .708
Lower-bound .120 1.000 .120 .538 .465
Error(BSI) Sphericity Assumed 17.855 320 5.580E-02
Greenhouse-Geisser 17.855 301.221 5.928E-02
Huynh-Feldt 17.855 320.000 5.580E-02
Lower-bound 17.855 80.000 .223





of Squares df Mean Square F Siq.
Intercept 50.189 1 50.189 143.216 .000
SEX 3.053E-02 1 3.053E-02 .087 .769
AGEGROUP 3.948 1 3.948 11.266 .001
SEX * AGEGROUP .458 1 .458 1.308 .256





95% Confidence Interval for
Difference3
(I) BSI (J) BSI (l-J) Std. Error Siq.a Lower Bound Upper Bound
1 2 -6.439E-02 .051 1.000 -.212 8.327E-02
3 -3.115E-02 .045 1.000 -.162 9.922E-02
4 -.134* .046 .045 -.266 -1.690E-03
5 -7.943E-02 .047 .939 -.215 5.583E-02
2 1 6.439E-02 .051 1.000 -8.327E-02 .212
3 3.324E-02 .045 1.000 -9.802E-02 .165
4 -6.956E-02 .056 1.000 -.230 9.136E-02
5 -1.504E-02 .048 1.000 -.155 .125
3 1 3.115E-02 .045 1.000 -9.922E-02 .162
2 -3.324E-02 .045 1.000 -.165 9.802E-02
4 -.103 .045 .256 -.233 2.767E-02
5 -4.829E-02 .044 1.000 -.174 7.792E-02
4 1 .134* .046 .045 1.690E-03 .266
2 6.956E-02 .056 1.000 -9.136E-02 .230
3 .103 .045 .256 -2.767E-02 .233
5 5.451 E-02 .047 1.000 -8.214E-02 .191
5 1 7.943E-02 .047 .939 -5.583E-02 .215
2 1.504E-02 .048 1.000 -.125 .155
3 4.829E-02 .044 1.000 -7.792E-02 .174
4 -5.451 E-02 .047 1.000 -.191 8.214E-02
Based on estimated marginal means
*
The mean difference is significant at the .05 level.
3 Adjustment for multiple comparisons: Bonferroni.



















SEX Mean Std. Deviation N
pho mean + 1 male .1574 .3002 20
transformed female .2657 .3302 48
Total .2338 .3233 68
dep mean + 1 male .3669 .3754 20
transformed female .4335 .3958 48
Total .4139 .3883 68
int mean +1 transformed male .2184 .2569 20
female .3541 .3029 48
Total .3142 .2949 68
som mean +1 transform male .3971 .2667 20
female .5193 .2576 48
Total .4834 .2643 68
anx mean +1 transform male .2128 .2952 20
female .3228 .3515 48
Total .2905 .3375 68
Mauchly's Test of Sphericity
Measure: MEASURE 1
Epsilon3





BSI .836 11.557 9 .240 .915 .990 .250
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the
Tests ofWithin-Subjects Effects table.
b.
Design: Intercept+SEX




Source of Squares df Mean Square F Sig.
BSI Sphericity Assumed 2.318 4 .579 10.099 .000
Greenhouse-Geisser 2.318 3.660 .633 10.099 .000
Huynh-Feldt 2.318 3.960 .585 10.099 .000
Lower-bound 2.318 1.000 2.318 10.099 .002
BSI * SEX Sphericity Assumed 3.783E-02 4 9.457E-03 .165 .956
Greenhouse-Geisser 3.783E-02 3.660 1.034E-02 .165 .946
Huynh-Feldt 3.783E-02 3.960 9.553E-03 .165 .955
Lower-bound 3.783E-02 1.000 3.783E-02 .165 .686
Error(BSI) Sphericity Assumed 15.149 264 5.738E-02
Greenhouse-Geisser 15.149 241.547 6.272E-02
Huynh-Feldt 15.149 261.360 5.796E-02
Lower-bound 15.149 66.000 .230





of Squares df Mean Square F Sig.
Intercept 29.788 1 29.788 102.253 .000
SEX .832 1 .832 2.856 .096





95% Confidence Interval for
Difference3
(I) BSI (J) BSI (l-J) Std. Error Sig.a Lower Bound Upper Bound
1 2 I 00 «3 .048 .002 -.327 -5.008E-02
3 -7.469E-02 .041 .752 -.195 4.531 E-02
4 -.247* .044 .000 -.374 -.120
5 -5.629E-02 .045 1.000 -.186 7.361 E-02
2 1 .189* .048 .002 5.008E-02 .327
3 .114 .043 .101 -1.094E-02 .239
4 -5.800E-02 .055 1.000 -.216 .100
5 .132 .048 .070 -5.860E-03 .271
3 1 7.469E-02 .041 .752 -4.531 E-02 .195
2 -.114 .043 .101 -.239 1 094E-02
4 -.172* .041 .001 -.291 -5.345E-02
5 1 840E-02 .040 1.000 -9.718E-02 .134
4 1 .247* .044 .000 .120 .374
2 5.800E-02 .055 1.000 -.100 .216
3 .172* .041 .001 5.345E-02 .291
5 .190* .046 .001 5.743E-02 .323
5 1 5.629E-02 .045 1.000 -7.361 E-02 .186
2 -.132 .048 .070 -.271 5.860E-03
3 -1.840E-02 .040 1.000 -.134 9.718E-02
4 -.190* .046 .001 -.323 -5.743E-02
Based on estimated marginal means
*• The mean difference is significant at the .05 level.
a Adjustment for multiple comparisons: Bonferroni.
Appendix 6 (c)
Regression Analysis for dependent variable SDS score
Variables Entered/Removed
Variables Variables

























a- Dependent Variable: total SDS
Model Summaryp
Adjusted Std. Error of
Model R R Square R Square the Estimate
1 ,417a .174 .164 2.1507
2 ,469b .220 .201 2.1025
a- Predictors: (Constant), LNANX
b- Predictors: (Constant), LNANX, LNSOM
c- Dependent Variable: total SDS
ANOV/f
Sum of
Model Squares df Mean Square F Sig.
1 Regression 79.868 1 79.868 17.268 ,000a
Residual 379.275 82 4.625
Total 459.143 83
2 Regression 101.070 2 50.535 11.432 ,000b
Residual 358.073 81 4.421
Total 459.143 83
a Predictors: (Constant), LNANX
b Predictors: (Constant), LNANX, LNSOM




















2 (Constant) 1.989 .639 3.112 .003
LNANX .766 .289 .298 2.650 .010
LNSOM .919 .420 .246 2.190 .031






Model Beta In t Sig. Correlation Tolerance
1 LNINTER .086a .706 .482 .078 .689
LNSOM 246a 2.190 .031 .236 .764
LNDEP ,098a .762 .449 .084 .615
LNPHOB .027a .218 .828 .024 .676
2 LNINTER ,019b .158 .875 .018 .642
LNDEP .057b .452 .652 .050 .601
LNPHOB -,057b -.451 .654 -.050 .616
a Predictors in the Model: (Constant), LNANX
b- Predictors in the Model: (Constant), LNANX, LNSOM
c- Dependent Variable: total SDS
Residuals Statistics*
Minimum Maximum Mean Std. Deviation N
Predicted Value 1.9890 6.6109 4.2857 1.1035 84
Residual -4.4310 5.5690 -8.78E-16 2.0770 84
Std. Predicted Value -2.081 2.107 .000 1.000 84
Std. Residual -2.107 2.649 .000 .988 84
a Dependent Variable: total SDS
Scatterplot
® Dependent Variable: total SDS
Regression Standardized Residual
Logistic Regression for dependent variable BZD
Case Processing Summary
Unweighted Cases N Percent
Selected Cases Included in Analysis 84 100.0
Missing Cases 0 .0
Total 84 100.0
Unselected Cases 0 .0
Total 84 100.0
a. If weight is in effect, see classification table for the total
number of cases.
Dependent Variable Encoding









cut off 4 Percentage
Correctproblem no problem
Step 0 cut off 4 problem 54 0 100.0
no problem 30 0 .0
Overall Percentage 64.3
a- Constant is included in the model,
b- The cut value is .500
Variables in the Equation
B S.E. Wald df Siq. Exp(B)
Step 0 Constant -.588 .228 6.662 1 .010 .556
Variables not in the Equation
Score df Sig.
Step Variables ANXMEAN 14.924 1 .000
0 INTMEAN 5.147 1 .023
SOMEAM 11.050 1 .001
DEPMEAN 11.204 1 .001
PHOBMEAN 6.639 1 .010
Overall Statistics 23.085 5 .000
Block 1: Method = Backward Stepwise (Conditional)
Omnibus Tests of Model Coefficients
Chi-square df Siq.
Step 1 Step 32.350 5 .000
Block 32.350 5 .000
Model 32.350 5 .000
Step 2? Step -.004 1 .951
Block 32.346 4 .000
Model 32.346 4 .000
Step 3* Step -2.557 1 .110
Block 29.789 3 .000
Model 29.789 3 .000
Step 4** Step -2.450 1 .118
Block 27.339 2 .000
Model 27.339 2 .000
a A negative Chi-squares value indicates that the
Chi-squares value has decreased from the
previous step.
Model Summary
-2 Log Cox & Snell Nagelkerke
Step likelihood R Square R Square
1 77.146 .320 .439
2 77.149 .320 .439
3 79.706 .299 .410
4 82.156 .278 .381
Classification Table*
Predicted
cut off 4 Percentage
CorrectObserved problem no problem
Step 1 cut off 4 problem 43 11 79.6
no problem 9 21 70.0
Overall Percentage 76.2
Step 2 cut off 4 problem 43 11 79.6
no problem 9 21 70.0
Overall Percentage 76.2
Step 3 cut off 4 problem 40 14 74.1
no problem 11 19 63.3
Overall Percentage 70.2
Step 4 cut off 4 problem 39 15 72.2
no problem 9 21 70.0
Overall Percentage 71.4
a- The cut value is .500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Sjep ANXMEAN -2.619 1.040 6.343 1 .012 .073
1 INTMEAN 1.348 .886 2.316 1 .128 3.851
SOMEAM -1.193 .692 2.969 1 .085 .303
DEPMEAN -1.304 .837 2.428 1 .119 .271
PHOBMEAN .046 .751 .004 1 .951 1.048
Constant 1.145 .518 4.878 1 .027 3.143
sJeP ANXMEAN -2.615 1.037 6.354 1 .012 .073
2 INTMEAN 1.359 .870 2.437 1 .119 3.891
SOMEAM -1.186 .683 3.020 1 .082 .305
DEPMEAN -1.290 .801 2.593 1 .107 .275
Constant 1.143 .518 4.881 1 .027 3.137
SJep ANXMEAN -2.145 .936 5.253 1 .022 .117
3 SOMEAM -1.007 .662 2.318 1 .128 .365
DEPMEAN -.948 .692 1.879 1 .170 .387
Constant 1.264 .513 6.073 1 .014 3.541
sJeP ANXMEAN -2.373 .916 6.713 1 .010 .093
4 DEPMEAN -1.061 .688 2.380 1 .123 .346
Constant .762 .379 4.030 1 .045 2.142
a Variable(s) entered on step 1: ANXMEAN, INTMEAN, SOMEAM, DEPMEAN, PHOBMEAN.









Step ANXMEAN -43.278 9.411 1 .002
1 INTMEAN -39.804 2.463 1 .117
SOMEAM -40.156 3.167 1 .075
DEPMEAN -41.195 5.244 1 .022
PHOBMEAN -38.575 .004 1 .951
Step ANXMEAN -43.318 9.488 1 .002
2 INTMEAN -39.879 2.609 1 .106
SOMEAM -40.184 3.219 1 .073
DEPMEAN -41.259 5.368 1 .021
Step ANXMEAN -43.544 7.382 1 .007
3 SOMEAM -41.082 2.459 1 .117
DEPMEAN -41.517 3.327 1 .068
Step ANXMEAN -46.425 10.695 1 .001
4 DEPMEAN -43.093 4.030 1 .045
a. Based on conditional parameter estimates
Variables not in the Equation
Score df Sip.
Step T? Variables PHOBMEAN .004 1 .951
Overall Statistics .004 1 .951
Step 2f> Variables INTMEAN 2.549 1 .110
PHOBMEAN .143 1 .705
Overall Statistics
2.552 2 .279
Step 4c Variables INTMEAN 1.815 1 .178
SOMEAM 2.466 1 .116
PHOBMEAN .006 1 .937
Overall Statistics 4.973 3 .174
a Variable(s) removed on step 2: PHOBMEAN.
b Variable(s) removed on step 3: INTMEAN.
c- Variable(s) removed on step 4: SOMEAM.
Regression Analysis for dependent variable PSQI score
Descriptive Statistics
Mean Std. Deviation N
global score 11.0714 4.0592 84
LNANX 1.0497 .9141 84
LNINTER .8752 .7153 84
LNSOM 1.6244 .6292 84
LNDEP 1.2310 .8221 84
LNPHOB .7824 .8689 84
Correlations
global score LNANX LNINTER LNSOM LNDEP LNPHOB
Pearson Correlation global score 1.000 .502 .232 .443 .408 .335
LNANX .502 1.000 .558 .486 .620 .569
LNINTER .232 .558 1.000 .460 .598 .579
LNSOM .443 .486 .460 1.000 .405 .492
LNDEP .408 .620 .598 .405 1.000 .601
LNPHOB .335 .569 .579 .492 .601 1.000
Sig. (1-tailed) global score .000 .017 .000 .000 .001
LNANX .000 .000 .000 .000 .000
LNINTER .017 .000 .000 .000 .000
LNSOM .000 .000 .000 .000 .000
LNDEP .000 .000 .000 .000 .000
LNPHOB .001 .000 .000 .000 .000
N global score 84 84 84 84 84 84
LNANX 84 84 84 84 84 84
LNINTER 84 84 84 84 84 84
LNSOM 84 84 84 84 84 84
LNDEP 84 84 84 84 84 84
LNPHOB 84 84 84 84 84 84
Variables Entered/Removed
Variables Variables

























a Dependent Variable: global score
Model Summarjp
Adjusted Std. Error of
Model R R Square R Square the Estimate
1 .5023 .252 .243 3.5312
2 .552" .304 .287 3.4271
a Predictors: (Constant), LNANX
b- Predictors: (Constant), LNANX, LNSOM
c- Dependent Variable: global score
ANOVA
Sum of
Model Squares df Mean Square F Sig.
1 Regression 345.102 1 345.102 27.676 ,000a
Residual 1022.470 82 12.469
Total 1367.571 83
2 Regression 416.203 2 208.102 17.718 000b
Residual 951.368 81 11.745
Total 1367.571 83
a. Predictors: (Constant), LNANX
b. Predictors: (Constant), LNANX, LNSOM




















2 (Constant) 6.587 1.042 6.323 .000
LNANX 1.668 .471 .376 3.542 .001
LNSOM 1.683 .684 .261 2.460 .016






Model Beta In t Sig. Correlation Tolerance
1 LNINTER -.oeg3 -.598 .551 -.066 .689
LNSOM .261a 2.460 .016 .264 .764
LNDEP .157a 1.294 .200 .142 .615
LNPHOB ,073a .623 .535 .069 .676
2 LNINTER -,151b -1.312 .193 -.145 .642
LNDEP .115b .965 .337 .107 .601
LNPHOB -,012b -.097 .923 -.011 .616
a Predictors in the Model: (Constant), LNANX
b. Predictors in the Model: (Constant), LNANX, LNSOM
c. Dependent Variable: global score
Coefficient Correlation^
Model LNANX LNSOM
1 Correlations LNANX 1.000
Covariances LNANX .180
2 Correlations LNANX 1.000 -.486
LNSOM -.486 1.000
Covariances LNANX .222 -.157
LNSOM -.157 .468
a- Dependent Variable: global score
Residuals Statistic^
Minimum Maximum Mean Std. Deviation N
Predicted Value 6.5869 15.7697 11.0714 2.2393 84
Residual -7.4360 5.9238 -1.82E-15 3.3856 84
Std. Predicted Value -2.003 2.098 .000 1.000 84
Std. Residual -2.170 1.729 .000 .988 84
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Regression Standardized Predicted Value
Scatterplot
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